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Abstract 
Acute myeloid leukaemia (AML) is an aggressive malignancy of the 
haematopoietic system. With a median age of approximately 70 years at 
diagnosis, survival rates for AML patients lag behind other haematological 
malignancies. This is in part, due to existing comorbidities and patient inability 
to tolerate intensive chemotherapy. Moreover, chemotherapy mainly targets 
AML cells in the peripheral blood (PB) but not those harboured in the bone 
marrow (BM). While studies focusing on the malignant blasts helped achieve 
advances in understanding AML biology and chemoresistance, less is 
understood about the role of the bone marrow microenvironment (BMM) in the 
progression of AML. It is predicted that improved patient outcomes will come 
from novel treatment strategies resulting from an improved understanding of 
the biology of the microenvironment in AML.  
Bone marrow stromal cells (BMSCs) are an instrumental component of the 
AML microenvironment and have been shown to play a role in its survival and 
evasion from apoptosis. The aims of my PhD research were to investigate 
novel interactions between AML cells and BMSCs which benefit AML survival 
in vitro and in vivo. Here, I identified an AML-BMSC feedback loop where AML-
derived macrophage migration inhibitory factor (MIF) stimulated BMSCs, 
through the activation of stromal protein kinase C, to secrete the pro-survival 
cytokine interleukin-8 (IL-8). Moreover, I found that MIF expression in the AML 
compartment is regulated by hypoxia through stabilisation of HIF1α. Inhibition 
of HIF1α or MIF significantly enhanced survival and reduced tumour burden in 
vivo. Finally, I showed that AML cells induce senescence in BSMCs through 
upregulation of the cyclin-dependent kinase inhibitor, p16. Deletion of p16 in 
BMSCs reduced AML survival in co-culture models.  
In summary, the data presented in this thesis provide important insights into 
the AML-BMSC interactions and could facilitate the development of future 
therapeutic approaches in the treatment of AML. 
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1. Chapter 1: Introduction  
 
1.1. Haematopoiesis  
Haematopoiesis is the process by which blood cells are generated in the bone 
marrow. Haematopoietic stem cells (HSCs) give rise to haematopoietic 
progenitor cells (HPCs) which in turn proliferate and differentiate to 
reconstitute all lineages of functional blood cells (1). Early findings that lead to 
the discovery of HSCs were made by Till, McCulloch, and colleagues in 1960. 
They showed that animals that received lethal doses of irradiation could be 
rescued from death via transplantation with unfractionated bone marrow cells 
from normal non-irradiated mice (2). Three years later, they demonstrated that 
the colonies they observed to have formed in the spleens of the irradiated 
animals were formed by single cells that were capable of multilineage 
differentiation (3). These cells are now referred to as HSCs and they are 
regulated by complex cellular and molecular signals, on both genetic and 
epigenetic levels. Modifications in these regulatory signalling networks can 
lead to the dysfunction and transformation of haematopoietic cells into 
leukaemic stem cells (LCS) and the induction of leukaemogenesis (Figure 1.1) 
(4, 5). Hence understanding the regulation of haematopoiesis is essential to 
understanding how leukaemia evolves.  
Many models have been developed to describe the process of haematopoiesis 
and to elucidate its complexity (6, 7). At the root of haematopoiesis are HSCs, 
which are defined by their ability to self-renew to allow blood production over 
the lifetime of an organism, and to differentiate into functional blood cells. 
According to the classical hierarchical models of haematopoesis, HSCs 
initially give rise to common myeloid and lymphoid progenitors. The myeloid 
lineage includes erythroid cells that form red blood cells, granulocytes and 
monocytes that play a role in pathogen immunity and megakaryocytes that are 
involved in the production of platelets. The lymphoid lineage gives rise to T-
cells, NK cells, and dendritic and B-cells that are responsible for cell mediated 
immunity (8). Although this simplified model still holds true, as scientific 
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evidence accumulates, we now know that individual HSCs gradually acquire 
lineage biases along multiple directions and do not necessarily pass through 
discrete hierarchically organised progenitor populations (9). Genetic defects in 
the different progenitors give rise to the different types of haematological 
malignancies that we know of today.  
 
Figure 1. 1 Normal haematopoiesis and Leukaemia stem cell model.  
Functional studies in acute and chronic leukaemias have led to the identification and 
characterisation of the leukaemic stem cell (LSC), which shares features with the 
normal haematopoietic stem cell (HSC). Leukaemic cells (LCs), also referred to as 
blasts, derive either from HSCs, multipotent progenitors (MPP) or committed 
progenitor cells (CMPs). They are characterised by increased self-renewal and 
reduced differentiation, compared to HSCs. 
 
1.2. Leukaemogenesis 
Leukaemogenesis is the process of developing leukaemia, during which many 
of the features of normal haematopoiesis are retained. Although genetic 
mutations in HSCs may pave the way for the malignant clonal expansion of 
leukaemic cells, these dominant clonal populations retain the hierarchical 
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organization found in normal haematopoiesis. Leukemic cells in acute 
leukaemias may acquire a primitive dysfunctional phenotype (10). 
Transcriptional regulators and signalling pathways that regulate the production 
of healthy blood cells may also be present in haematopoietic malignancies 
(11). Leukaemic cells replace normal bone marrow cells and, consequently, 
decrease and suppress haematopoiesis. Therefore, patients often present 
with anaemia, thrombocytopenia and granulocytopenia, that manifest in the 
form of frequent bruising or bleeding and a higher susceptibility to infections 
(12), resulting in fatigue and poor health.  
Haematological malignancies originate from myeloid or lymphoid progenitors 
residing in the bone marrow or lymph tissues. Major myeloid malignancies 
include acute myeloid leukaemia (AML), which is characterised by immature 
and poorly differentiated cells, chronic myeloid leukaemia (CML), which is for 
most patients characterised by more mature cells, and myelodysplastic 
syndromes (MDS), which are generally disorders of bone marrow maturation 
where the blast count (< 20% myeloid blasts) is lower than a definite diagnosis 
of AML (>20% myeloid blasts). The molecular heterogeneity of these 
malignancies are increasingly recognised and revisions of their classification 
are constantly underway (13).  
1.3. Acute Myeloid Leukaemia 
AML is the most common adult form of leukaemia and represents 
approximately 33% of all leukaemia cases in the UK. Over the last decade, 
AML incidence rates have increased by 8%, though this includes an incidence 
rate rise of 10% in male patients and stable rates in female patients (Cancer 
Research UK, 2014).  
1.3.1.  Genetic defects in AML 
A large body of evidence indicates that AML arises through the accumulation 
of genomic alterations which affect the genes regulating cell proliferation, cell 
death and the tightly regulated pathways of haematopoietic differentiation. 
These key oncogenic events are often divided into two classes according to 
the two-hit model hypothesis of AML leukaemogenesis. In this model, class I 
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mutations impair normal haematopoitic differentiation, due to changes in the 
tyrosine kinase pathways, conferring a proliferation or survival advantage to 
blast cells (e.g. mutations in the fms-like tyrosine kinase-3 (FLT3), c-
KIT/CD117 and RAS genes). Class II mutations are those that block myeloid 
differentiation and maintain self-renewability (e.g. via mutations in the 
AML1/ETO and CEBPA genes), or mutations that affect genes implicated in 
cell cycle regulation or apoptosis (e.g. p53 and nucleophosmin 1 (NPM1)) (14).  
However approximately 50% of AML patients do not carry a class I mutation 
and recent research has shown the presence of numerous common mutations 
which cannot be identified as either class I or II (15). These mutations, 
generally termed class III, incorporate mutations in epigenetic modifiers such 
as DNA (cytosine-5)-methyltransferase 3A (DNMT3A), and mutations in the 
hydoxylmethylation pathway, such as tet methylcytosine dioxygenase 2 
(TET2) and isocitrate dehydrogenase 1/2 (IDH1/2) mutations (16). These 
findings demonstrate the limitations of the two-hit model. Furthermore, the 
identification of new groups of mutations would extend our understanding of 
the complex pathogenesis of AML.  
In addition to genetic mutations, cytogenetic abnormalities can be detected in 
approximately 50% to 60% of newly diagnosed AML patients. These are 
mainly non-random chromosomal translocations that often result in gene re-
arrangements (17, 18). Cytogenetic and molecular genetic aberrations 
associated with AML are not mutually exclusive and often co-exist in the 
leukaemic cells (19). These co-existing aberrations can influence patient 
prognosis and/or predict response to therapy. Thus, their detection at the time 
of diagnosis represents an important clinical need.  
An analysis of data collected from the Medical Research Council (MRC) AML 
10 trial, which included 1612 children and adults up to 55 years of age, has 
shown that pre-treatment cytogenetics is an independent prognostic factor for 
AML. In this study, three prognostic groups (favourable, intermediate and poor 
prognosis) were defined by cytogenetic abnormalities detected at presentation 
in comparison with outcomes of patients with a normal karyotype (20).  
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Recently, McKerrell and colleagues developed and validated “Karyogene”, a 
comprehensive one-stop next generation sequencing (NGS)-based diagnostic 
platform for the genomic analysis of myeloid malignancies. It simultaneously 
detects substitutions, insertions, deletions, chromosomal translocations, copy 
number and zygosity changes in a single assay. The platform was validated 
on 62 AML and 50 MDS diagnostic samples previously characterised using 
conventional diagnostic approaches (21). The authors conclude that 
Karyogene represents an important advance that can accelerate the 
introduction of genomics to clinical diagnosis, this certainly holds true in the 
light of the complexity of AML.  
1.3.2. Classification of AML 
A marrow or blood blast count of ≥20% with blasts expressing myeloid 
associated lineage and precursor cell markers is required for AML diagnosis. 
Additional specific lineage markers are helpful for identifying mixed-phenotype 
acute leukaemia, and so these may also be used (22).  
The first descriptions of leukaemia as an alternation of “white blood” were 
made in 1844 by French physician, Alfred Donne, and a year later by John 
Hughes Bennett. In 1995, the Leukaemia Research Fund commemorated 
Bennett's work as the first description of leukaemia (23). What he imagined to 
be a single disease is now classified into multiple subgroups. The first 
internationally accepted classification of acute leukaemia was proposed in 
1976 by the French–American–British (FAB) Cooperative Group (24). It relied 
primarily on morphologic and cytochemical characteristics of patient samples, 
and did not account for the diverse cytogenetic background of AML patients 
within a given group, which was, of course, unrecognised at the time of writing. 
Thus, this classification is presently thought to provide limited prognostic 
information for these groups (25) . 
The more recent classification schemes proposed by the World Health 
Organization (WHO) require the additional evaluation of leukaemic blasts by 
molecular analysis and flow cytometry. This was last updated in 2008. Since 
then, there have been important advances in identifying unique biomarkers 
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associated with selected myeloid neoplasms and acute leukaemias, which 
were mainly obtained via gene expression analysis and NGS analysis (13). 
Revisions to the categories of myeloid neoplasms and acute leukaemia were 
published in a monograph in 2016 and reflect a consensus of the opinions of 
haematopathologists, haematologists, oncologists, and geneticists (Table 
1.1). The major changes in the classification and their rationale are presented 
in a review article by Arber et al (13) and summarised in Table 1.1 below. 
Dr. Elli Papaemmanuil and colleagues (26) extended the WHO profile by 
combining clinical and cytogenetic information with targeted sequencing of 
111 candidate driver genes in 1,540 AML patients. They concluded that 11 
distinct subtypes of AML could be distinguished in their study. Most of patients 
in the study were younger, undergoing intensive therapy and enrolled in trials 
of the German-Austrian AML study groups. Interestingly, the existing WHO 
classification system could not sufficiently categorise 50% of the study 
patients. A key finding was the identification of three novel genetic subgroups 
that were not previously described in the WHO classification. These included 
mutations in genes encoding chromatin, RNA-splicing regulators, or both (18% 
of patients); p53 mutations, chromosomal aneuploidies, or both (13% of 
patients); and an uncommon subgroup of IDHR172 mutation (1% of patients) 
(26). In terms of prognosis, this study identifies that prognostic effects of some 
driver mutations were influenced by the presence or absence of mutations in 
other genes. For example, FLT3-ITD conferred a particularly poor prognosis 
when combined with NPM1 and DNMT3A mutations, supporting the notion 
that the clinical effect of some driver mutations may have depended on the 
existence of co-mutations in a broader genomic setting. 
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Table 1. 1 WHO classification of AML and related neoplasms.  
Table extracted from Arber et al. 2016. 
Acute myeloid leukaemia (AML) and related neoplasms 
 AML with recurrent genetic abnormalities 
  AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1 
  AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11 
  APL with PML-RARA 
  AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A 
  AML with t(6;9)(p23;q34.1);DEK-NUP214 
  AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM 
  AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1 
  Provisional entity: AML with BCR-ABL1 
  AML with mutated NPM1 
  AML with biallelic mutations of CEBPA 
  Provisional entity: AML with mutated RUNX1 
 AML with myelodysplasia-related changes 
 Therapy-related myeloid neoplasms 
 AML, NOS 
  AML with minimal differentiation 
  AML without maturation 
  AML with maturation 
  Acute myelomonocytic leukaemia 
  Acute monoblastic/monocytic leukaemia 
  Pure erythroid leukaemia 
  Acute megakaryoblastic leukaemia 
  Acute basophilic leukaemia 
  Acute panmyelosis with myelofibrosis 
 Myeloid sarcoma 
 Myeloid proliferations related to Down syndrome 
  Transient abnormal myelopoiesis (TAM) 
  Myeloid leukaemia associated with Down syndrome 
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1.3.3. Current treatment of AML 
AML is primarily a disease of the elderly with a meidian age at diagnosis of 72 
years (quartile value, 60-79 years; range, 16-97 years; mean, 68 years) (27). 
Over the last 50 years there has been improved survival in the minority group 
of younger fitter patients mainly under the age of 65. However, older frail 
patients have seen no similar improvement, because the capacity to safely 
deliver the necessary intensive cytotoxic treatment to achieve a cure is 
compromised by the patients general physical health (28). 
AML in younger fitter patients is mainly treated with chemotherapeutic drugs 
that inhibit cell proliferation. Induction therapy with cytarabine and an 
anthracycline remains the standard of care in AML Treatment happens in two 
phases – (i) intensive induction therapy to abolish the bulk of leukaemia cells, 
and (ii) a tailored consolidation therapy, aiming to maintain long term 
remission. The standard approach involves 7-10 days of cytarabine and 3 days 
of anthracycline administration (29).  
Although advances in the treatment of AML have led to significant 
improvements in outcomes for younger patients, prognosis in the elderly who 
account for the majority of new cases remains poor (30). Even with current 
treatments, as much as 70% of patients aged ≥65 would die of their disease 
within 1 year of diagnosis (31). Current AML management still mostly depends 
on intensive chemotherapy and +/- allogeneic haematopoietic stem cell 
transplantation (HSCT), at least in younger patients who can tolerate such 
intensive treatments better, for older patients however, the existence of co-
morbidities (non-AML related factors) complicates treatment decisions and 
calls for more personalised management plans and frequent palliative 
symptom based care (32).  
1.4. The bone marrow microenvironment (BMM) 
The bone marrow (BM) is the major site of haematopoiesis and bone 
formation. Thus, in addition to containing haematopoietic cells, the BM 
contains cells that contribute to bone homeostasis. Recently, researchers 
have focused on the bone marrow microenvironment (BMM) and its role in 
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haematopoietic malignancies. Multiple studies have demonstrated that 
interactions with the different non-haematopoietic cell types in the BM 
contributes to the survival of leukaemic cells both in vitro and in vivo. 
Additional studies have shown that leukaemic cells compete for BMM 
resources, thereby creating a medium that co-participates in the development 
and progression of the disease. This section will give an overview of these 
studies and highlight the role of BM cells in regulating normal HSC function. 
1.4.1. Cellular components of the BMM  
The BM is made of a combination of cells that interact to regulate 
haematopoiesis, including arteriolar and sinusoidal type endothelial cells 
(ECs), osteolineage cells (osteoclasts and osteoclasts), fat cells (adipocytes), 
sympathetic neurons, non-myelinating Schwann cells, bone marrow 
(mesenchymal) stromal cells (BMSCs), CXCL12-abundant reticular cells 
(CAR cells), macrophages, megakaryoctyes and the extracellular matrix 
(ECM) (33, 34). These cellular components work in harmony to regulate all the 
steps of the haematopoiesis cascade, and are thought to affect HSC and HPC 
number, location, proliferation, self-renewal, and differentiation. Therefore, 
they are also likely to affect the production parameters of leukaemic cells 
similarly (35). 
Histological and functional assays indicated that HSCs and HPCs 
preferentially occupy the endosteal and subendosteal regions (endosteal 
niche) , closer to the bone surface (36). On the other hand, committed 
progenitors and differentiated cells are distributed in the central and peri-
sinusoidal regions (vascular niche), respectively (Figure 1.2) (37-39). BM cells 
are organised into niches that support specific subsets of haematopoietic 
progenitors. A niche is defined as the anatomical location in which HSC reside 
(40). The existence of the niche was first proposed by Schofield in 1978 (41). 
Since then, considerable progress has been made in defining the structure 
and components of the niche (42, 43), which has helped to understand the 
contribution of each individual cell type within the BMM to the pathogenesis of 
AML.  
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Figure 1. 2 A model of the haematopoietic stem cell (HSC) niche.  
Regions within the BM are broadly divided into endosteal and vascular niches. HSCs 
transit between the endosteal and vascular niche, the endosteal niche facilitates HSC 
maintenance and quiescence (the state of cell dormancy) while the vascular niche 
facilitates HSC proliferation and differentiation.  
 
Central to the establishment of the HSC niche are BMSCs, sometimes called 
multipotent or mesenchymal stem/stromal cells, which can differentiate into 
the different types of cells that make up the stromal components of the BM, 
including adipocytes, chondrocytes, myocytes, osteoblasts and osteoclasts 
(44, 45). The role of each of these cell types is extensively reviewed by Shafat 
et al. (46). The following sections will, however, focus on defining the BMSC 
population and explaining their role in haematopoiesis and in the 
leukaemogenesis of AML.  
1.4.2. Bone marrow mesenchymal stem cells (BMSCs) 
The identification of mesenchymal stem/stromal cells represents one of the 
most controversial and puzzling areas in stem cell biology. Recently, efforts 
have been made in this field to clearly define what BMSCs are and a common 
understanding is that they are ubiquitous in connective tissue and are 
phenotypically similar to skeletal progenitor cells and pericytes (46). Bianco et 
al., pioneers in the field of bone and marrow cell biology and development, 
have recently identified a progenitor for these BMSCs and have redefined 
them more stringently, based on in vivo differentiation capability, as skeletal 
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stem cells (SSC) (47). These cells are found on the surface of the blood 
vessels of the bone marrow (sinusoids) and are capable of organizing the 
haematopoietic microenvironment and stem cell niche (48). Sacchetti et. al. 
contributed further by demonstrating that BMSCs are not ubiquitous but have 
a different transcriptome and varying differentiation capacities for every tissue 
of a certain origin. They were identified as CD34 negative, CD45 positive, and 
CD146 positive cells and in the BM they are referred to as pericytes or 
perivascular cells (49).  
Conventionally, BMSCs cultured in vitro are characterised by their adherence 
to plastic, their capacity for osteogenic, chondrogenic and adipogenic 
differentiation, their expression of a panel of fibroblast related surface markers, 
(namely CD105, CD106, CD90 and CD73) and their lack of expression of 
haematopoietic markers such as CD34 and CD45 (50). This characterization 
approach was applied to the cells used in the research presented in this thesis.  
1.4.3. BMSCs and normal haematopoiesis 
Nearly all factors that regulate HSC maintenance are expressed by multiple 
cell types in BM niches, including BMSCs. These factors interact with their 
counterparts that are expressed on HSCs. The crucial decision between self-
renewal or differentiation and quiescence or proliferation is tightly regulated by 
the integration of intrinsic and extrinsic signals provided by the 
microenvironment in which HSCs reside (51).  
BMSCs secrete a number of cytokines that are essential for HSC function and 
maintenance, including CXCL12 (also called stromal derived factor-1, SDF-1) 
and stem cell factor (SCF) which are involved in HSC maintenance (35). 
Depletion of SDF-1 expressing BMSCs leads to reduced retention of HSCs 
and to reduced homing of transplanted HSCs (52). HSC homing to and 
retention in the BM, or its mobilisation to the peripheral blood is to a large 
extent regulated through SDF-1 (53). SDF-1 is produced by more than one 
type of BM cell including osteoblasts (54), BMSCs and CAR cells (55, 56). 
SDF-1 binds and activates the CXCR4 receptor on HSCs (56). This is 
demonstrated by studies in which the administration of plerixafor (Mozobil, 
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AMD3100) – a bicyclam that inhibits SDF-1 binding to CXCR4 – resulted in 
the mobilisation of HSCs to the peripheral blood of healthy subjects (57, 58). 
Other studies have shown that SDF-1 and CXCR4 binding activated a number 
of integrins such as very late antigen 4/5 (VLA-4/5) and lymphocyte function-
associated antigen-1 (LFA-1) on HSCs, which in turn induced cell adhesion to 
BMSCs and other BM cells that bore the vascular cell adhesion molecule-1 
(VCAM-1) and the intracellular adhesion molecule-1 (ICAM-1) (59).  
SCF functions by binding to c-Kit, a tyrosine kinase receptor expressed on all 
HSCs. It was found that even small changes in c-Kit signalling profoundly 
affected HSC function (60). Therefore, almost all cytokine combinations used 
for culturing HSCs, to date, include SCF. Deletion of SCF in perivascular 
BMSCs led to a decrease in HSC frequency in the BM of mice (61). The 
membrane-bound form of SCF is also an adhesive molecule for HSCs to the 
BMM (62).  
In addition to SCF and SDF-1, BMSCs isolated from BM produce several other 
haematopoietic growth factors and chemokines, including Flt-3 ligand (FL), 
thrombopoietin (TPO), the interleukins (IL) IL-6, IL-7 and IL-11, macrophage 
colony-stimulating factor (M-CSF), tumour necrosis factor-α (TNF-α), 
transforming growth factor-β1 (TGF-β1) and leukaemia inhibitory factor (LIF) 
(63, 64). Each of these factors, either individually or collectively, are known to 
contribute to haematopoietic homeostasis.  
1.4.4. The role of BMSCs in the malignant BM  
Genetic aberrations in self-renewing HSCs are well established as main 
intrinsic drivers of leukaemogenesis. These cells gain a competitive advantage 
over normal HSCs and give rise to the disease-propagating leukaemic cells, 
also referred to as leukaemic stem cells (LSCs) (65).  
In the haematopoietic niche, leukaemic cells interact with BMSCs to create a 
microenvironment that is favourable for leukaemic cell survival. BMSCs play a 
fundamental role in the growth, proliferation and survival of leukaemic cells, by 
facilitating interactions between them both through paracrine and autocrine 
signalling molecules. Furthermore, cell–cell and cell–matrix adhesion 
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promotes leukaemia cell survival through activation of pro-survival and anti-
apoptotic pathways, chemotherapy resistance, and consequently, the 
persistence of (minimal) residual disease (66-68).  
For example, both direct stromal contact and stroma-derived soluble factors 
are involved in extracellular regulated kinase (ERK)-mediated resistance to 
FLT3 inhibitors in FLT3-mutated AML (69) and resistance to anti-CD44 
therapy. CD44 is an adhesion molecule that is highly expressed by AML cells, 
where its inhibition induces differentiation and apoptosis of the leukaemic 
blasts (70-72). Likewise in CML, which overexpress CD44, anti-CD44 
treatment reduces CML burden in CML xenografts (73). BMSCs can also 
activate survival pathways in leukaemic cells. Recently, AML-derived BMSCs 
have been shown to induce NOTCH signalling in AML cells, the inhibition of 
NOTCH in AML abrogated their chemo-resistance (74). Goh and colleagues 
found that the blockade of a stromal derived cytokine, named colony 
stimulating factor-1 (CSF-1), delayed AML progression in vivo (75). These 
studies, thus, highlight the role of BMSC-derived signals in the progression of 
myeloid malignancies and their resistance to chemotherapy.  
The interaction between VCAM-1 and VLA-4 on BMSCs and AML cells, 
respectively, plays an integral role in the activation of nuclear factor kappa B 
(NF-κB) survival pathways in the stromal and tumour cell compartments (76). 
AML cells have been shown to express high levels of CXCR4 which responds 
to SDF-1 produced by BMSCs. Homing of leukaemic cells to the BM 
contributes to their protection from chemotherapy, which is why inhibitors have 
been developed to interrupt this interaction and mobilise AML cells to the 
peripheral blood where they can be killed by chemotherapy (77). In fact, the 
inhibition of the CXCR4–SDF-1 interaction overcomes AML cell line resistance 
to kinase inhibitors (78, 79).  
AML cells have been found to remodel BMSCs and increase their expression 
of SDF-1 (80). However, in a recent study Agarwal and colleagues showed 
that in a mouse model of CML, the decreased expression of SDF-1 by ECs 
reduced the number of long term repopulating HSCs, whereas the decreased 
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expression of BMSC-derived SDF-1 lead to an increase in the number of the 
HSCs (81). These findings suggest that SDF-1 serves different functions 
depending on its cell of origin.  
Since SDF-1 is expressed in both ECs and BMSCs (82) it could be assumed 
that a similar mechanism would hold plausible. A recent study has shown an 
interesting mechanism by which myeloproliferative neoplasm (MPN) cells 
caused the mobilisation of HSCs to the peripheral blood, due to increased 
neuropathy and BMSC apoptosis. These studies found that MPN-derived 
Interleukin-1β (IL-1β damaged Schwann cells that protect the endings of 
sympathetic nerves, leading to neuropathy, increased BMSC apoptosis, and 
the decreased expression of HSC retention factors and adhesion molecules 
by BMSCs (VCAM1, SDF-1 and SCF). This eventually lead to the mobilisation 
of normal HSCs to the peripheral blood (83). Taken together, these studies 
demonstrate that a deregulated expression of SDF-1 by BMSCs appears to 
be a common feature in myeloid malignancies.  
Extracellular vesicles, such as exosomes, traffic protein and RNA between 
cells and are key players in cell-cell communications (84). In multiple myeloma 
(MM), which is a malignancy of plasma cells, exosomes isolated from BMSCs 
of patients with MM induced MM tumour growth and promote disease 
progression in an in vivo translational model (85). Similar findings have 
recently been demonstrated in MDS where MDS- patient derived 
macrovesicles were found to contain microRNAs that differed from those 
derived from healthy donors, which induced changes in CD34+ HSCs in vitro 
(86). Stromal exosome trafficking is also a candidate mechanism for extrinsic 
chemoresistance within the AML niche. Stromal exosomes have been shown 
to be enriched for a number of known pro-tumoural factors, including TGF-
β1, MIR155 and MIR375 as well as cytokines essential for AML survival such 
as interleukin-8 (IL-8) (87). To summarise all the points above, BMSCs play a 
central role in AML pathogenesis via a multitude of cell-cell interactions.  
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1.4.5. Leukaemic cell remodelling of the BMM 
Leukaemic cells have been shown to modify niche signalling and to remodel 
the niche in their favour, allowing them to evade therapy and to disrupt normal 
HSC development (88-90). The mechanisms underlying this have been the 
focus of numerous studies. For instance, a number of AML mutations, 
including the FLT3-ITD mutation, can increase AML reactive oxygen species 
(ROS) levels (91), This in turn increases the proliferative ability of AML cells 
and, possibly, decreases the proliferation of the surrounding normal progenitor 
cells (92).  
AML cells can also actively participate in boosting the BM vascular density, 
which is a recognised feature of the leukaemic BM (93). This happens partially 
due to the AML activating the endothelial cells (EC) and recruiting them to the 
site of vasculogenesis, and by inducing the ECs to produce vascular-
endothelial growth factor (VEGF), which amplifies angiogenesis in the BM (94, 
95).  
Another common feature of myeloid malignancies is increased bone fibrosis. 
A landmark study by the Passegué laboratory demonstrated that through a 
combination of direct cell-cell contact and soluble factors (thrombopoetin, TPO 
and macrophage inflammatory protein 1a, MIP-1a), mouse CML cells were 
able to stimulate the overproduction of osteoblasts by BMSCs, thereby leading 
to fibrosis (96). In a human primary MDS co-culture model, MDS cells were 
sufficient to induce an MDS-like phenotype in BMSCs from healthy donors. 
MDS-like features included increased expression of proangiogenic factors 
(VEGF and IGFBP2 – insulin growth factor binding protein 2) and of fibrosis 
mediators such as LIF (97). Interestingly, MDS patients with fibrotic bone 
marrow are more likely to progress to AML than MDS patients with non-fibrotic 
BM features (98).  
As mentioned earlier in Section 1.4.4, communication between BMSCs and 
MDS cells is partly mediated by extracellular vesicles. CML-derived exosomes 
stimulate BMSCs to produce IL-8, which in turn can modify the leukaemic 
malignant phenotype in vitro and in vivo (99). Similarly, primary AML cells and 
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AML cell lines release microvesicles containing RNAs that has been shown to 
alter the secretory profile of murine bone marrow stromal cells (100). More 
recently, Kumar et al elegantly demonstrated that AML-derived exosomes 
primed animals for accelerated AML growth, they found that treatment of 
BMSCs with AML-derived exosomes decreases the expression of genes 
supporting normal haematopoiesis and osteogenesis and increases 
expression of genes supporting AML growth (101). Therefore, exosomes 
appear to be part of the malignant phenotype across a spectrum of myeloid 
malignancies. 
Jacamo and colleagues very recently performed gene expression profiling of 
BMSCs isolated from normal C57BL/6 mice versus BMSCs isolated from mice 
inoculated with syngeneic murine leukaemia cells carrying different human 
AML genotypes (that were developed in mice with p53 wild-type or nullgenetic 
backgrounds). They revealed that all the tested AML genotypes modified a 
unique set of genes in the BMSCs. Also, that there were sets of differentially-
expressed genes in AML-exposed BMSCs that were unique to the particular 
AML genotype or p53 status (102). These findings support the hypothesis that 
AML cells alter the transcriptome of BMSCs, in both common and genotype-
specific ways, and might, in part, explain the variation in response to therapy 
that is observed in AML patients of different genetic profiles. 
Taken together these findings reinforce the notion that AML cells and BM niche 
cells are tightly interweaved dynamic structures that, together, drive the 
development and progression of disease in the BM microenvironment. 
1.4.6. Niche-induced oncogenesis 
Different niche cells can harbour genetic defects that may initiate and 
contribute to AML development. This is termed niche-induced oncogenesis. 
For instance, genetic modifications such as the deletion of Dicer1 (coding for 
a protein involved in microRNA biogenesis) and SBDS (the gene mutated in 
Schwachman–Bodian–Diamond syndrome, related to bone marrow failure 
and with a high risk of developing leukaemia) in osteoprogenitor cells led to 
MDS and secondary AML in murine models (103-105). Reduced expression 
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of Dicer1 and the SBDS gene has also been observed in BMSC from patients 
with MDS (106, 107). Geyh and colleagues reported that AML and MDS 
derived BMSCs had limited osteogenic differentiation, partially due to an 
overexpression of Jagged1, a NOTCH signalling ligand (108, 109).  
Cytogenetic abnormalities have been reported in 30-70% of BMSCs from MDS 
and AML patients, albeit in relatively small sample sizes (110, 111). Further 
studies have shown that BMSCs originating from MDS and AML patients have 
a distinct expression profile and harbour some genetic abnormalities that are 
believed to be pro-leukaemic (112-114), including transcriptional (97) and 
epigenetic modifications (115). Other studies, however, report that BMSCs 
from MDS, CML and AML patients exhibit normal differentiation, adhesion, 
expression, survivability and a capacity to normally support haematopoiesis in 
vitro (116, 117). Overall, these studies leave us with an open debate as to 
what the functional consequences of genetically deregulated BMSCs might 
mean for myeloid malignancies.  
1.4.7. Chemokine and cytokine profiles in the malignant BM 
Cytokines and chemokines are involved in the cross talk between AML cells 
and the microenvironment. Systemic (serum or plasma) chemokine levels are 
suggested to serve as biomarkers for disease development or activity, as well 
as treatment responses (118). The overexpression of cytokines in AML 
patients declines in complete remission, suggesting that these events are 
dependent on AML activity and, in part, due to autonomous blast cytokine 
secretion (119). High constitutive release is not necessarily associated with 
increased systemic chemokine levels however, this may, at least, partly be 
explained by the fact that the systemic levels are determined by a balance 
between release and binding/degradation. This observation also 
demonstrates that systemic cytokine levels do not necessarily reflect the local 
BM cytokine network (118).  
Deregulated cytokine, chemokine and growth factor expression, and abnormal 
responsiveness to the aforementioned in leukaemia are well documented 
(120). For example, levels of interleukin-3 (IL-3), interleukin-6 (IL-6), 
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interleukin-8 (IL-8), thrombopoietin, tissue necrosis factor alfa (TNF-α), 
macrophage colony-stimulating factor (M-CSF), interferon-γ (IFN-γ), and SCF 
have been shown to be elevated in leukaemia patients compared to healthy 
controls (121). AML patients with a lower serum concentration of hepatocyte 
growth factor (HGF) had improved leukaemia-free survival rates compared to 
patients with higher HGF levels (122). In AML and MDS patients, higher levels 
of TNF-α negatively affected overall survival (123), whereas increased VEGF-
A levels correlated with reduced survival in AML (124). These studies have 
mainly focused on cytokines, chemokines, and growth factors that are typically 
found in the serum of untreated or treated AML patients. Nevertheless, 
cytokine and chemokine profiles of BM samples from AML patients are 
relatively fewer, and are mainly derived from in vitro co-culture studies that aim 
to replicate the microenvironment.  
A recent study by Reikvam and colleagues looked at the cytokine network in 
co-cultures of cells derived from 18 unselected AML patients, as well as with 
BMSCs derived from three healthy donors. They report that BMSCs cultured 
on their own showed relatively high levels (comparable or higher than the 
corresponding median level for AML cells alone) of IL-8, IL-6, and a few matrix 
metalloproteinases (MMP) (such as MMP-1, MMP-2 and TIMP-1). The levels 
of these mediators in AML–BMSC co-cultures were also relatively high, and 
included IL-8 and IL-6. Interestingly, normal HSCs did not induce as much 
change when co-cultured with BM-MSCs. AML cells increased the BMSC 
expression of genes involved in TLR initiated and NFκB mediated intracellular 
signalling, which is vital to cytokine/chemokine signalling in these cells (68).  
A more recent study by Lope and colleagues employed a similar approach and 
methodology. However, this study used patient-derived BMSCs, and they 
reveal that de novo AML derived BMSCs expressed high levels of SDF-1, 
receptor of prostaglandin E2 (RPGE2), indoleamine 2,3-dioxygenase (IDO), 
interleukins IL-1β, IL-32, IL-6 and VEGF, which are secreted by the leukaemic 
cells to promote their survival and proliferation. Furthermore, the increased 
SDF-1, RPGE2 and IDO levels helped in remodelling the mesenchymal niche 
in the BM (125).  
40 
 
 
 The cytokine/chemokine release profile of the bone marrow is modified by a 
number of factors including hypoxia, differentiation status, pharmacological 
interventions, and T-cell cytokine responses (126). So far, the best 
investigated single chemokine in AML is SDF-1, which binds to CXCR4, and 
which has been discussed in previous sections of this introduction (sections 
1.4.3 and 1.4.4). Also of particular importance is IL-8, which is usually released 
at highest levels (126, 127). The research from this thesis will partially address 
the regulation of the AML pro-survival cytokine, IL-8, in the stromal 
compartment. 
The following sub-sections will review cytokines and chemokines that are of 
relevance to the work presented in this thesis.  
1.4.7.1. Interleukin-8 (IL-8) 
IL-8, also called CXCL8, is a pro-inflammatory chemokine, which was first 
discovered to be associated with the promotion of neutrophil chemotaxis and 
degranulation (128). This chemokine activates multiple intracellular signalling 
pathways downstream of two cell-surface G protein–coupled receptors 
(GPCRs), namely CXCR1 and CXCR2 (129). Increased expression of IL-8 
and/or its receptors has been observed and characterised in cancer cells, ECs, 
infiltrating neutrophils, and tumour-associated macrophages (130).  
Bruserud and colleagues attempted to classify a cohort of AML patients based 
on constitutive chemokine release from AML cells. They investigated the 
release of a wide range of chemokines from 68 primary human AML blasts, 
and learned that chemokine levels varied widely, even for those patients with 
detectable release. They found that the highest level of constitutive expression 
was detected for IL-8, a mediator angiogenesis in the BM via its receptor, 
CXCR2 (127, 131). This data sggests that IL-8 may function as a significant 
regulatory factor within the tumour microenvironment. In fact, the importance 
of IL-8 and CXCR2 in the pathogenesis of cancer comes from studies in solid 
tumour, and in particular preclinical studies in breast cancer, in which IL-8 
seemed to have an important microenvironmental role (132-134).  
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In AML, evidence of the importance of IL-8 to leukaemic cells dates back to 
1993 (135). IL-8 was found to be overexpressed (136), and moreover serum 
IL-8 levels were found to be increased in haematological malignancies 
compared to healthy controls (137). Interestingly, in normal haematopoiesis, 
IL-8 seems to play an inhibitory role in proliferation and differentiation (138, 
139), which suggests that IL-8 provides a survival advantage to leukaemic 
cells. 
Jacamo et al. reported high IL-8 mRNA levels in BMSCs derived from AML 
and acute lymphoblastic leukaemia (ALL) patients, compared to BMSCs 
derived from healthy donors. In addition, co-cultures of normal BMSCs with 
AML and ALL cell lines and primary samples induced the expression of IL-8 in 
an NF-κB-dependent manner (76). Finally, in an another study, inhibition of 
the IL-8 receptor, CXCR2, selectively inhibited proliferation of MDS/AML cell 
lines and patient samples (140). Together, these studies suggest a complex 
role for IL-8 in regulating the survival and proliferation of multiple tumours, 
including AML. 
1.4.7.2. Interleukin-6 (IL-6) 
IL-6 is a multifunctional cytokine, with pleiotropic inflammatory effects, and is 
important for immune responses, cell survival, apoptosis, and proliferation 
(141). IL-6 has been reported to be important for the development of CML 
(142). A monoclonal antibody directed against human IL-6 has been evaluated 
in haematological malignancies such as MM, MDS and non-Hodgkin 
lymphomas (143). AML cells have been shown to secrete IL-6, however, IL-6 
on its own is not known to be sufficient to stimulate in-vitro colony formation. 
Rather, it acts as a co-stimulator to enhance CSF-induced clonogenicity of 
AML blast cells (144).  
Sanchez-Correa and colleagues reported that in AML, patients with higher 
serum IL-6 and lower serum IL-10 levels had worse survival rates than those 
with low IL-6 serum levels. Contrary to IL-8 which is consistently reported to 
be pro-leukaemic, IL-6 demonstrated different effects (stimulatory, inhibitory 
or neutral) on the growth of leukaemic cells derived from AML and MDS 
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patients (123, 145). These studies suggest that the role of IL-6 in AML remains 
undefined.  
1.4.7.3. Macrophage migration inhibitory factor (MIF)  
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that, 
under normal conditions, regulates cell mediated immunity and inflammation 
(146). MIF was originally discovered in 1966 by Bloom and Bennett as an 
activated T-cell and macrophage derived cytokine (147). In the early 1990s, 
MIF was rediscovered as a clinically relevant factor that potentiated lethal 
endotoxemia (defined as the presence of endotoxins in the blood) (148). In 
contrast to other pro-inflammatory cytokines that require de novo synthesis 
before being secreted MIF is pre-formed and stored within vesicles in the cell 
cytoplasm, allowing for rapid release upon cell stimulation (149).  
Recently, a study investigating metastasis of pancreatic ductal 
adenocarcinomas showed that MIF can also be transported in exosomes that 
affect surrounding niche cells (150). The MIF gene does not encode for a N-
terminal signal sequence and, therefore, the MIF protein cannot translocate to 
the endoplasmic reticulum (ER) for mediated secretion, following the classical 
ER pathway. MIF is released from cells via a non-classical pathway involving 
the ATP-binding cassette transporters (ABCA1), and exhibits autocrine as well 
as paracrine effects (151).  
In terms of biological function, MIF has been shown to override the anti-
inflammatory effects of glucocorticoids and its plasma levels have been shown 
to correlate to cortisol circadian levels. These observations led some to 
propose its principal role as that of an endogenous counter regulator of 
glucocorticoids (152, 153). In the context of human cancers, studies have 
shown that MIF can inhibit p53-mediated apoptosis of human lung 
adenocarcinoma cell lines and stimulate cell proliferation (154). Moreover, 
MIFs have also been shown to affect cell migration and chemotaxis in a 
pulmonary metastasis model, where it was identified as a key effector of 
human MSC tumour homing in vitro (155). These studies together suggest a 
wide spread activity of MIF in normal and malignant cells.  
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MIF has been shown to exert its effects by binding to CD74, CXCR2, CXCR4 
and CXCR7 chemokine receptors (156). CD74 is MIFs widespread and most 
extensively studied receptor. It is a cell surface protein expressed as the 
invariant chain (Ii) of the major histocompatibility complex class II (MHC II) and 
forms a complex with CD44, initiating an intracellular signalling cascade (157, 
158). Moreover, emerging evidence suggests the formation of heterodimers of 
CD74 with either CXCR2 or CXCR4 (159, 160) and MIF binding to CXCR7 
(161).  
In cancer, MIF has been shown to be overexpressed in various types of solid 
tumours including breast, prostate, and colon (162-164). In a model of lung 
cancer, a suicide substrate inhibition of MIF inhibited lung adenocarcinoma 
cell migration and anchorage-independent growth (165). In haematological 
malignancies, namely chronic lymphocytic leukaemia (CLL) and MM, MIF is 
believed to drive malignant development (166, 167). A number of mechanisms 
have been proposed as to how MIF may influence the development of cancer. 
Recently, MIF has been shown to induce NF-kB activity and increase the 
expression of antiapoptotic molecules (168). Early evidence for MIF 
involvement in haematological malignancies came from a mouse model of 
myc-driven B-cell lymphoma where loss of MIF expression was shown to delay 
the onset of B-cell lymphoma development (169). In CLL, it has been shown 
that MIF is expressed by the malignant cells and induces protective IL-8 
release in an autocrine dependent manner, and that blocking either MIF or IL-
8 reduces the survival of CLL cells (170).  
Taken together, these studies show that the heightened expression of MIF and 
the increased secretion of IL-8 has wider significance to the tumour 
microenvironment. This is of particular interest in AML, as evidenced by the 
role of IL-8 in its development. The role of MIF in AML remains to be addressed 
and the research in this thesis will in part define the role that MIF plays in the 
AML microenvironment.  
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1.4.8. Cell signalling in the AML microenvironment 
Cytokines, chemokines, and adhesion molecules activate pro-survival 
signalling pathways in their target cells. A number of signalling pathways have 
been identified in AML. These include, but are not limited to the 
phosphatidylinositol-3 kinase PI3K/Akt/mTOR, mitogen-activated protein 
kinase (MAPK), signal transducer and activator of transcription 3 (STAT3), and 
NF-κB pathways, that regulate downstream components by promoting 
autonomous and microenvironment dependent survival and proliferation of 
AML cells (171).  
Simultaneous activation of signalling pathways have been shown to confer 
adverse prognosis for AML patients (172). Several therapies have been 
developed to target these pathways in AML cells. However due to AML being 
a heterogeneous disease, and also due to the fact that these signalling 
pathways are important for stromal cells in the BM micro-environment, 
therapies undergoing developed will need to take these factors into 
consideration.  
The following sections will briefly review the signalling kinase pathways that 
are relevant to the research presented in this thesis.  
1.4.8.1. Phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR signalling  
The members of this pathway control the expression of proteins that regulate 
both apoptosis and cell cycle progression/proliferation (173, 174), and cell 
migration downstream of the SDF-1/CXCR4 axis (175). Studies have shown 
that 50%–80% of AML patients display Akt that is phosphorylated at T308, 
S473 or both. The causes for the activation of PI3K-Akt-mTOR signalling 
include activating mutations in FLT3, c-KIT/CD117 or RAS genes, as well as 
growth factor stimulation such as SDF-1. Taken together this has made 
inhibition of PI3K-Akt-mTOR a strong therapeutic strategy of interest in AML 
(176).  
It is however, important to remember that this pathway is also important for 
signalling in other cellular components of the BM, including BMSCs, where it 
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is involved in BMSC differentiation into the three mesenchymal lineages and, 
furthermore, trans-differentiation into myoblasts and neurons (177). Moreover, 
the pathway is important for BMSC adaptation to the hypoxic BM 
microenvironment (178), and for regulation of BMSC metabolism and the 
induction of autophagy (179). Finally, the pathway contributes to the regulation 
of BMSC communication with other BMM cells (180). As a result, one would 
expect PI3K-Akt-mTOR inhibition to alter the BMSC functional characteristics 
and thus also affect the AML BM microenvironment crosstalk.  
1.4.8.2. Mitogen-activated protein kinase (MAPK) signalling 
Three major groups of MAP kinases exist: the p38 MAP kinase family, the 
extracellular signal-regulated kinase (ERK) family, and the c-Jun NH2- 
terminal kinase (JNK) family. All three are important signalling molecules in 
normal hematemesis as well as in leukaemogenesis (181). The relevance of 
these pathways in AML has been shown in several reports describing a 
constitutively activated MAPK in AML (182, 183). Therapeutic targeting of 
MAPK activation using a pharmacological blocker, PD98059 decreases both 
growth and survival of AML cell lines as well as primary cells (184).  
The ERK pathway has been shown to cooperate with FLT-3 in regulation of 
cell survival (185). Moreover, BMSCs are known to activate PI3K/Akt and 
ERK/MAPK in FLT3 mutant AML cells, and to confer resistance to both 
chemotherapy and FLT3 inhibition (78). MAPK signalling in the stromal 
compartment is relatively less defined. Studies however, have exhibited the 
activation of this pathway in BMSCs. In a Chinese study, AML derived 
proteases have been shown to up-regulate VEGF production in AML BMSCs 
via the PAR-2, ERK1/2, and MAPK signalling pathways (186). Moreover, in a 
study on paediatric MDS, inhibition of MAPK disrupted proinflammatory factor 
production by MDS-derived BMSCs. Da Costa and colleagues observed 
MAPK to be constitutively expressed in MDS-AML derived BMSCs (187).  
1.4.8.3. Protein kinase C (PKC) signalling 
The PKC family comprises of 12 closely related serine/threonine kinase 
isoforms. Mammalian PKCs share common catalytic domains but differ in their 
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regulatory domains which dictate the co-factors required for required for the 
kinases’ activation (188). PKC isoforms are subdivided into three subfamilies 
according to their activation profiles: conventional PKCs (cPKC: α, βI, βII, γ), 
novel PKCs (nPKC: δ, ε, η, θ), atypical PKCs (aPKC: ζ, ι/λ), and additionally, 
the more distantly related PKCμ/PKD and PKCν (189). conventional PKCs 
require DAG, Ca2+, and phospholipid for activation. Novel PKCs do not require 
Ca2+ for activation, but are still dependent on phospholipids and DAG. Atypical 
PKC isoforms are activated independently of Ca2+ and DAG (190, 191). 
PKCs are ubiquitously expressed and are essential for the regulation of cell 
proliferation, apoptosis, differentiation and migration (190, 192). PKCs have 
been linked to oncogenes, including RAS and MYC, which places them at the 
core of cancer signalling pathways (193). Interestingly not all PKCs act as 
oncoproteins, for example, PKCδ is anti-apoptotic in CLL (194), but pro-
apoptotic in AML (195, 196). Also, PKCα shows proliferative functions in 
several malignancies but has antiproliferative functions in colon cancer cells 
(197). In AML, high levels of PKCα conferred an adverse prognosis for AML 
patients (198), while a PKCδ agonist, PEP005, induces apoptosis in AML cells 
(199). Interestingly, PEP005 can increase the release of several cytokines, 
both via AML cells and the neighbouring non-leukaemic immune cells (200). 
Activation of PKC in the stromal environment has first been shown in CLL 
where the co-culturing of CLL cells with BMSCs led to an up-regulation in 
PKCβII expression, and the consequent activation of NF-κB signalling in 
BMSCs, which was essential for CLL cell survival (201). Part of the research 
presented in this thesis investigates the role of PKCs in AML remodelling of 
BMSCs.  
1.5. Hypoxia in Cancer 
Hypoxia is defined as a sub-physiological level of oxygen; the physiological 
range varies due to diverse vascular density in different organs (202). Hypoxic 
conditions develop during cancer progression due to rapidly proliferating 
tumour cells that reduce O2 diffusion, as well as due to impaired perfusion of 
the abnormal blood vessels in the tumour. The oxygen level in hypoxic tumour 
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tissues is found to be less than 1.3% O2, far below the physiologic oxygenation 
level (5%–10% O2) (203).  
The presence of hypoxia in cancerous tissue was first reported in solid 
tumours. In 1955, Thomlinson and Gray observed in samples of human lung 
cancer tissue that hypoxic, yet viable, lung carcinoma rods were surrounded 
by a necrotic core caused by a tissue oxygen gradient (204). All types of solid 
tumours, in particular malignant solid tumours, are subject to hypoxia. Often 
displaying oxygenation levels significantly lower than their tissue of origin, 
hypoxia in solid tumours is widely involved in angiogenesis, metastasis, and 
tumour resistance (205). The overexpression of hypoxia-inducible factor alpha 
(HIFα) subunits in solid tumours is associated with aggressive cancer 
phenotype and is correlated with poor overall survival of patients (206). As 
haematological malignancies are not considered solid tumours, the role of 
hypoxia in these diseases was initially presumed to be insignificant (207). 
However, hypoxia is a hallmark of the haematopoietic niche (208, 209) and is 
now an actively researched topic in haematological malignancies.  
Next, the current understanding of the role of both, hypoxia and hypoxia-
inducible factors in the BMM, will be reviewed. 
1.5.1. Hypoxia inducible factors (HIFs)  
The hypoxic state is principally maintained by members of the hypoxia-
inducible factor (HIF) family. Both HIF1α and HIF2α respond to hypoxia; HIF1α 
responds to acute hypoxia and HIF2α to a chronic hypoxic state (210). HIF1α 
is expressed ubiquitously in all cells, whereas HIF2α is selectively expressed 
in specific tissues, including vascular ECs and cells of the myeloid lineage 
(211).  
Upon hypoxia, the HIFα subunits are stabilised and accumulate in the nucleus, 
where they dimerise with HIF1β, allowing them to bind to DNA and stimulate 
the transcription of their target genes. There are over 70 known direct HIF 
target genes that function in normal physiology and disease processes. One 
of the largest functional categories of HIF target genes include those 
responsible for a shift in cellular energy metabolism from oxidative 
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phosphorylation towards glycolysis (212). Gene expression profiling confirms 
significant overlap between HIF1α and HIF2α regulated genes with a degree 
of non-redundancy of function, and differential basal and cell-specific 
expression of the HIFα isoforms (213). Notably, HIF1α and HIF2α exhibit 
different degradation kinetics, which have been shown to be cell-specific 
(214). To be tagged for degradation, the α subunits are hydroxylated at 
conserved prolyl and asparaginyl residues by prolyl-hydroxylases (PHD), and 
are targeted for degradation by the von Hippel-Lindau (VHL) ubiquitin E3 
ligase complex. Inhibition of hydroxylation results in the stabilisation of HIF1α 
and HIF2α, and leads to the transcriptional activation of target genes (215). 
The process of HIF stabilsation is depicted in Figure 1.3 (216). HIFs can also 
be stabilised independent of hypoxia, for instance in response to infections 
(217) and, chromosomal mutations. For example, aberrant c-Myc activation in 
MM (218) and growth factor signalling pathways such as PI3K and AKT, which 
upregulate protein translation of HIF genes (219). Non-hypoxic 
HIF1α stabilsation can also be achieved through loss-of-function mutations 
in VHL, and lead to the full activation of HIF-mediated responses (220).  
 
 
Figure 1. 3 Hypoxia gradient across the bone marrow.  
The upper panel showing the oxygen-dependent degradation of HIF-α subunits, 
which when hydroxylated by prolyl hydroxylases (PHD) are ubiquitinated by the von 
Hippel-Lindau (VHL) complex and undergo proteasomal degradation. The lower 
panel shows the stabilisation of hypoxia-inducible factor α (HIF-α) subunits in low 
oxygen tension, and their heterodimerisation with the beta subunit, followed by 
translocation to the nucleus, and binding to the hypoxia response element along with 
other co-factors and transactivation of target genes. 
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1.5.2. Hypoxia as a component of the BMM 
Several studies have analysed aspects of the composition and function of the 
complex bone marrow microenvironment. Spencer and colleagues measured 
oxygen pressure in live animals and found that cells residing in perisinusoidal 
areas, further away from the bone surfaces, encounter the lowest oxygen 
concentrations (pO2 of ∼5-20 mmHg or 2%) compared with those in the 
proximity of arterioles (pO2 of ∼35 mmHg or 4%–5%) (221). Jensen et al. 
observed an increase in BM hypoxia during disease progression, using a rat 
AML model. The BM became increasingly hypoxic, as detected by 
nitroimidazol, and hypoxic conditions were observed in 80% of AML cells in 
the bone marrow of rats and in 40% of circulating cells (222). Using 
pimonidazole staining for measuring hypoxia levels, Konopleva et al. elegantly 
demonstrated the high levels of hypoxia in human leukaemic BM (223).  
In numerous other studies that aimed to define the haematopoietic niche, the 
BM has been shown to be hypoxic (224-227). Consequently, BM hypoxia is 
now a well-established key microenvironmental factor that influences the 
biology of the HSC as well as of leukaemic cells within the BM (209, 228, 229). 
A number of studies have shown that LSCs tend to localize in the more hypoxic 
regions of the BM (Figure 1.4) (208, 230, 231), However, in situ tissue analysis 
showed that HPCs exhibited a hypoxic profile regardless of cell-cycle status 
or localisation throughout the BM, suggesting that the distinctive hypoxic state 
of HPCs was a result of hypoxic niches as well as of cell-specific mechanisms 
(232). 
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Figure 1. 4 The Hypoxia gradient across the bone marrow.  
Diagram showing the distribution of leukaemic cells in the BM. More primitive, non-
cycling leukaemic stem cells (LSC) localise to the hypoxic endosteal niche, while 
actively cycling leukaemic cells localise to the vascular niche.  
 
1.5.3. The role of hypoxia in HSC versus leukaemic cells 
The link between CXCR4 and hypoxia has been suggested: (i) after the 
recognition that the CXCR4 and SDF-1 genes are targets of HIF1α, and (ii) 
after the observation that at 1% O2 CXCR4 is up-regulated on monocytes, 
monocyte-derived macrophages, tumour-associated macrophages, ECs, and 
cancer cell lines (233). In relation to homing and migration, hypoxia has been 
shown to regulate SDF-1 (234) and CXCR4 expression on HSCs (235). These 
observations suggest that hypoxia enhances retention of HSC and arguably 
leukaemic cell retention in the BM as well.  
Interestingly, HSCs seem to downregulate CXCR4 in response to 
pharmacological HIF1α induction, whereas HIF1α activation induces the 
opposite effect in leukaemic cells (236, 237). In fact, Azab and colleagues 
demonstrated that hypoxia regulates the trafficking of CML cells. Hypoxia was 
shown to decrease the CML expression of E-cadherin and increased CXCR4 
expression in vivo and in vitro, resulting in decreased adhesion to BMSCs and 
enhanced chemotaxis (238). Moreover, blockade of HIF1α impairs CLL cell 
homing into the BM and spleen in mouse models (239).  
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In AML, Fiegl and colleagues found that mild hypoxia (6% O2) increased 
CXCR4 surface expression on AML cells and its association to lipid rafts, 
conversely, re-oxygenation (20% O2) resulted in CXCR4 depletion (240). 
Hypoxia was shown to be important in maintaining leukaemia initiating cells 
(LIC) in vitro; Griessinger et. al. have shown that hypoxia is vital factor in 
creating an in vitro niche culture system, where AML LIC were cultured over a 
stromal cell feeder layer under hypoxia, incubated with recombinant IL-3, G-
CSF and thrombopoietin and maintained in a stem-like state for over three 
weeks (241). Consequently, inhibition of hypoxia eliminated these cells. 
Indeed, in a murine model, the HIF1α inhibitor echinomycin seemed to 
selectively spare the self-renewal and differentiation capacity of normal HSCs 
while targeting AML leukaemic stem cells (242). Interestingly, in a more recent 
study on normal HSCs, data showed that HIF1α was dispensable for self-
renewal and long-term haematopoiesis in normal, unstressed HSCs (243). 
Finally HIF1α was found to be highly expressed in the BM biopsy sections of 
normal karyotype AML patients and to be negatively correlated with survival 
(244). These observations suggest a fundamental difference in the role of 
hypoxia in HSCs versus leukaemic cells.  
Understanding the altered hypoxic profile of the malignant BM has led to 
investigating the efficacy of a number of pro-drugs that are showing promising 
results in preclinical and clinical studies in solid tumours. Currently there are 
two hypoxa-activated prodrugs that are being investigated in AML:  
(i) TH-302, which effectively inhibited onset and progression of AML, 
extended the overall survival, both in systemic AML xenograft 
models and in mice with advanced AML disease. In vitro, TH-302 
decreased HIF1α protein expression and reduced ROS 
production, which resulted in decreased proliferation and 
increased cell-cycle arrest (245, 246). 
(ii) PR-104, which was evaluated in patients with refractory/relapsed 
AML in phase I/II study. Although PR-104 reduced hypoxia 
markers in this study, the treatment responses were transient and 
52 
 
 
higher doses resulted in prolonged myelosuppression (223). 
Nevertheless, these biomarker studies provided further evidence 
that hypoxia is a prevalent feature of the leukaemic 
microenvironment (247). 
 
1.5.4. HIF1α and HIF2α in AML leukaemogenesis 
Using a murine AML model, Velasco-Hernández et al investigated the 
contribution of HIF1α to AML leukaemogenesis using models of oncogene-
driven AML. Either Meis1 or Mml (both known to activate HIF1α) were retro-
virally transduced into HSCs of HIF1α conditional knockout mice, and 
subsequently transplanted into wild-type recipients. The authors found that 
HIF1α loss-of-function did not affect AML initiation, progression or LSC self-
renewal in the Meis1/Mml1- driven models, whereas it shortened LSC latency 
and accelerated disease in a third HIF1α-independent Aml1-Eto9a-driven 
AML model (248, 249).  
Altogether, these results suggest that the oncogene-enforced expression of 
HIF1α does not play a role in leukaemia dormancy, and that HIF1α does not 
act as a classical oncogene or tumour suppressor in this particular molecular 
context. However, one can conclude from the third Aml1-Eto9a-driven AML 
model, in which HIF1α expression was independent of oncogene expression 
(and therefore was more subject to BM microenvironmental hypoxia) that 
hypoxic HIF1α stabilsation limits AML progression, but not initiation, making it 
a tumour suppressor in this context (249).  
In agreement with this study, pharmacological HIF1α inhibition with 
echinomycin decreased CD34+CD38– LSC self-renewal and engraftment 
after serial transplantations in a mouse model of human AML. This effect was 
lost by HIF1α silencing, suggesting that the inhibition of HIF1α-dependent 
transactivation is a reasonable approach to eradicate LSCs in AML, thus, in 
theory, reducing the risk of relapse (250). 
Fewer studies have investigated HIF2α function in HSC and leukaemic cells. 
Recent work by Rouault-Pierre and colleagues showed that HIF2α silencing 
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in patient-derived AML cells impaired engraftment in mouse transplantation 
experiments (251). In agreement with this, ectopic overexpression of 
HIF2α accelerated disease progression in mouse AML models (252). In an 
elegant study, Vukovic et al. further addressed the role of both HIF1α and 
HIF2α in AML initiation and progression where they used a mouse model in 
which leukaemia was induced through co-expression of the AML proto-
oncogenes Meis1 and Hoxa9. They showed that simultaneous deletion of 
HIF1α and HIF2α in pre-leukaemic HSCs resulted in a synergistic increase of 
AML proliferation and progression. Although HIF2α silencing on its own did 
not impair LSC clonogenicity, it did increase the percentage of cycling cells 
(253). Taken together, these data suggest that HIF1α and HIF -2α can 
cooperate to maintain LSC quiescence, thus promoting self-renewal of the 
stem cell compartment. 
HIFs have also been implicated in chemotherapy resistance of AML. AML 
chemoresistant LSCs were shown to favourably localize in the hypoxic 
endosteal regions of the mouse BM where they were protected from the 
proapoptotic effect of the chemotherapeutic agent Ara-Ca. Moreover, it has 
shown that hypoxic HIF1α stabilsation decreased the in vitro sensitivity of AML 
cell lines to cytosine arabinoside (Ara-C) (254). 
1.6. Senescence in health and disease 
Being a disease of the elderly, AML poses the question of whether age-related 
biological processes contribute to the pathology of the disease. One important 
process in aging is cell senescence. Cellular senescence was described over 
five decades ago by Hayflick (255) and it is defined as a state of irreversible 
arrest of cell proliferation in response to persistent DNA damage induced by a 
variety of potentially oncogenic signals. It is thought to function as a primary 
tumour-suppression mechanism (256).  
In addition to arrested growth, senescent cells are thought to be “in disguise”, 
concealing a highly active metabolic cell state with diverse functionality. 
Furthermore, senescent cells show widespread changes in chromatin 
organization and gene expression (257). These changes include the secretion 
54 
 
 
of several inflammatory cytokines, chemokines, growth factors and matrix-
remodelling factors, in a newly identified phenotype of cellular senescence, 
called senescence-associated secretory phenotype (or profile) (SASP). SASP 
incites not only tumour-suppressive, but also tumour-promoting responses, 
depending on the biological context (258, 259).  
There is growing evidence that senescent cells contribute to age-related 
phenotypes and age-related pathologies (260). Furthermore, in the context of 
cancer, several cellular functions and organs can undergo distinct pathologic 
pro-tumoural changes (261). However, although SASP can contribute to a pro-
carcinogenic microenvironment, recent findings show it can also promote 
tissue remodelling and wound healing (262). Therefore, depending on the 
context, it is now clear that cellular senescence and the SASP contribute to 
myriad physiological functions, both favourable and damaging.  
This next section will review the pathways activated in senescent cells and the 
consequences, thereof, in the context of cancer.  
1.7. Effector pathways of senescence and the senescent phenotype 
There are many inducers of the senescence phenotype: oncogene-induced 
senescence (OIS), telomere dysfunction (known as replicative senescence, 
(RS)), therapy-induced senescence (TIS), and chronic stress stimuli such as 
high levels of ROS, among others. All of these inducers converge upon the 
activation of a chronic DNA-damage response (DDR), the induction of the 
tumour suppressor p53, or the independent activation of the cell cycle inhibitor 
p16INK4A (shortly called p16) (263).  
Activation of p16 drives cells to exit from the cell cycle through inhibition of 
cyclin dependent kinases (CDK) and the mediated phosphorylation of the 
retinoblastoma protein (RB) (264). The p21 protein, one of the cell cycle 
inhibitors, is the downstream target gene of the p53 pathway and its activation 
causes cell cycle arrest until repair takes place. In the case of the cells failing 
to repair, this pathway then activates p16 (265). Interestingly, p53 plays a key 
role in suppressing the SASP; indeed, loss of p53 in the face of a chronic DDR 
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leads to increased expression of various SASP factors (261). The processes 
activated in the senescent response are depicted in Figure 1.5.  
It is important to note that cell cycle arrest in senescence is near permanent 
as compared to reversible cell cycle arrest that happens in quiescence. In a 
broader perspective, quiescence occurs due to a lack of nutrition and growth 
factors, while senescence takes place due to aging and serious DNA damages 
(266). Phenotypically, senescent cells have a large and flat cell morphology 
and acquire hyper-active cellular functions (267). Senescent cells often exhibit 
increased lysosomal b-galactosidase activity, which is responsible for the 
characteristic senescence-associated b-gal (SA-b-gal) staining at near neutral 
pH (268). While SASP cytokines may differ from one cell type to another, their 
production generally depends on stress-induced NF-kB and MAPK signalling, 
and their regulation is governed by the mTOR dependent protein translation 
(269). 
SASP factors relevant for pro-tumoural activity can be divided into the 
following groups (270):  
(i) Inflammatory cytokines: ones such as TNF-α and IL-6, that affect 
neighbouring cells by activating the NF-kB pathway and by inducing 
epithelial-mesenchymal transition, which marks pre-malignant 
development 
(ii) Members of the CXCL and CCL families: ones like IL-8, growth related  
oncogene (GRO) -α and -β, and SDF1 and its receptor CXCR4  
(iii)  MMPs that alter the extracellular matrix 
(iv)  The urokinase-plasminogen-activator/urokinase-plasminogen-activator 
receptor (uPA/uPAR) system 
(v) Almost all insulin-like growth factor (IGF)-binding proteins and their 
regulators 
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Figure 1. 5 Effectors of the senescence pathway.   
DNA damage and various stress factors activate the DNA damage response (DDR) 
in the affected cells. This in turn activates either the p53/p21 pathway or the p16 
pathway, or both. Activation of the former leads to a transient arrest of cell growth, 
which becomes irreversible in case the cell fails to repair. A persistent activation of 
the DDR then leads to prolonged arrest and, possibly, alterations in the SASP. P16 
activation leads to a Cyclin-dependent kinase–mediated activation of retinoblastoma 
protein (RB). Early senescent cells are SA-β-GAL positive and may not have a SASP. 
However, senescent cells may evolve further into a truly irreversible full senescence 
with SA-β-GAL positivity and a SASP that can eventually promote tumourogenesis. 
SASP is negatively regulated by p53.  
 
1.8. Role of senescence and SASP in tumourigenesis 
Early evidence associating senescence with cancers comes from an 
observation in patients with Li-Fraumeni syndrome, where cells with mutated 
p53 suffered accelerated senescence, often preceding cancer development 
(271, 272). The presence of senescent cells in tissues with hyperplastic 
pathological or premalignant alterations might indicate that senescence is a 
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step in the process of cancer development, or, that cancer development is 
age-dependant, and a mechanism that is tumour-suppressive in young age is 
tumour-promoting in old age (273).  
The SASP has been shown to create a pro-tumourigenic microenvironment in 
various ways. SASP factors promote cancer cell invasion and metastasis 
through tissue remodelling. Senescent cells secrete large amounts of 
proteases that degrade the ECM (extracellular matrix), making the tissue 
structure more relaxed and thus, facilitating the invasion of cancer cells (274). 
Recently, in a study on papillary thyroid carcinoma, Kim and colleagues 
showed that senescent tumour cells exhibited high invasion ability, compared 
to non-senescent tumour cells, through SASP expression. Interestingly, in this 
study senescent cells increased the survival of cancer cells via SDF-1/CXCR4 
signalling, with the expression of SDF-1 being significantly increased in tumour 
areas where p16INK4A-immunopositive senescent cells were present (275).  
Studies have also shown that the SASP promotes tumour growth by 
establishing an immunosuppressive microenvironment. Recently, in a study 
on metastatic bone lesions in breast cancer patients, Lou et al developed a 
model to induce reactive senescent osteoblasts and found that they increased 
breast cancer colonisation of the bone, which was also IL-6 mediated. 
Neutralisation of IL-6 was sufficient to limit senescence-induced osteoclast 
generation and tumour cell localisation to bone, thereby reducing tumour 
burden (276).  
In a similar study, Ruhland et al developed a mouse model that mimicked the 
aged skin microenvironment and showed that senescent stromal cells 
secreted IL-6, a main interleukin in the SASP. As a result, this caused localised 
increases in suppressive myeloid cells, and inhibited anti-tumour T-cell 
responses, hence, contributing to tumour promotion (277).  
1.9. Therapy-induced senescence 
Senescence can be induced in cancer cells upon treatment with a variety of 
drugs. In particular, chemotherapeutic agents that cause DNA damage. In this 
context, the induced senescence is expected to halt cancer progression (278). 
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However, a number of studies suggest that senescent cancer cells acquire 
resistance to cytotoxic chemotherapies (279) or give rise to stem-like cells 
accountable for post-therapy recurrence of cancer (280).  
Young adult women who had breast cancer and were treated with cytotoxic 
chemotherapy showed increased expression of markers of cellular 
senescence for decades after chemotherapy. Astonishingly, a few months of 
adjuvant chemotherapy for breast cancer, on average, increases T cell p16 
expression to an amount equivalent to 15 years of chronological aging (281). 
Campisi and colleagues studied the role of senescent cells in the toxicities of 
cytotoxic chemotherapy by inducing senescence in murine tissues using a 
variety of DNA damaging chemotherapy agents. In the breast model used in 
this study, senescent non-tumour cells were important for cancer relapse and 
spread to distal tissues after chemotherapy. When these senescent cells were 
cleared, several side effects of chemotherapy were improved. In particular, 
senescence free animals were less fatigued compared to untreated mice. 
Moreover, in a cohort of 80 breast cancer patients that were included in the 
study, p16 expression in peripheral T-cells predicted chemotherapy-induced 
fatigue in these patients (282).  
In another recent study, clearance of p16 positive senescent cell also delayed 
the onset of age related phenotypes and extended the murine lifespan (283). 
Thus, therapy-induced senescence may be relevant to AML as it is heavily 
treated with chemotherapeutic agents.  
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1.10. Research rationale, aims and objectives 
1.10.1. Rationale 
Acute myeloid leukaemia (AML) is a disease predominantly of older adults. 
However, the survival rate of AML patients has not been significantly 
favourably impacted, despite the development of currently available AML 
therapies and interventions targeting tumour cells. Extensive research has 
shown that leukaemic cells arise and thrive due to a leukaemia-permissive 
bone marrow microenvironment (BMM). Bone marrow stromal cells (BMSCs) 
are considered a major protective cell type that protect AML cells from 
spontaneous and chemotherapy-induced apoptosis.  
So far, only few microenvironmental factors favouring leukaemogenesis have 
been identified, as opposed to the widely explored genetic landscape of AML. 
Characterising the AML-driven biologic changes that occur in the BMSCs of 
the marrow niche would help identify new therapeutic targets, that could 
disrupt the pro-tumoural relationship between AML and its microenvironment. 
Consequently, this may ultimately lead to much needed novel therapeutic 
approaches in AML.  
1.10.2. Aims 
 To investigate the role of BMSCs in the microenvironment of AML.  
 To identify AML-driven signals that alter the profile of BMSCs towards 
tumour-promotion.  
 To identify possible new therapeutic targets that could disrupt the pro-
tumoural relationship between AML and BMSCs. 
1.10.3. Objectives 
The approach taken to achieve the above aims is as follows: 
1. To stablish an in vitro co-culture of patient derived AML cells and 
BMSCs, followed by determining the secretory profile thereof, and to 
identify potential AML-derived factors that regulate BMSC function 
(Chapter 3 and Chapter 6). 
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2. To develop investigations to determine the downstream effects of AML-
derived factor(s) in the BMSCs, including signalling transduction 
pathways and their ultimate effect on AML survival (Chapter 4 and 
chapter 6). 
3. To establish the regulatory mechanism of AML-derived factor(s), 
(identified in chapter 3) within the AML blast, and to identify the 
consequences of their inhibition in in vivo murine models of AML 
(Chapter 5 and chapter 6).  
The materials and methods used in this research are presented in Chapter 2. 
A general discussion and concluding remarks are presented in Chapter 7.  
 
 
 
  
61 
 
 
2. Chapter 2: materials and methods 
2.1. Reagents and chemicals 
All reagents were obtained from Sigma-Aldrich (Dorset, UK), unless otherwise 
indicated in the text. All inhibitors were purchased from Tocris Bioscience 
(Bristol, UK).  
2.2. Blocking antibodies and recombinant cytokines 
The CD74 blocking and IgG control blocking antibodies were purchased from 
BD Biosciences (Allschwil, Switzerland) and recombinant human MIF (rhMIF) 
was purchased from R&D Systems (Wiesbaden, Germany). Recombinant 
murine stem cell factor (SCF), murine Interleukin-6 (IL-6) and murine 
interleukin-3 (IL-3) were purchased from Peprotech (Neuilly-sur-Seine, 
France). Antibodies used in flow cytometry analysis are listed in table 2.1 and 
antibodies used in western blotting are listed in table 2.2 Assay kits were 
purchased from suppliers indicated in the text.  
 
Table 2. 1 Antibodies used in flow cytometry analysis. 
Antibody Clone Supplier  
Mouse IgG2a-FITC - Miltenyi Biotec 
(Paris, France) 
 
 
 
 
 
 
 
 
 
 
 
Mouse IgG2a-PE - 
Mouse IgG2a-APC - 
Mouse IgG2a-VioBright FITC - 
CD105-FITC 43A4E1 
CD73-PE AD2 
CD74-FITC 5-329 
CD184 (CXCR4)-PE 12G5 
CD182 (CXCR2)-VioBright FITC REA208 
CD33-APC AC104.3E3 
CD34-PE AC136 
CD45-FITC 5B1 
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Table 2. 2 Primary and secondary antibodies used in western blotting. 
Antibody Species 
and 
antibody 
clonality 
MW (kDa) Dilution Supplier 
 Primary antibodies  
Anti-GAPDH Rabbit 
mAb  
37 1:2000 CST 
(Massachusetts, 
USA) 
Anti- β- actin Mouse 
mAb 
 
45 1:2000 Sigma (Dorset, UK) 
Anti-Phospho-Akt (Ser473) Rabbit 
mAb 
60 1:1000 CST 
Anti-Akt (pan) (C67E7)  Rabbit 
mAb 
60 1:1000 CST 
Anti-Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204)  
Rabbit 
mAb 
42, 44 1:1000 CST 
p44/42 MAPK (Erk1/2)  Rabbit 
pAb 
42, 44 1:1000 CST 
Phospho-PKCa/b II (Thr638/641) Rabbit 
pAb 
80, 82 1:1000 CST 
Phospho-PKC (pan) (βII Ser660)  Rabbit  
pAb 
78, 80, 82, 85 1:1000 CST 
Phospho-PKD/PKCµ (Ser916)  Rabbit 
pAb 
115 1:1000 CST 
Phospho-PKCd (Thr505)  Rabbit 
pAb 
78 1:1000 CST 
Phospho-PKCδ/θ (Ser643/676)  Rabbit 
pAb 
78 1:1000 CST 
PKCBII (pan) 
pAb 
Mouse 78 1:500 R&D systems 
HIF1α Mouse 
mAb 
116-120 1:500 BD Biosciences 
HIF2α /EPAS1 Rabbit 
pAb 
118 1:500 Novus Bio 
p16INK4a (CDKN2A) Rabbit 
mAb 
17 1:500 Abcam 
 Secondary antibodies 
Goat anti-Mouse IgG HRP pAb  1:2000 Dako (Agilent) 
Goat anti-Rabbit IgG HRP pAb  1:2000 Dako (Agilent) 
Abbreviations: mAb, monoclonal antibody, pAb, polyclonal antibody.  
CST (Massachusetts, USA), Sigma (Dorset, UK), R&D Systems (Wiesbaden, Germany), BD 
Biosciences (Allschwil, Switzerland), Novus Bio (Colorado, USA), Abcam (Cambrisge, UK), 
Dako – Agilent (Cheadle, UK).  
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2.3. Cell culture 
2.3.1. Cell lines 
The human leukaemia OCI-AML3 cell line was obtained the German 
Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) and 
was maintained in RPMI-1640 medium, supplemented with 10% foetal calf 
serum (FCS), 2mM L-glutamine, 100U/ml penicillin and 10μg/ml streptomycin 
(pen-strep). Cells were kept at a density of 0.3-0.6 x106 cells/ml and sub-
cultured accordingly.  
293T cells were kindly provided by Dr Ariberto Fassati (University College 
London, London, UK) and maintained at 60-90% confluence in antibiotic-free 
Dulbecco's Modified Eagle's medium (DMEM) with 10% FCS and 6mM L-
glutamine. 293T cells are a highly transfectable derivative of human embryonic 
kidney 293 cells. 293T cells were sub-cultured at a 1:4 ratio in fresh culture 
media; culture media was gently aspirated and the cells were washed once 
with phosphate buffered saline (PBS). Gentle pipetting was very critical as 
these cells easily detached. 0.25% Trypsin was diluted 1:1 with PBS and 5 ml 
of this mixture was added to each of the 10mm plates. The plates were then 
incubated at room temperature (RT) for 2 to 3 minutes and swirled from side 
to side to help detach the cells. Next, the cells were re-suspended in the 
appropriate volume to achieve the required sub-culturing ratio, and pipetted 
vigorously to obtain a single cell suspension. 10 ml of cell suspension was 
dispended in 10 mm dishes and incubated overnight in a humidified culture 
incubator. Culture media was replaced with fresh media each following day, 
and returned to the incubator.  
The murine MN1 leukaemia cells are lineage depleted murine mononuclear 
cells carrying the MN1 AML gene, these were kindly gifted by Professor Keith 
Humphries (Terry Fox Laboratory, Vancouver, Canada) (284), and cultured in 
DMEM supplemented with 20% FCS and murine recombinant cytokines – SCF 
at a final concentration of 100ng/ml final, and IL-6 and IL-3 at 10ng/ml. All cells 
were cultured in a humidified culture incubator at 5% CO2 and 37 °C. 
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HS-5 stromal cells are a human stromal cell line derived from the bone 
marrow of a healthy volunteer and immortalized by transduction with human 
papilloma virus E6/E7 constructs (285) and were obtained from the American 
Type Culture Collection (ATCC, USA). Cells were maintained in DMEM with 
10% FCS and subcultured when they were 80% confluent. Subculturing was 
performed in the same manner as BMSC subculturing described in section 
2.3.2. 
2.3.2. Primary cell isolation and culture 
Primary AML cells were obtained from patient bone marrow, following 
informed consent and approval by the Health Research Authority of the 
National Health Service (NHS), United Kingdom (LRECref07/H0310/146). For 
primary cell isolation, 10 to 20 ml bone marrow aspirates were obtained 
in heparinised blood tubes., and mononuclear cells were isolated by 
Histopaque-1077 density gradient centrifugation. 10 ml of blood was carefully 
and slowly layered on 10 ml of Histopaque-1077 in a 50 ml falcon tube; the 
slow layering prevented mixing of the two layers. The tubes were then 
centrifuged at 400g for 20 minutes with slow acceleration and slow 
deceleration in order to aid the gentle separation of the different blood 
components. Figure 2.1 illustrates the different layers that formed at the end 
of this step.  
 
Figure 2. 1 A schematic of the Histopaque density gradient centrifugation step 
in isolating AML cells from BM aspirates.   
Four layers resulted from the density gradient performed. The mononuclear cell layer 
was carefully aspirated and used for isolating AML cells.  
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The buffy coat layer containing mononuclear cells was diluted in 40 ml of FCS 
and centrifuged at 400g for 5 minutes at RT. Red cell lysis was performed by 
suspending the cell pellet in 1-3 ml Red Blood Cell Lysing Buffer Hybri-Max 
for 1 minute, and then diluting the buffer with 10-15 ml of sterile PBS. The 
suspension was centrifuged again at 400g for 5 minutes and the cell pellet was 
suspended in complete growth medium, containing DMEM supplemented with 
20% FCS, 1% L-glutamine and pen-strep.  
AML samples that contained less than 80% blasts were purified using the 
CD34 MicroBead Kit UltraPure (Miltenyi Biotec,), unless the sample was 
identified as CD34 negative by the pathology department at the Norwich and 
Norfolk University Hospital (NNUH). Next, the cells were cultured at a density 
of 2X106 cells/ml, and incubated for the expansion of BMSCs. A fraction of the 
cells were cryopreserved in FCS with 10% Dimethyl sulphoxide (DMSO) for 
future use.  
 
BMSCs were isolated by removing non-adherent cells after 2 days of AML 
culture. Fresh complete growth media containing 10% FCS was added and 
changed every 3 days. When the cells were 60%-80% confluent, adherent 
BMSCs were trypsinised by adding 2.5 ml of 0.25% trypsin, and incubated for 
no longer than 5 minutes at 5% CO2 and 37 °C. Once the cells were detached, 
fresh complete growth medium was added and the cultures were expanded 
for 3-5 weeks. The cells were sub-cultured when they are about 80% 
confluent.  
BMSCs were checked for positive expression of CD105, CD73, and CD90 and 
the lack of expression of the myeloid marker CD45 by flow cytometry. All cells 
were cultured in complete growth medium with 10% FCS at 5% CO2 and 37 °C 
in a humidified tissue culture incubator.  
Non-malignant normal CD34+ HSCs were obtained from the peripheral blood 
of patients with genetic haemachromatosis undergoing therapeutic 
venesection, but with non-raised ferritin levels. On average, 250 to 300 ml of 
heparanised peripheral blood were collected and aliquoted into 50 ml falcon 
tubes, followed by centrifugation at 400g for 30 minutes. This step separated 
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the blood into three layers as shown in Figure 2.2. The mononuclear cell layers 
were collected and pooled into a 50 ml falcon tube (an average of 25 ml would 
be recovered) and diluted 1:1 with PBS. 10 ml of diluted blood was carefully 
and slowly layered onto 10 ml of Histopaque-1077 in a 50 ml falcon tube, and 
centrifuged at 400g for 20 minutes. From this step onwards, the same isolation 
protocol that was used for AML cells was followed and the cells were purified 
using CD34+ magnetic cell purification.  
 
Figure 2. 2 A schematic of the additional centrifugation of large volumes of 
peripheral blood prior to Histopaque density gradient centrifugation and 
isolation of CD34+ cells.  
Three layers were obtained after centrifugation at 400g for 30 minutes, the central 
layer of mononuclear cells was carefully aspirated and used for isolating normal 
CD34+ cells. 
 
2.3.3. CD34+ magnetic purification  
CD34+ cells were isolated using positive selection of magnetically labelled 
CD34+ cells. The CD34 MicroBead Kit UltraPure, human (Miltenyi Biotec) was 
used to purify CD34+ AML and CD34+ HSCs. Cells were pelleted by 
centrifugation and re-suspended in 300 μl of MACS Buffer (a sterile solution 
of PBS containing 0.5% bovine serum albumin (BSA) and 2 mM EDTA, stored 
at 4oC). Next, 100 μl of human FcR Blocking Reagent (which helped eliminate 
non-specific binding) and 100 μl of the CD34 MicroBeads were added. The 
cell suspension was mixed well by pipetting, and incubated for 30 minutes at 
4ºC.  
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After incubation, the cells were washed in 5ml of MACS Buffer, and then 
pelleted and re-suspended in 500 μl of MACS buffer. The cell suspension was 
then applied to the MS MACS separation column fitted on the MiniMACS 
magnet. Only cells that were positively labelled with CD34 Microbeads were 
retained by the column. The column was then washed three times with 500 μl 
MACS Buffer and then removed from the separation magnet and placed in a 
15 ml collection tube. 1ml of MACS Buffer was applied onto the column and, 
using the supplied plunger, labelled cells were forced out by firmly pushing the 
plunger through the column. Isolated CD34+ cells were then cultured in 
complete DMEM with 10% FCS.  
2.3.4. Cryopreservation and defrosting of primary cells  
Cells were collected by centrifugation at 350g for 5 minutes and re-suspended 
in freezing medium (10% DMSO in FCS). 1 ml cell aliquots were transferred 
into labelled cryovials and stored overnight at -80°C in a CoolCell cell freezing 
container, before being transferred to the appropriate storage facilities. When 
needed, cells were defrosted quickly by briefly immersing the bottom part of 
the cryovial in a water bath at 37 °C. This was done to ensure maximum cell 
recovery. Next, the cell suspension was transferred to a 15 ml falcon tube 
containing 9 ml of complete growth medium, and centrifuged at 350g for 5 
minutes. The cell pellet was then suspended in complete growth medium with 
20% FCS, and incubated at 5% CO2 and 37 °C in a humidified tissue culture 
incubator. 
2.3.5. Cell viability assays: 
2.3.5.1. Trypan blue exclusion test using a haemocytometer 
The Trypan blue exclusion assay is an inexpensive and widely used cell 
viability assay. Trypan blue is taken up by dead cells and excluded by viable 
cells due to their intact cell membranes. In this assay, A 10 μl aliquot of cell 
suspension was mixed in a 1:1 ratio with trypan blue solution (0.4% w/v). Cells 
were then pipetted onto a Neubauer Haemocytometer Counting Chamber, and 
those that had excluded the dye were counted as viable cells. All four 
quadrants were counted and averaged. The total number of cells in the original 
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suspension was calculated by multiplying this value by 10,000 x dilution factor 
of two. Only cell cultures that were 85% viable were used in experiments.  
2.3.5.2. CellTiter-Glo viability assay 
AML cells were seeded into 96-well plates in quadruples and their viability was 
determined at the time points indicated in the results section. Cell viability was 
determined indirectly by measuring the intracellular levels of ATP using the 
Cell Titer-Glo Luminescent Cell Viability Assay kit (Promega, Wisconsin, 
USA), where a luminescent signal was produced due to a firefly luciferase 
reaction and was directly proportional to cell number and viability. The test was 
performed according to the manufacturer’s instructions: 50 μl of the cell 
suspension was transferred to a white 96 well plate. Cells were lysed by the 
addition of 50 μl of the CellTiter-Glo reagent and incubated for 10 minutes at 
RT with gentle shaking. Luminescence was measured at a peak emission 
wavelength of 560nm on a lumiStar Microplate Reader (BMG Labtech GmbH, 
Ortenberg, Germany). 
2.3.5.3. Annexin V – PI detection of apoptosis 
This assay is based on the fact that dead cells are able to take up the 
membrane impermeable fluorescent propidium iodide (PI) dye, which then 
binds to DNA and enhances its fluorescence properties, while Annexin V binds 
to the exposed phosphatidylserine (PS) molecules on the outer side of the 
plasma membrane, this being one of the early events of apoptosis (286) 
The percentage of early apoptotic, apoptotic or dead (necrotic) cells is 
calculated according to the cell PIV Annexin V staining parameters. The 
eBioscience Annexin V-FITC Apoptosis detection kit (Thermo Fisher 
Scientific, UK) was used to determine the percentage of apoptotic cells. Cells 
were harvested by centrifugation and washed twice in cold PBS (350g for 5 
min) and resuspended to 0.2 × 106 cells/ml. 5 μl of Annexin V-FITC was then 
added to 195 μl cell suspension, mixed and incubated for 10 minutes at RT. 
Next, the cells were washed with 200 μl binding buffer and resuspended in 
190 μl bidding buffer. Finally, 10 μl PI (20 μg/ml) was added to the sample and 
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incubated for 1-2 minutes at RT in the dark. Cells were immediately analysed 
by flow cytometry.  
2.3.6. Hypoxic assays 
To establish hypoxic cultures, cells were either incubated in a hypoxia 
chamber (Billups-Rothenberg Inc, Del Mar, USA) at 1% O2/ 5% CO2/ N2 200 
bar at 37 °C for the periods of time indicated in the text, or treated with cobalt 
chloride (CoCl2) and desferrioxamine (DFO) at 100uM or 150uM respectively 
at the time points indicated in the text. Control cell cultures, not deprived of 
oxygen, were incubated under normal culture conditions. 
2.3.7. Methylcellulose Human Colony Forming Cell (CFC) Assay 
The colony forming cell (CFC) assay, also called the methylcellulose assay, is 
one that aims to determine the progenitor capacity of the haematopoietic cells 
of interest. The assay is based on the ability of haematopoietic progenitors to 
proliferate and differentiate into colonies in a semi-solid media, in response to 
cytokine stimulation. The colonies formed can then be counted and 
characterised according to their unique morphologies (287).  
4x104 cells were washed in sterile PBS and re-suspended in 400 ul cell 
resuspension solution (R&D systems). The cells were added to 4 ml of human 
methylcellulose complete media HSC003 (R&D systems) in a 15 ml falcon 
tube, mixed by a brief vortex. A quick centrifuge on a short spin setting for 20 
seconds allowed any bubbles in the solution to rise to the surface and any 
media that was stuck on the inside walls of the tube to be recovered. It was 
vital that the spin was short, to prevent cells from pelleting or becoming 
concentrated towards the bottom of the semi-solid media.  
Next, 1.1 ml of the solution was aspirated using a 16 gauge 1½ inch blunt end 
needle, and dispensed into a 35mm culture dish. This step was repeated a 
total of three times to obtain triplicate samples. The three dishes, as well as 
an uncovered dish containing 3-4 ml sterile water, were placed in a Corning 
square bioassay dish and were loosely covered to allow for gas exchange. 
The sterile water dish served to maintain the humidity necessary for colony 
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development. Finally, the plates were incubated for 10-14 days at 37 °C and 
5% CO2. It was essential to avoid disturbing the cultures during the incubation 
period to prevent shifting of the colonies. Light microscopy was used to 
visualise and score colonies at days 10-14 using a scoring grid. 
2.4. Molecular biology techniques 
2.4.1. RNA extraction 
Total RNA was extracted from cells using the ReliaPrep RNA extraction kit 
from Promega, according to the manufacturer’s instructions. Suspension cells 
(OCI-AML3 cell line or primary AML cells) were collected by centrifugation at 
400g for 5 minutes. The supernatant was either discarded or stored at -20 for 
cytokine analysis. Culture media was collected from adherent BMSCs and 
either discarded or stored at -20 for cytokine analysis.  
Adherent or suspension cells were washed once with PBS. 250l BL+TG lysis 
buffer was then added and the solution was pipetted up and down 7 times to 
lyse the cells. The lysate was transferred to a ReliaPrep™ minicolumn and 
centrifuged at 14000g for 30 seconds at RT. Next, 500μl of RNA Wash solution 
were added to the minicolumn and centrifuged at 14000g for 30 seconds. 24μl 
of Yellow Core Buffer, 3μl 0.09M MgCl2 and 3μl of DNase I enzyme were 
mixed in order and added to each minicolumn membrane, followed by 
incubation for 15 minutes at RT. 200μl of column wash solution was added 
and centrifuged at 14000g for 15 seconds. 500μl of RNA wash solution were 
added and the minicolumn was centrifuged at 14000g for 30 seconds. The 
minicolumn was placed into a new collection tube, 300 μl of RNA wash solution 
added, and they were centrifuged at 14000g for 2 minutes. Finally, the 
minicolumn was transferred to an elution tube, and 20 l nuclease-free water 
was added directly onto the membrane and incubated at RT for 1min. The 
minicolumn was centrifuged at 14000g for 1min to elute RNA, which was 
stored at -20°C until further use. 
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2.4.2. Nucleic acid quantification using a Nanodrop 
RNA yield was quantified and its purity determined using a NanoDrop 2000 
Spectrophotometer (ThermoScientific, UK). Briefly, 1 l sample was measured 
and referenced to a blank sample of nuclease-free water, in which the RNA 
was eluted. An RNA sample with an A260/A280 ratio of 1.9-2.1 was 
considered pure and of accepted quality. For plasmid DNA, an A260/A280 
ratio of 1.7–2.0 was accepted as sufficiently pure. 
2.4.3. Reverse transcription and cDNA synthesis 
Reverse transcription was performed using the qPCRBIO cDNA synthesis kit 
(PCR Biosystems, London, UK). For a 10 μL reaction, 2 μL of 5x cDNA 
Synthesis Mix and 0.5 μL of 20x RTase were added to 7.5 μL nuclease free 
water, carrying up to 100ng RNA. The PCR tubes are Incubated in the 
Thermocycler (Bio-Rad, Watford, UK) at 42°C for 30 minutes and at 85°C for 
10 minutes to denature RTase, and then kept at 4°C for up to three hours or 
stored at -20°C. The samples were diluted 1:5 or 1:10 before performing gene 
expression using qRT-PCR.  
2.4.4. Relative quantitative real-time PCR (qRT-PCR) 
 qRT-PCR was performed using the qPCRBIO SyGreen Mix 
(PCR Biosystems, London, UK) on cDNA generated from the reverse 
transcription of purified RNA. For a 10 μL reaction, 5 μL of SyGreen Mix and 
1 μl of forward and reverse primer mix were added to 4 μL of diluted cDNA. 
Samples were run in triplicates on a 96-well white PCR plate. Larger qRT-PCR 
sample runs were performed in 384-well plates and a 5 μl reaction volume was 
used instead of 10 μl.  
After a pre-amplification incubation step (95°C for 2 minutes), the cDNAs were 
amplified over 45 cycles (95°C for 15 seconds, 60°C for 10 seconds and 72°C 
for 10 seconds), followed by a melting curve analysis (95°C for 5 seconds, 
65°C for 1 minute and 97°C continuous). The melting curve analysis was 
performed to confirm product specificity and to detect the formation of primer 
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dimers which could give false positives if unidentified. Finally, the reactions 
were cooled at 40°C for 30 seconds.  
The qRT-PCR reactions were run on a LightCycler 480 (Roche Life Science, 
Burgess Hill, UK). Predesigned qRT-PCR primers were purchased from 
Sigma (KiCqStart® SYBR® Green Primers, Cat. No. KSPQ12012) and are 
listed in table 2.3. qRT-PCR primers to detect PKCB, IL-8 and CD74 mRNA 
expression were purchased from Qiagen (Hilden, Germany) (QIAGEN 
QuantiTect Primer Assay) and are listen in table 2.4. The lyophilised primers 
were dissolved in the volumes of nuclease free water specified by the 
manufacturers, briefly vortexed and then stored at -20°C until further use. 
 
Table 2. 3 KiCqStart® SYBR® Green Primers (Sigma).  
Gene name, forward and reverse primer sequences are shown in the table.  
Gene Forward primer sequence 5' → 3' Revers primer sequence 5' → 3' 
GAPDH CTTTTGCGTCGCCAG TTGATGGCAACAATATCCAC 
β -actin GATCAAGATCATTGCTCCTC TTGTCAAGAAAGGGTGTAAC 
MIF AACTATTACGACATGAACGC AAACCGTTTATTTCTCCCC 
IL-6 GCAGAAAAAGGCAAAGAATC CTACATTTGCCGAAGAGC 
HIF1α GAAACTACTAGTGCCACATC GGAACTGTAGTTCTTTGACTC 
GLUT1 (SLC2A1) AGTTCTACAACCAGACATGG CAGGTTCATCATCAGCATTG 
HIF2α (EPAS1) CAGAATCACAGAACTGATTGG TGACTCTTGGTCATGTTCTC 
p16 (CDKN2A) AGGTCCCTCAGACATCC AATGAAAACTACGAAAGCGG 
p21 (CDKN1A) CAGCATGACAGATTTCTACC CAGGGTATGTACATGAGGAG 
 
Because MIF gene contains an antisense coding sequence on the minus 
strand (MIF-AS1, Entrez ID: 284889), it is possible that the MIF gene is 
expressed in both directions, generating (i) MIF mRNA from the sense strand 
and possibly a (ii) MIF antisense 1 from the minus strand. The RT-PCR 
reactions used in this study, utilised sense-directed primers and hence should 
only amplify transcripts from the sense strand. Moreover, using the BLAST 
tool to test primer specificity helped determine that the primers would only 
amply MIF transcripts and not non-specific or antisense transcripts.  
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Table 2. 4 QuantiTect Primers (Qiagen).  
Primer sequences were not disclosed by the manufacturer. 
Gene Assay name Catalogue number 
IL-8 (CXCL8) Hs_CXCL8_1_SG QT00000322 
PKCB (PRKBC) Hs_PRKCB_1_SG QT00073920 
CD74 Hs_CD74_1_SG QT00059402 
                                                                                                                                                                                                      
2.4.5. Analysis of qRT-PCR data 
 A cycle threshold (Ct) value was measured and generated at the end of the 
reaction described in 2.5.1.4. GAPDH or β-actin were used as housekeeping 
genes to calculate a fold change correction for each sample (Delta Ct = Ct 
target gene – Ct housekeeping gene), the house keeping genes were selected 
based on the fact that their expression does not change with treatment or 
genetic manipulation of the cells. Next, the Delta-Delta Ct method was used 
for analysis. The change in expression was expressed as a fold change 
relative to control samples (equivalent to 2-(Delta Ct treated-Delta Ct control)). 
2.4.6. Protein expression analysis 
2.4.6.1. Western immunoblotting 
2.4.6.1.1. Whole cell lysate preparation 
Whole cell lysate was extracted using radioimmunoprecipitation assay (RIPA) 
buffer supplemented with protease and phosphatase inhibitors (Roche Life 
Sciences) to inhibit protein dephosphyorylation and degradation. For adherent 
cells, media was removed and cells were washed with cold PBS. For 
suspension cells, the cells were pelleted at 400 g for 5 min and the supernatant 
was discarded.  
Next, 100 µL of RIPA buffer was added to the cells and a cell scraper was 
used to aid the lysis of the adherent cells, while pipetting was used to aid the 
lysis of the suspension cells. Cells were collected in a 1.5 ml eppendorf tube 
and incubated on ice for 20 minutes, followed by a spin at 15000 g and 4°C 
for 20 minutes. The supernatant was collected and the pellet was discarded. 
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Finally, 4x sample loading buffer, containing β-mercaptaethanol, glycine and 
bromophenol blue were added to the samples, mixed and then denatured at 
100 °C for 5 minutes. Thereafter, the samples were ready to be loaded onto 
the gels.  
2.4.6.1.2. SDS-PAGE and immunoblotting 
10% acrylamide gels (30% Acrylamide/Bis Solution, BioRad) were casted for 
resolving proteins of large molecular weight and 12-14% acrylamide gels, for 
proteins of lower molecular weight. The gel mix contained 10% SDS (to 
linearise and mask protein charge), 7.5 M of Tris-EDTA at pH 8, 10% 
Ammonium persulphate and TEMED, to aid polymerisation. Samples were 
loaded into the designated wells of the gels alongside Precision Plus Protein™ 
All Blue Prestained Protein Standards (Bio-rad). Gels were run at 200V for 55 
minutes in running buffer containing 10% SDS, 20µM Glycine and 157µM Tris-
Base. For lower molecular weight proteins, gels were run at 180V, to start off 
with, and then at 200V under careful observation, so that the proteins did not 
run off the gel.  
At the end of the run, proteins were transferred from the gel onto a 
polyvinyladine fluoride (PVDF) membrane pre-treated with methanol and pre-
wetted in transfer buffer containing 20 µM Glycine and 157 µM Tris-Base. The 
transfer took place at 100V for 50 minutes. An ice pack was placed in the 
transfer tank to lower the temperature from the heat generated due to the 
electric current. The membranes were then blocked for 1 to 2 hours at RT in 
5% BSA for total proteins and in 5% non-skimmed milk for phosphorylated 
proteins. Membranes were then incubated overnight at 4°C in primary 
antibodies at the dilutions indicated in table 2.1. Horseradish peroxidase 
(HRP) conjugated secondary antibodies were used for detection. The blots 
were incubated with respective secondary antibodies for an hour at RT, 
followed by five 5 minute washes in PBS + 0.01% Tween 20. 
2.4.6.1.3. Chemiluminescent detection 
Membranes were imaged using enhanced chemiluminescence (ECL) reagent 
(GE healthcare, Little Chalfont, UK). Solution A and solution B were mixed in 
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a 1:1 ratio. The membranes were then covered in the resulting solution and 
incubated for 1 minute, before excess solution was drained off. The 
membranes were imaged on a Chemdoc-It2 Imager (UVP, LLC, Upland, CA, 
USA), with the UVP set to filter 3.  
2.4.6.2. ELISA  
To examine MIF and IL-8 secretion into culture media, the Human MIF Douset 
ELISA Kit (R&D systems) and Human IL-8 ELISA Ready-SET-Go ELISA kit 
(eBioscience) were used.  
For the Human MIF Douset ELISA Kit, capture antibody was diluted in coating 
buffer and 100 µL of the solution was pipetted into each micro-well of a 96 
micro-well plate, using a multi-channel pipette. The plate was incubated 
overnight at RT. The next day, the micro-wells were washed four times with 
300 µl wash buffer. For blocking, 300 µl reagent diluent was added to each 
well and the plate was incubated for one hour at RT. The micro-wells were 
then washed three times with wash buffer. Thereafter, 100 µL aliquots of 
standard solutions, blanks and samples were added in duplicates to the micro-
wells, and were then diluted 1:2 in reagent diluent. The plate was incubated 
for 3 hours at RT. Next, the micro-wells were washed four times with wash 
buffer. 100 µL of the detection antibody diluted in reagent diluent was 
subsequently added, and the plate was incubated for 2 hours at RT. At the 
end of the incubation time, the micro-wells were washed to remove excess 
detection antibody and to minimize unspecific binding. 100 µl streptavidin-HRP 
was added to each well and incubated for 20 minutes in the dark. The micro-
wells were washed to remove excess streptavidin-HRP. Substrate A and 
substrate B were mixed in a 1:1 ratio, 100 µl of which was subsequently added 
to all wells. The plate was incubated in the dark for 20 min, at which point a 
blue colour started to develop. Following this colour change, 50 µL of stop 
solution was added to quench the reaction and the absorbance was 
immediately recorded at 450 nm and 570nm on a FLUQstar Omega plate 
reader (BMG Labtech, Offenburg, Germany). The colour remains stable for up 
to four hours after the stop solution is added.  
76 
 
 
For the IL-8 ELISA Ready-SET-Go ELISA kit, a 96 micro-well plate was 
incubated overnight at 4°C, with 100 µL of well coating-antibody solution . The 
micro-wells were then washed tree times with 300 µL wash buffer (PBS 
containing 0.05% Tween20) and were then blocked by adding 200 µL of 1X 
ELISA/ELISPOT diluent for 1-2 hours at RT. The micro-wells were washed 
three times with wash buffer, then 100 µL of standards, blanks and samples 
were added in duplicates to the micro-wells, each of which were diluted 1:2 in 
reagent diluent. The plate was incubated overnight at 4°C. Next, the micro-
wells were washed 5 times with wash buffer and 100 µl of diluted detection 
antibody was added to the wells and incubated for 2 hours. Excess detection 
antibody was later washed off, as previously described, and 100 µl 
streptavidin-HRP was added to each well and incubated for 30 minutes in the 
dark. The micro-wells were then washed 7 times to remove excess 
streptavidin-HRP, after which 100 µl of 1X TMB solution was added to all the 
wells and incubated for 15 minutes in the dark. Next, 50 µL stop solution (2N 
H2SO4, sulphuric acid) was added, and the absorbance was immediately read 
at 450 nm and 570nm on a FLUQstar Omega plate reader. 
To analyse the readouts, the readings at 570nm were subtracted from the 
readings at 450nm, to reduce disturbance from dust and air particulates that 
absorb light equally at both wavelengths. A four-parameter logistic regression 
fitting method was employed to analyse standard curves, using the 
ELISAanalysis online software (ELISAKIT, Australia). Standard curves with R 
values of 0.9-0.99 were used to calculate unknown cytokine concentrations. 
2.4.6.3. Proteome Profiler Human XL Cytokine Array  
The Proteome Profiler Human XL Cytokine Array  (R & D systems, # ARY022) 
was used to determine the levels of 102 secreted cytokines in AML only, 
BMSC only or AML/BMSC co-cultures. It employs capture and control human 
antibodies that have been pre-spotted in duplicates on a nitrocellulose 
membrane. Then, via a series of incubation steps gives a measure of cytokine 
protein expression in a sample of culture media, cell lysate, serum or plasma. 
77 
 
 
Each well contained a final volume of 1 ml culture supernatant. The 
supernatant culture media was collected, and particulate matter was 
disregarded after centrifugation at 400 g for 5 minutes, and the supernatant 
stored at -20°C. When the array was due to be performed, the samples were 
defrosted on ice. The array membranes were blocked by adding 2 ml of the 
provided block buffer and incubated for 1 hour at RT. Next, 0.5 ml block buffer 
was added to 1 ml of the cell culture supernatant, which was then and applied 
onto each of the respective membranes and left overnight at 4˚C with gentle 
rocking. The membranes were then washed three times for 10 minutes (while 
on a rocking platform for efficient washing), with the provided wash buffer. 
Thereafter, the supplied detection antibody cocktail was added and the 
membranes were incubated for 1 hour on a rocking platform. The detection 
cocktail was aspirated and the array washed three times for 10 minutes. 
Streptavidin-HRP was then added at 1:2000 (diluted with array buffer) and 
incubated for 30 minutes with gentle rocking. After the membranes were 
washed thrice for 10 minutes, the array ECL detection reagent was made by 
mixing Chemi reagent 1 and Chemi reagent 2 in a 1:1 ratio. Each of the 
membranes were then covered with 1 ml of the mixed chemi solution, after 
which the array membranes were wrapped in plastic wrap and imaged as 
described in section 2.5.2.1.3. 
The optical density of the resulting images were quantified and analysed using 
the HLimage++ software (Western Vision Software, Salt Lake City, UT, USA) 
which had pre-designed templates for all R and D protein arrays. The output 
files, contained average pixel densities of each of the duplicates representing 
each cytokine. They also contained reference spots that were used to confirm 
that the assay had worked, and to compare assay to assay variability.  
2.4.6.4. Flow cytometry 
Flow cytometry was used to measure surface and internal protein expression 
on target cells. For surface marker staining, cells were washed with cold 
MACS buffer (PBS + 0.5% BSA + 2 mM EDTA) and centrifuged at 300 g for 5 
min. Next, the cells were re-suspended in 90 µl MACS buffer and 10 µl FCR 
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blocking reagent. Thereafter, 2 µl of the respective control, or marker of 
interest fluorochrome-conjugated antibodies were added. Cells were 
incubated for 10-15 minutes at 4°C in the dark. At the end of incubation, cells 
were washed with MACS buffer, pelleted at 300 g for 5 minutes, and then re-
suspended in 1 ml cold filtered PBS. The cells were immediately analysed on 
the BD Accuri C6 (BD Biosciences, Allschwil, Switzerland) or on the CyFlow® 
Cube 6 (Sysmex-Partec, Görlitz, Germany) flow cytometers. A minimum of 
3000 events were collected and data was analysed on the respective software. 
Newly synthesised CD74 is expressed on the cell surface, followed by rapid 
internalisation to the endosomal pathway. The surface half-life of CD74 is very 
short (less than 10min) (288). Therefore, experiments that study cell surface 
CD74 expression are complicated by the fact that CD74 remains on the cell 
surface for a very short time. Accordingly, various flow cytometry protocols 
recommend cells to be fixed and permeablised when staining for CD74. The 
fix and perm kit (Invitrogen, Thermo Fisher Scientific, UK) was used to detect 
CD74 expression in BMSCs. First, BMSCs were trypsinised, pelleted and 
washed once in PBS with 5% FCS (wash buffer). Next, the cells were re-
suspended in 100 l Reagent A (fixation medium) and incubated for 15 
minutes at RT. The cells were then washed with 1.5 ml wash buffer, re-
suspended in 100 l of Medium B, followed by the addition of 2 l CD74-FITC 
antibody – this suspension was then vortexed and incubated for 20 minutes at 
RT in the dark. 3 ml wash buffer was then added to wash off excess antibody. 
Finally, the cells were re-suspended in 1 ml of filtered PBS for analysis on the 
CyFlow® Cube 6 flow cytometer. A minimum of 3000 events were collected. 
Data was subsequently analysed using the FCS express 5 software 
(FCS express version 5 software (De Novo Software, Thornhill, ON, Canada).  
2.4.7. shRNA-mediated gene silencing 
In this study, MISSION shRNA lentiviral knockdown was used to achieve long 
term silencing of gene expression in target cells. MISSION shRNA lentiviral 
clones are sequence-verified shRNA lentiviral plasmids for gene silencing in 
mammalian cells (Sigma). The MISSION® TRC shRNA plasmid was 
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transformed into E.coli strain DH5αT1R, expressing shRNA, which targeted 
either MIF, HIF1α or HIF2α genes (in pLKO.1-puro plasmid vectors).  
The plasmids expressing the shRNAs can either be directly transfected into 
target cells to attain transient gene knockdown, or they can be co-transfected 
with packaging plasmids into the 293T cell line, for long-term knockdown by 
integration into the host cell genome. The latter method was used in the 
research presented in this thesis.  
Bacterial cultures were amplified from glycerol stocks in order to extract 
sufficient amounts of shRNA plasmid DNA. Lentiviral stocks were prepared by 
co-transfecting 293T cells with the shRNA plasmid and two other plasmids: a 
packing plasmid, pCMVΔR8.91 (expressing gag-pol) and an envelope 
plasmid, pMD.G (expressing VSV-G). These were kindly provided by Dr 
Ariberto Fassati (University College London, London, UK).  
Lentiviral titres were determined using the Lenti-X™ qRT-PCR titration kit 
(ClonTech Laboratories, California, USA) and viral stocks were concentrated 
using Amicon® Ultra centrifugal filters (EMD Millipore, Massachusetts, USA). 
Figure 2.3 shows a schematic summarising the work-flow that was followed to 
obtain successful knockdown of target genes. 
 
 
Figure 2. 3 A schematic showing the work flow followed in the production of 
lentiviral particles from bacterial glycerol stocks.  
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For silencing of IL-8, CD74 and PKCβ PKCβ genes, pre-packaged 
MISSION® TRC shRNA Lentiviral Transduction Particles were used. In this 
case, step 1 to 6 of the workflow shown in Figure 2.3 was performed. The 
MISSION pLKO.1-puro Control Vector (SHC001, Sigma-Aldrich) was used as 
a control, which is an empty vector confirmed to not activate the RNAi 
pathway, as it does not contain an shRNA insert. All bacterial glycerol stocks 
were stored at -80oC. ShRNA sequences of mission shRNA lentiviral particles 
are provided in table 2.3. The following sections will cover the process of 
lentiviral knockdown in detail.  
 
Table 2. 5 Sigma mission shRNAs used for stable knockdown of target genes.  
Gene  Clone ID TRC number Sequence 5' → 3' 
IL-8 NM_000584.2-
178s1c1 
0000058030 CCGGCAAGGAGTGCTAAAGAACTTACTCG
AGTAAGTTCTTTAGCACTCCTTGTTTTTG 
PKCβ NM_002738.6-
292s21c1 
0000435447 CCGGATGAGGTCAAGAACCACAAATCTCG
AGATTTGTGGTTCTTGACCTCATTTTTTTG 
CD74 NM_004355.1-
742s1c1 
0000008635 CCGGCCACACAGCTACAGCTTTCTTCTCG
AGAAGAAAGCTGTAGCTGTGTGGTTTTT 
MIF NM_002415.1-
374s1c1 
0000056818 CCGGGACAGGGTCTACATCAACTATCTCG
AGATAGTTGATGTAGACCCTGTCTTTTTG 
HIF1α NM_001530.x-
1492s1c1 
0000010819 CCGGCCGCTGGAGACACAATCATATCTCG
AGATATGATTGTGTCTCCAGCGGTTTTT 
p16 NM_058197.3-
971s21c1 
0000255849 CCGGGCTCTGAGAAACCTCGGGAAACTC
GAGTTTCCCGAGGTTTCTCAGAGCTTTTTG 
HIF2α NM_001430.x-
2419s1c1 
0000003805 CCGGGCGCAAATGTACCCAATGATACTCG
AGTATCATTGGGTACATTTGCGCTTTTT 
 
2.4.7.1. Amplification of bacterial cultures 
For bacterial cultures, agar plates were made by combining Lysogeny Broth 
(LB) (containing 10 g/L Tryptone, 10 g/L NaCl and 5 g/L yeast) with agar at 10 
g/L. The LB-Agar media was sterilised and cooled to 50oC before 
supplementing with ampicillin at 100 µg/ml. 10 ml aliquots were pipetted into 
10 cm dishes and stored for usage at 4oC for up to a month. Frozen bacterial 
glycerol stocks were rapidly thawed at RT and streaked onto the agar plates 
using a sterile streaking loop, followed by incubation at 37oC overnight. 
Thereafter, single bacterial colonies were picked with a sterile pipette tip and 
inoculated in 5 ml of LB broth with shaking at 37oC for 16 hours. 
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The selection of Individual, isolated colonies ensured colony homogeneity and 
helped to avoid picking satellite colonies that tend to grow in antibiotic depleted 
areas of the plate. 4 to 5 colonies were cultured per plasmid to ensure high 
yield of plasmid DNA. 
2.4.7.2. Plasmid DNA isolation and precipitation 
kit (Macherey-Nagel, Germany). Firstly, the bacterial cultures were pelleted by 
centrifugation and re-suspended in 500 µl re-suspension buffer A1, followed 
by the addition of 500 µl of SDS/alkaline lysis buffer A2, and incubation at RT 
for 4 min. Next, 300 µl A3 buffer was added to neutralise the suspension and 
aid the binding of plasmid DNA onto the silica membrane of the spin columns. 
The contents were mixed by gentle inversion. Precipitated proteins, genomic 
DNA and cell debris were pelleted by centrifuging the tubes at 11000 g for 7 
minutes. The supernatant was then loaded onto the spin column. The column 
was washed twice at 11000 g for 1 minute using ethanolic wash buffer A4, 
followed by a final drying spin for 3 min. Finally, the DNA was eluted in 50ul 
nuclease-free water at 70oC.  
The optimal concentration of plasmid DNA required for transfection of 
packaging cells is <180ng/µl. To achieve this, plasmid DNA of the highest 
purity from different colonies was pooled together and ethanol-precipitated. 
Ethanol precipitation is a well-established method for the concentration and 
desalting of nucleic acids. In this method, 3M solution of sodium acetate (pH 
5.2) was added at 1/10th of the volume of pooled plasmid DNA. Next the 
volume was completed to 1 ml with ice-cold ethanol, which forced the plasmid 
DNA to precipitate out of solution. The resulting solution was then stored over-
night at -20°C, or for 4-5 hours at -80°C to precipitate. After precipitation, the 
DNA was pelleted by centrifugation at maximum speed (14000 g) for 15 
minutes. The pellet was washed in cold 70% ethanol and centrifuged again. 
Ethanol was aspirated without disturbing the pellet, which was then left to dry 
in a culture hood. As it dried, the translucent pellet became whiter and more 
opaque. Finally, the pellet was rehydrated in nuclease free water and stored 
at -20oC. 
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2.4.7.3. 293T packaging cell transfection 
24-48 h prior to transfection, 293T cells were cultured in 10 cm culture dishes 
and passaged so that the cells were ~ 80% confluent. On the day of 
transfection, packaging cell media was replaced with 7.5-8 ml of fresh, 
antibiotic free, complete culture media. DNA mix was prepared so that it 
contained 1 g of each of the packaging plasmids, 1.5 g of the specific 
shRNA plasmid and TE buffer up to 15 L. In a separate tube, a transfection 
vehicle was prepared by adding 18 L FuGENE® (Promega, Fitchburg, WI, 
USA), and 6 to 200 µl of Opti-MEM (Life Technologies, 
Gaithersburg, MD, USA.) reduced serum media. The DNA mix was then 
added onto the transfection vehicle mix, and the two were gently mixed by 
pipetting, before being incubated at RT for 15 minutes. The resulting solution 
was added drop wise onto the plate of packaging cells. The plates were 
incubated in normal culture conditions and the media was changed every 24 
hours, with 7.5 ml of fresh culture media. Culture media was collected in 15 ml 
falcon tubes at 48, 72 and 96 hours. 150 µl was also taken from each plate at 
specific time points to be used for extraction of viral RNA. All media was stored 
at -80 °C.  
2.4.7.4. Viral RNA isolation 
Viral RNA was isolated using the NucleoSpin® RNA Virus isolation kit 
(Macherey-Nagel). Aliquots of media that were frozen in the previous step 
were defrosted on ice. 70 µl from the media collected at each time point was 
pooled into one Eppendorf. From this, a 150 µl aliquot was taken out into a 
new Eppendorf tube. 600 µl of RAV1 was added to the tube, vortexed, and 
incubated at RT for 5 minutes. 600 µl of absolute ethanol was next added and 
the tube was vortexed for 30 seconds. 675 µl of this solution was transferred 
into a spin column and centrifuged at 8,000g for 1 minute. The spin step was 
repeated with the remaining 675 µl. Next, the column was washed once with 
500 µl of (full form) RAW buffer and then with 600ul of RAV3, followed by 
centrifugation at 8,000g for 1 minute. Waste was discarded after every wash 
step. To dry the columns, a final wash step was required, where 200 µl of 
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RAV3 was added to the tube and centrifuged at 11,000g for 5 minutes. Finally, 
viral RNA was eluted by adding 50 µl of nuclease-free water (at 70 °C, as hot 
water aids in RNA elution), and incubating at RT for 1 – 2 minutes at followed 
by a spin at 11,000 g for 1 minute. Viral RNA was then stored at -80 °C for 
long term use. 
2.4.7.5. Determination of viral titres 
(Thermo Fisher Scientific) to remove any contaminating plasmid DNA prior to 
qRT-PCR. DNase treatment is key, as contaminating plasmid DNA could lead 
to false high copy numbers. 25 µl reactions were incubated at 30oC for 30 
minutes and at 70oC for 5 minutes with a 4oC hold.  
Serial dilutions of the stock DNase-treated viral RNA and of an RNA control 
(known copy number of 109–102, provided with the kit) were prepared, and 2 
µl each were aliquoted per well, in a 96 multi-well PCR plate. Next, a master 
mix was made following the manufacture’s recommendation, using the Quant-
X™ One-Step qRT-PCR SYBR® kit (Clontech). 18 µl of the master mix was 
added to the samples to make a final reaction volume of 20 µl and the plate 
was sealed. The following program was used for the qRT-PCR run: RT 
Reaction (42C for 5 minutes and 95C for 10 seconds), qPCR x 40 cycles 
(95C for 5 seconds and 60C for 30 seconds) and melt Curve analysis (95C 
for 15 seconds, 60C for 30 seconds).  
The lentiviral copy number in the initial viral stocks was determined by 
comparing their Ct values to Ct values on a standard curve generated from 
serial dilutions of the calibrated Lenti-X RNA Control Template, and by 
accounting for the dilution factors. A copy number of at least X108 is required 
to achieve reasonable knockdown. The formula below was used for back-
calculating copy number/ml: 
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Next, copies per ml were converted into transducing units per ml (TU/mL):  
 
The division factor (100,000) was estimated from an experiment where the 
qRT-PCR titration method was normalised to a conventional fluorescent 
microscopy method for titrating lentiviral vectors expressing GFP. GFP 
positive cells/colonies were counted and a normalising factor was generated 
(performed by Dr Lyuba Z, Norwich Medical School, UEA, Norwich, UK).   
Next, using the determined values for TU/ml, the volume needed to achieve 
the desired number of viral particles was calculated for multiplicities of 
infections (MOI) ranging from 1-30 as follows:  
 
Viral stocks were concentrated using Amicon® Ultra centrifugal filters. During 
the concentration procedure, all plastic ware and samples were kept on ice to 
prevent degradation of viral particles at RT. The above calculated volume was 
divided by the concentration factor to obtain the right volume of concentrated 
stock required to achieve the desired infectious particles/cell. A range of MOIs 
were tried out to determine an MOI that achieves gene knockdown with 
minimal off target effect and without compromising cell viability.  
2.4.7.6. Lentiviral infection of target cells 
Viral stocks were stored in -80oC and when needed, thawed at 4oC on ice. The 
required number of cells to be infected was cultured in 0.5 ml of antibiotic free 
complete culture media, in 12 well culture plates. Polybrene was added at a 
final concentration of 1 µg/ml to the cell cultures, to increase the efficiency of 
infection. Polybrene works by countering electrostatic charges between the 
virus and the cell membrane, which both have a negative charge on their 
surfaces. Next, the required volume of virus for the desired MOI was added 
and the plate was gently swirled to ensure even distribution. At 24 hours, the 
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cultures are topped up with an additional 500 µl of antibiotic-free culture media 
and incubated for an additional 48 hours at RT. At 72 hours, RNA was 
extracted as described before (section 2.4.1) and the gene knockdown 
efficiency was determined by qRT-PCR. At 96 hours, protein was extracted as 
described before (2.4.6.1.1) and western blotting was performed (2.4.6.1) to 
determine protein knockdown.  
2.4.8. Senescence associated β- galactosidase staining 
The senescence β-galactosidase staining kit (Cell Signaling Technology 
(CST), Massachusetts, USA) was used to detect Senescence associated β-
galactosidase in BSMCs. Cells of interest were cultured and treated in 35 mm 
culture dishes. The culture media was removed and cells were washed once 
with PBS and fixed with 1 ml 1x fixative solution for 15 minutes at RT. Cells 
were next washed twice with PBS and incubated at 37oC overnight, in 1 ml of 
β-galactosidase staining solution. The pH of the staining solution was 
measured and, if needed, adjusted to a pH of 6. A low pH can result in false 
positives while a high pH can result in false negatives. The plates were sealed 
with parafilm to prevent changes in pH due to atmospheric carbon dioxide.  
The cells were checked for the development of a blue colour, which usually 
happens within 48 hours, and is indicative of SA-β galactosidase positive cells. 
The staining solution was removed and replaced with 1 ml of 70% glycerol. 
Stained plates were viewed under a light microscope and pictures were 
acquired using a camera and the 10x lens. The plates were resealed and 
stored at 4oC. The fixed plates are stable for over 12 months if stored properly.  
2.5. In vivo animal models  
All animal work was carried out in accordance with regulations set by the UK 
Home Office and the guidelines outlined in the Animal Scientific Procedures 
Act, 1986. Animals were housed in the Disease Modelling Unit (DMU) facility 
at the University at East Anglia, in individually ventilated cages, and 
maintained under specific pathogen-free conditions. The animals were 
regularly screened for common mouse pathogens. 8 – 10 week old mice were 
used for all the experiments. Non-obese diabetic/severe combined 
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immunodeficiency (NOD/SCID) mice were purchased from Jackson 
Laboratories (Bar Harbor, ME, USA). The p16-3MR senescence mouse model 
was kindly gifted to our lab by Dr Campisi (The Buck Institute for Research on 
Aging, Novato, USA). A full description of the procedure employed to generate 
the p16-3MR Mouse model is described by Demaria et. al., 2014 (262). 
2.5.1. Non- diabetic (NOD) severe combined immunodeficiency (SCID) 
and gamma model (NSG) mice for human xenograft models 
Cell line and primary patient derived xenografts require the recipient animal to 
be immunodeficient to avoid rejection of transplanted human cells. The most 
commonly used immunodeficient mouse strain is the NSG or NOD scid 
gamma mouse, also called the NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ mouse, 
developed by Dr. Leonard Shultz at The Jackson Laboratory. Genetically, this 
mouse model harbours a functionally null allele for the IL-2 receptor gamma 
chain (IL2Rgnull) and the severe combined immune deficiency mutation 
(Prkdcscid) on the nonobese diabetic NOD/ShiLtJ background (289). 
Phenotypically, these mutations translate into the lack of mature B and T, 
natural killer cells, and defective dendritic cells. Together, this makes it 
possible for cancer cell lines and human cells to be engrafted easily in this 
model (290). 
2.5.2. Patient derived xenografts 
Primary AML cells were infected with a pCDHluciferase-T2A-mCherry 
lentiviral construct, kindly gifted by Prof. Dr. Med. Irmela Jeremias, (Helmholtz 
Zentrum München, Munich, Germany) (291), and sorted by flow cytometry 
using the red channel on a BD FACSARIA III cell sorter (BD Biosciences), with 
the help of Zhigang Zhou (School of Biological Sciences, UEA, Norwich, UK). 
The luciferase moiety allowed monitoring of disease development via in vivo 
bioluminescent (BL) imaging. 2x106 viable AML cells were washed and re-
suspended in PBS.  
Injections of the AML cells into non-irradiated, 6-8 week-old, NSG was 
performed by Chris Marlein, R Piddock and S Rushworth (Norwich Medical 
School, UEA, Norwich, UK). Prior to being injected, the mice were warmed in 
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individual warming boxes at 37oC for 10 minutes (which helped to dilate the 
tail veins for easy and visible introduction of needles). 200 µl of AML cell 
suspension was injected into their tail veins using a sterile, 27-gauge needle, 
attached to a 1 ml syringe . Immediately following injections, mice were closely 
monitored for signs of bleeding from the injection site and returned to the cages. 
2.5.3. OCI-AML3 human xenograft model 
OCI-AML3 cells were infected with the pCDH-luciferase-T2A-mCherry 
lentiviral construct, followed by infection with control-ShE, MIF KD or HIF KD 
lentiviral particles. Next, the cells were sorted on a BD FACSARIA III 
(BD Biosciences, Allschwil, Switzerland) cell sorter.  1x106 cells were washed 
and re-suspended in PBS. The cells were then injected into the tail vein of 
NSG mice, as described in section 5.2.5. The MIF-KD and the HIF1α-KD in 
vivo experiments were carried out simultaneously, therefore, the same control-
KD (ShE-KD) mice were used for both, MIF-KD and HIF1α-KD mice.  
2.5.4. In vivo bioluminescent (BL) imaging 
Animals were imaged on on the Bruker In-Vivo Xtreme Imaging Systems 
(Bruker Corp., Massachusetts, USA) imager. In vivo imaging was performed 
with the help of Chris Marlein, R Piddock and S Rushworth (Norwich Medical 
School, UEA, Norwich, UK). Each animal was imaged at the days specified in 
the text (section 5.9) . D-luciferin (Thermo Fisher Scientific) was dissolved in 
sterile PBS (15 mg/ml) and aliquots were stored at −20°C. Each animal was 
injected with 200 µl of D-luciferin at RT by intraperitoneal injection (IP), and 
allowed to settle for 10 minutes before they were anesthetised with 2-3% 
isofluorane/oxygen in an induction chamber, and then carefully transferred to 
the Bruker specimen chamber.  
Anaesthesia was maintained during imaging using a nose cone isoflurane-
oxygen delivery device fitted in the chamber. Bioluminescent images were 
acquired within 20 minutes after IP of D-Luciferin. The camera took a light, an 
X-ray and a luminescent image of the animals. Finally, the animals were 
allowed to recover under close observation and returned to their cages. 
Luminescent signal intensity was quantified and final images were analysed 
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using the Bruker MI SE software. The output images represented matched-
scale luminescent images overlaid on light images showing the animal 
skeleton, thus allowing to determine where the tumour cells are (as seen in 
Figure 5.14A).  
2.5.5. Sacrificing animals and harvesting of the bone marrow and 
spleen cells 
Animals were monitored daily for the development of clinical signs of illness, 
and when these became apparent (such as weight loss, reduced motility, 
bilateral hind leg paraplegia due to tumour burden, over grooming and rough, 
patchy fur), mice were sacrificed by exposure to CO2 and dislocation of the 
neck. BM and spleen cells were harvested and analysed for human CD33 and 
CD45 expression. The tibia and femurs (Figure 2.4A) were isolated whole and 
de-fleshed (Figure 2.4B). Next the bones were cut from the thinner end and 
placed in a 0.5 ml Eppendorf tube in which a hole was made using an 18 gauge 
syringe. This tube was placed in an intact 1.5 ml Eppendorf tube and 
centrifuged at high speed for 10 seconds to collect total BM cells. The open 
end allowed BM cells to escape into the 1.5 ml collection tube.  
The spleen was immersed in PBS, minced in a 35 mm culture dish using a 1 
ml sterile tip and filtered through a 4 micron mesh to obtain a single cell 
suspension. Red cell lysis was performed with the Hybri-Max buffer. BM and 
spleen cells were then double stained for CD33/CD45 and assayed by flow 
cytometry. If more than 1% of human CD33/CD45 cells were detected in the 
BM or spleen, the AML sample was considered to have been successfully 
engrafted. 5 x106 cells were re-suspended in RNA BL+TG lysis buffer for 
mRNA expression. Excess cells were discarded.  
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A.                                                           B. 
       
Figure 2. 4 Bones and spleens harvested from NSG mice.   
(A) A schematic depicting the different parts of the hind limbs of a mouse (adapted 
from The Anatomy of the Laboratory Mouse, Margaret J. Cook (292)). (B) The top 
panel shows excised and de-fleshed tibias and femurs from 2 NSG mice; the bottom 
panel shows excised spleens from 2 NSG mice. 
 
2.6. Bioinformatics analysis 
Bioinformatics analysis was performed with the help and guidance of Manar 
Shafat (Norwich Medical School, UEA, Norwich, UK). Publicly available RNA 
sequencing data were downloaded for a panel of 43 AML patients, comprised 
of 22 AML samples obtained from peripheral blood and 21 AML samples 
obtained from BM aspirates (Gene Expression Omnibus Accession ID: 
GSE49642).  
Reads per kilobase per million (RPKM) data for MIF were extracted and 
processed further by first replacing zero-valued entries, with one followed by 
logarithmic transformation to the base 2. MIF RPKM values for blood and bone 
marrow samples were compared with a Wilcoxon rank-sum test. Data were 
extracted for genes that have been shown to be upregulated as a result of 
HIF1α overexpression, HIF2α overexpression and hypoxia (293) .These data 
were processed further by first replacing zero-valued entries with one, 
followed by logarithmic transformation to the base 2. 
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2.7. Statistical analyses 
All data were analysed using Prism software (Version 5.0, GraphPad 
Software, San Diego, CA, USA). The Mann-Whitney U test was used to 
compare test groups unless stated otherwise in the figure legend. Survival 
data were analysed by Kaplan-Meier log-rank test. Results where P<0.05 were 
considered statistically significant and are denoted by *. Results represent the 
mean ± standard deviation of 3 or more independent experiments. Standard 
error of the mean was used to present cytokine array data deviation (Figure 
3.5 and Figure 3.6).  
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3. Chapter 3: AML influences the secretory profile of BMSCs 
In this chapter, I first aimed to in vitro characterise BMSCs and subsequently 
establish an AML/BMSC co-culture. From the co-cultures, using a cytokine 
array assay, I determined potential AML pro-survival cytokines.  
3.1. In vitro expansion of primary AML-derived BMSCs 
Whole BM aspirates from AML patients, who consented at the NNUH 
haematology clinic, were processed in the tissue culture laboratory according 
to the protocol described in materials and methods (section 2.3.2). I used 
isolated mononuclear cells to expand BMSCs in vitro. Human BMSCs are 
initially isolated based on their selective adherence to plastic culture surfaces, 
followed by phenotypic characterisation to confirm the expression of a panel 
of cell surface molecules, including CD90, CD105 and CD73, and excluding 
of CD45 (294).  
I cultured the isolated bone marrow mononuclear cells at 1 million cells per mL 
in T-75 culture flasks overnight and observed the cells the next day for 
adherence. Contrarily to BMSCs, AML cells are non-adherent to plastic, and 
thus, can be selectively removed from culture after the initial medium change, 
24 - 48 hours post isolation. The chosen time point depended on when I was 
able to identify adherent BMSCs that were 80% confluent. Any contaminating 
AML cells were eliminated as the BMSC cultures were passaged and this 
process was usually complete at passage 2 or 3 (Figure 3.1A). Before using 
the BMSC cells for experiments, I would check for expression of BMSC 
markers (CD90, CD105 and CD73) and negative expression of the myeloid 
marker CD45 (Figure 3.1B) to further confirm the purity of the BMSC 
population. Purities of > 99.99% were routinely achieved with this method. 
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A.                 Day 5 (P=0)                                            Day 15 (P=4) 
        
 
B.   
 
Figure 3. 1 In vitro expansion and characterization of bone marrow stromal cells 
(BMSCs). 
(A) Growth of BMSCs over 15 days. P, passage number. (B) Surface marker 
expression on BMSCs at day 15 of culture, cultured cells were CD45 negative and 
CD73, CD90 and CD105 positive – which is characteristic of BMSCs. The red peak 
represents the marker of interest and the black peak represents the isotype control. 
 
Over time, I noticed that after 6-8 weeks of passaging (the average number of 
passages depended on the individual BMSC sample), cell proliferation began 
to slow down and their morphology changed from a fibroblastic spindly shape, 
to a flatter rounder shape with cell-free gaps (Figure 3.2). When the cells 
stared displaying this phenotype, I would deem them unsuitable for further use 
and the culture would be terminated. No primary BMSCs were cultured past 
passage 6. BMSCs could also be derived from cryopreserved AML cell 
samples with a similar prolife. 
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                 1                                          2                                         3  
   
Figure 3. 2 Morphology of primary cultured BMSC over time.  
(1) BMSCs after 7 passages; the arrows indicate cell-free gaps (2) BMSCs after 9 
passages (3) BMSCs after 10 passages; the arrows indicate cells with a different 
morphology.  
 
Cytogenetics of the six primary BMSCs used for the experiments described 
below were initially examined, following Huang et. al.’s previous observations 
of cytogenetic abnormalities in 75% of the BMSCs of patients with AML (295). 
My results found three of six to be normal, whereas genotyping failed for the 
other three (table 1 of the appendix).  
3.2. BMSCs support AML survival in vitro 
AML cells exhibit a high level of spontaneous apoptosis when cultured in vitro 
but have a prolonged survival time in vivo, indicating that the BMM plays a 
critical role in promoting AML cell survival and proliferation (296-298). For my 
research, I aimed to investigate how well BMSCs support the in vitro survival 
of primary human AML cells, and to do so I established a co-culture system 
with primary AML cells and BMSCs from AML patients who never had 
chemotherapy to treat the AML. 
For the co-culture I used two cell populations in transwell plates, with BMSCs 
cultured on the bottom of the plate and AML cells placed above. As a 
monoculture control, AML cells were placed in the transwell with no BMSCs. 
The survival of AML cells with BMSCs versus monoculture was assessed by 
viable cell counting, utilising trypan blue exclusion and a hemocytometer on 
day 6 (n=20) and day 14 (n=6). I found that AML survival was significantly 
improved when co-cultured with BMSCs, compared to the controls at both, 
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days 6 and 14 (Figure 3.3). The cytogenetics and WHO diagnosis of the AML 
patient samples used in chapter 3 and 4 are shown in table 3.1.  
A.                                                                B. 
                              
Figure 3. 3 Primary AML survival in mono-cultures versus on primary BMSCs.  
Scatter graph depicting the survival of AML cells cultured on BMSCs versus AML 
cells alone (A) for 6 days and (B) for 14 days. AML blasts (0.25x106) were co-cultured 
with primary BMSCs on a 12 well plate for 6 days (n=20) or 14 days (n=6), AML blast 
number was assessed using a trypan blue exclusion hemocytometer-based counts. 
* denotes p < 0.05. 
 
Table 3. 1 AML patient sample characteristics used in chapter 3 and 4.   
This table defines the nature of the AML patient samples used in the studies 
conducted in chapter 3 and 4.   
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3.3. AML cells induce changes in the BMSC cytokine secretion profile 
Both BMSCs and primary AML cells demonstrate constitutive release of 
several soluble mediators (295). Previous studies have shown that BMSCs 
can inhibit AML apoptosis, be it cell line or murine stromal cell derived BMSCs 
(66, 299). To study cell-cell communication between BMSCs and AML cells, 
and to understand the role of soluble factors in mediating the cross-talk 
between them, I analysed cytokines and chemokines from the supernatants of 
cultures of AML only, BMSC only and AML cells with BMSCs (AML/BMSC). I 
performed this assay on six different primary AML samples cultured on four 
different BMSCs. Figure 3.4 shows a representative cytokine array of one 
data-set. Table 3.2 contains the corresponding data set for figure 3.4. Full data 
sets of the co-cultures are provided in Table 2 of the appendix.  
A.                                                             B. 
         
Figure 3. 4 A representative image of the developed cytokine array from AML, 
BMSC and AML/BMSC culture media.  
(A) Representative cytokine antibody arrays of cell culture conditioned media, using 
the Human cytokine proteome profiler array is shown; from top to bottom: AML cells 
(0.25x106) only, BMSCs only, and BMSC/AML co-culture, after 24 h (n=6). (B) 
Corresponding cytokine array coordinates, cross-reference with table 3.2.  
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Table 3. 2 Cytokine mean pixel densities data set for figure 3.4.  
Coordinates correspond to the location of the cytokine duplicate on the 
nitrocellulose membrane.  
 
(coordinate)(Cytokine) 
AML only BMSC Only Co-culture
AML#6 BMSC#4   + AML#6
(A1-A2)(Reference Spots) 63192.82 48901.689 62755.2
(A3-A4)(Adiponectin) 884.41 547.75556 1088.22
(A5-A6)(Aggrecan) 1047.96 2305.5867 3694.74
(A7-A8)(Angiogenin) 605.73 2309.6489 3505.02
(A9-A10)(Angiopoietin-1) 1425.77 873.39556 1256.51
(A11-A12)(Angiopoietin-2) 2070.05 1115.5422 1615.3
(A13-A14)(BAFF) 936.83 592.82667 936.61
(A15-A16)(BDNF) 1009.02 1187.7467 1790.19
(A17-A18)(CC C5/C5a) 433.14 492.33333 357.21
(A19-A20)(CD14) 800.94 752.84444 909.27
(A21-A22)(CD30) 3027.78 1376.2489 1248.02
(A23-A24)(Reference Spots) 63176.06 49905.689 62734.33
(B3-B4)(CD40 ligand) 1574.01 621.29778 1278.62
(B5-B6)(Chitinase 3-like 1) 1062.98 12551.991 30837.3
(B7-B8)(Complement Factor D) 1823.75 2890.0756 4093.83
(B9-B10)(C-Reactive Protein) 1592.78 992.85778 1288.39
(B11-B12)(Cripto-1) 970.45 552.02667 910.9
(B13-B14)(Cystatin C) 1321.68 1550.1822 2361.83
(B15-B16)(Dkk-1) 1722.99 25905.956 41937.41
(B17-B18)(DPPIV) 273.54 277.12889 148.29
(B19-B20)(EGF) 2454.38 1698.12 1796.85
(B21-B22)(EMMPRIN) 4671.4 2785.5289 5266.98
(C3-C4)(ENA-78) 1428.45 868.36889 3777.9
(C5-C6)(Endoglin) 2662.32 2087.3022 5554.34
(C7-C8)(Fas Ligand) 1135.54 718.50667 989.58
(C9-C10)(FGF basic) 2283.03 1350.8933 1880.08
(C11-C12)(FGF-7) 880.67 930.12889 1619.2
(C13-C14)(FGF-19) 3639.62 2693.4311 6549.95
(C15-C16)(Flt-3 Ligand) 470.05 550.09778 792.47
(C17-C18)(G-CSF) 458.74 421.57778 445.61
(C19-C20)(GDF-15) 1231.6 2432.0089 7845.77
(C21-C22)(GM-CSF) 3148.77 2467.7022 4411.59
(D1-D2)(GRO-a) 895.58 498.23556 861.27
(D3-D4)(Growth Hormone) 716.54 319.39556 521.8
(D5-D6)(HGF) 5712.68 1626.0711 4255.5
(D7-D8)(ICAM-1) 1019.02 837.54667 1267.75
(D9-D10)(IFN-?) 1727.49 847.39556 983.44
(D11-D12)(IGFBP-2) 425.47 10678.218 21641.79
(D13-D14)(IGFBP-3) 1107.73 9329.8622 14991.33
(D15-D16)(IL-1a) 2176.53 950.63556 1667.69
(D17-D18)(IL-1ß) 893.32 747.32444 1466.6
(D19-D20)(IL-1ra) 245.31 292.50667 612.91
(D21-D22)(IL-2) 922.69 983.55556 1052.91
(D23-D24)(IL-3) 483.34 572.78667 500.68
(E1-E2)(IL-4) 729.22 506.43556 879.42
(E3-E4)(IL-5) 394.21 129.09778 81.62
(E5-E6)(IL-6) 3088.62 25541.88 45003.57
(E7-E8)(IL-8) 3785.28 27160.342 56680.79
(E9-E10)(IL-10) 740.96 681.05333 729.94
(E11-E12)(IL-11) 2816.3 9500.0933 12850.61
(E13-E14)(IL-12 p70) 1367.28 770.91111 1253.46
(E15-E16)(IL-13) 616.07 484.37333 616.05
(E17-E18)(IL-15) 517.27 451.75111 878.56
Culture condition 
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Table 3. 2 continued  
 
 
(coordinate)(Cytokine) 
AML only BMSC Only Co-culture
AML#6 BMSC#4   + AML#6
(E19-E20)(IL-16) 1496.52 252.32444 1250.05
(E21-E22)(IL-17A) 3719.76 4590.3511 7113.14
(E23-E24)(IL-18 BPa) 451.64 526.77778 492.61
(F1-F2)(IL-19) 1430.78 574.78667 1058.75
(F3-F4)(IL-22) 1869.53 986.90667 1694.07
(F5-F6)(IL-23) 568.16 619.91556 1372.52
(F7-F8)(IL-24) 1246.49 1063.1467 2039.13
(F9-F10)(IL-27) 1967 874.72 1232.97
(F11-F12)(IL-31) 1024.71 511.66667 533.34
(F13-F14)(IL-32a/ß/?) 1141.81 570.42222 912.98
(F15-F16)(IL-33) 887.65 381.99556 656.82
(F17-F18)(IL-34) 336.94 284.54222 535.43
(F19-F20)(IP-10) 278.34 315.70667 719.82
(F21-F22)(I-TAC) 532.48 780.64 652.21
(F23-F24)(Kallikrein 3) 1180.96 1353.6178 1556.86
(G1-G2)(Leptin) 862.54 311.87111 660.63
(G3-G4)(LIF) 698.36 5493.4889 8668.34
(G5-G6)(Lipocalin-2) 4285.76 873.42222 2245.12
(G7-G8)(MCP-1) 3099.85 17755.151 37175.71
(G9-G10)(MCP-3) 1057.68 714.72 1173.28
(G11-G12)(M-CSF) 1781.94 856.75556 998.53
(G13-G14)(MIF) 32650.14 2950.8044 16923.52
(G15-G16)(MIG) 1169.51 677.63111 1142.44
(G17-G18)(MIP-1a/MIP-1ß) 207.31 98.462222 603.61
(G19-G20)(MIP-3a) 246.06 750.36444 1959.89
(G21-G22)(MIP-3ß) 449.45 466.06222 567.42
(G23-G24)(MMP-9) 937.32 727.62667 1432.96
(H1-H2)(Myeloperoxidase) 1280.86 297.56444 1340.23
(H3-H4)(Osteopontin) 2653.11 1742.9378 3287.79
(H5-H6)(PDGF-AA) 7407.75 7417.8133 11701.57
(H7-H8)(PDGF-AB/BB) 686.42 356.8 536.45
(H9-H10)(Pentraxin-3) 3262.26 9850.3822 19073.93
(H11-H12)(PF4) 498.75 278.16 819.94
(H13-H14)(RAGE) 815.25 491.02667 769.31
(H15-H16)(RANTES) 1765.24 636.97778 1237.22
(H17-H18)(RBP4) 1744.64 1141.5956 1610.47
(H19-H20)(Relaxin-2) 1174.76 768.87556 933.84
(H21-H22)(Resistin) 2871.19 1802.7644 3246.27
(H23-H24)(SDF-1a) 712.46 7946.1289 10744.88
(I1-I2)(Serpin E1) 3989.99 27899.329 62439.02
(I3-I4)(SHBG) 1379.65 945.24 1716.52
(I5-I6)(ST2) 1231.26 1340.3289 1870.67
(I7-I8)(TARC) 1487.42 833.50667 1314.85
(I9-I10)(TFF3) 312.72 537.66222 1358.82
(I11-I12)(TfR) 1168.7 468.81778 1259.33
(I13-I14)(TGF-a) 556.73 483.05333 541.6
(I15-I16)(Thrombospondin-1) 2817.13 4882.6489 7540.79
(I17-I18)(TNF-alpha) 779.46 636.26222 801.67
(I19-I20)(uPAR) 1261.01 3206.6756 5474.14
(I21-I22)(VEGF) 213.56 10987.147 19452.53
(J1-J2)(Reference Spots) 63192.82 48901.689 62753.72
(J5-J6)(Vitamin D BP) 3962.03 1639.5867 2455.87
(J23-J24) negative control 0 0 0
Culture condition 
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I next analysed the cytokine array blots using HLImage++ software to quantify 
the duplicate dots for each cytokine. Ultimately the aim of this experiment was 
to determine what cytokines and chemokines were differentially expressed by 
BMSCs in response to co-culture with AML cells. Therefore, I performed the 
analysis of the array data in two ways: 
1. I subtracted the AML mono- culture profile from the AML/BMSC co-culture 
profile, and then used the latter for comparison with the BMSC mono-culture 
profile (Figure 3.5A). This enabled me to correct for any background readings 
from the AML only mono-culture data. There are associated caveats in this 
method of analysis which are mentioned in the discussion (section 7.1.2). 
2. Comparison of the AML/BMSC co-culture profile directly with that of the 
BMSC mono-culture (Figure 3.5B).  
The two methods showed a consistent number of cytokines and chemokines 
that were differentially expressed in the media of the AML/BMSC co-culture, 
versus the BMSC monoculture (Figure 3.5). Cytokines that were consistently 
upregulated in all co-cultures from both analyses were IL-6 and IL-8. 
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A. 
 
B. 
 
Figure 3. 5 Bar graphs comparing the fold increase in cytokines between 
BMSC/AML co-cultures and BMSC monocultures. 
 (A) Cytokines that were upregulated in co-cultures after subtraction of the AML 
monoculture profile. (B) Cytokines that are upregulated in the co-cultures, without 
subtraction of AML monocultures. Results from 7 different primary AML samples on 
four different BMSCs are shown, together with the mean and standard error of the 
mean (SEM). 
I also wanted to determine the cytokines and chemokines that were high in 
AML samples only. I did this because I wanted to verify if there was an AML 
derived factor that was responsible for activating BMSCs. For this analysis, I 
compared the optical density values obtained by the HLImage++ software in 
all three culture conditions (AML only, BMSC only, AML/BMSC). The results 
showed that a number of cytokines and chemokines were high in AML and 
AML/BMSC cultures, but low in BMSC media (Figure 3.6). Particularly, it was 
apparent that levels of macrophage migration inhibitory factor (MIF), were 
consistently high in all AML and AML/BMSC supernatants, but low in the 
BMSC supernatants. 
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Figure 3. 6 Bar graph depicting the results of a cytokine array optical density 
quantification of AML only arrays.  
The graph reports the expression levels of the top 7 cytokines found in the media of 
AML monocultures, in the form of mean pixel density. 8 individual AML samples were 
included in the analysis, 6 of which were used in the co-cultures. Bars, mean and 
SEM.  
 
In summary, from the cytokine and chemokine array experiments I identified 
MIF as being highly expressed in AML cells compared to BMSCs. On the other 
hand, I found IL-6 and IL-8 to be increasingly upregulated in the AML/BMSC 
co-cultures, compared to BMSC monocultures.  
Serum IL-8 is known to be higher in patients with AML, myelodysplasia (MDS) 
and non-Hodgkin Lymphoma than in normal controls. Also, levels of IL-8 in 
these patients are comparable to those found in patients with multiple organ 
failure of non-septic origin (118, 137). Furthermore, leukaemic cells from 
patients with AML have been shown to constitutively express IL-8 (136) and, 
inhibition of the IL-8 receptor, CXCR2 selectively inhibits proliferation of 
MDS/AML cell lines and patient samples (140).  
MIF overexpression has been observed in a cohort of AML patients and was 
found to be related to poor outcomes for these patients (300). Moreover, in 
CLL, MIF was observed to induce IL-8 production by primary CLL, and 
targeted deletion of the MIF gene delayed the development of CLL in vivo, 
thereby resulting in prolonged survival of the CLL mice models (166). Together 
these studies suggest a link between MIF and IL-8, which lead me to 
101 
 
 
hypothesise that MIF and IL-8 have a unique function in establishing 
AML/BMSC crosstalk which could drive AML survival. 
AML cells have been shown to spontaneously secrete IL-6 (301) and survival 
of patients with AML have been shown to be inversely correlated with IL-6 
expression (302). In 1988, Hoang and colleagues reported that IL-6 had little 
effect by itself. However, it synergised with granulocyte macrophage colony- 
stimulating factor (GM-CSF) and IL-3, thus stimulating AML blast colony 
formation  (303). Nevertheless, it seems that IL-6 may have a direct effect on 
the growth of leukaemic blasts: Saily et. al. demonstrated that only three of the 
16 AML samples in their study were influenced by IL-6, two of them being 
stimulated and, one inhibited by it (145).  
IL-6 has been shown to be regulated by MIF in lymph node cells (LNC) in MIF 
knockout mice (mif−/−), where they had severely impaired production of IL-6 
(304). Furthermore, MIF was shown to regulate Vibrio vulnificus-induced IL-6 
production in human peripheral blood cells (305). MIF was also shown to 
cause dose-dependent increase in IL-6, IL-8, and prostaglandin E2 (PGE2) 
release from chondrocytes (306) and to induce IL-6 and IL-12 production from 
macrophages (307). These data lead me to hypothesise that MIF may regulate 
IL-6 secretion in AML cells as well.  
Next, I examined the effect of AML on IL-8 and IL-6 expression in BMSCs. 
3.4. AML but not BMSCs express high levels of MIF mRNA under normal 
basal conditions 
To confirm which cell type (BMSCs or AML cells) are the main producers of 
MIF in the co-cultures, I examined mRNA expression levels of MIF 
monocultures of primary AML cells (n=5) and  BMSCs (n=5). This showed that 
AML but not BMSCs, express high levels of MIF mRNA under normal basal 
conditions (Figure 3.7). 
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Figure 3. 7 Bar graph comparing MIF mRNA expression levels in AML and 
BMSC cultures. 
BMSCs and primary AML cells were cultured alone for 48 hours and measured for 
MIF mRNA levels using qRT-PCR, mRNA expression was normalised to GAPDH 
mRNA levels, (n=5). 
 
3.5. IL-8 specific ELISAs confirm IL-8 upregulation in AML/BMSC co-
cultures  
To verify that MIF was highly expressed in AML and that IL-8 was up-regulated 
in AML/BMSC clutures, I used MIF and IL-8 specific ELISA. I found that IL-8 
concentrations peak at 8 and 24 hours in the AML/BMSCs co-culture 
supernatants (Figure 3.8), whereas MIF concentrations were high at similar 
levels in both AML only and in AML/BMSCs co-culture supernatants (Figure 
3.9). This data shows that MIF is constitutively secreted by the AML cells, and 
that IL-8 levels are maintained high in co-cultures over a 24-hour period.  
 
Figure 3. 8 Bar graph representing IL-8 protein expression (pg/ml) in 
monocultures and AML/BMSC co-cultures over 24 hours. 
AML cells or BMSCs were cultured alone or together for the indicated times. IL-8 
ELISA was used to determine IL-8 concentration in culture supernatants (n=3). 
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Figure 3. 9 Bar graph representing MIF expression (pg/ml) in monocultures and 
AML/BMSC co-cultures over 24 hours. 
MIF ELISA of each of the cell culture conditioned media from various time points are 
plotted, similar to Figure 3.8 above (n=3).  
 
3.6. IL-6 is not upregulated in BMSCs in AML/BMSCs to co-cultures 
To determine if IL-6 is up regulated in AML/BMSC co-cultures, I used target 
specific ELISA and found that IL-6 concentrations are high in BMSC 
monocultures but not upregulated in co-culture (Figure 3.10A). Moreover, I 
extracted total RNA from BMSC mono- and co-cultures and performed real-
time PCR for IL-6 mRNA expression. Figure 3.10B shows that IL-6 mRNA 
expression is not upregulated in BMSCs co-cultures with AML cells at any of 
the chosen time points. This result led me to focus my further experiments 
towards the role of BMSC-derived IL-8 in regulating AML survival. 
 
A.                                                                 B. 
    
Figure 3. 10 Bar graph depicting IL-6 expression (pg/ml) in monocultures and 
AML/BMSC co-cultures over a period of 24 hours. 
(A) IL-6 ELISA of each of the cell culture conditioned media from various time points. 
(B) IL-6 mRNA expression was determined using qRT-PCR, expression was 
normalised to GAPDH mRNA levels (n=3). 
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3.7. AML induced IL-8 expression in BMSCs is contact independent 
Interactions between AML cells and BMSCs can take many forms. Some 
interactions require cell-to-cell contact while others do not (78, 308). I wanted 
to determine if BMSCs needed direct contact with AML cells to increase IL-8 
in the co-cultures. I therefore, co-cultured BMSCs in direct contact with AML 
or with the AML held within transwell inserts. The transwell inserts prevent cell 
to cell contact but allow the transfer of soluble factors between the two 
compartments. Figure 3.11 shows that IL-8 mRNA from BMSCs incubated with 
AML increased 57-fold when in direct contact (DC), and 50-fold when in 
indirect contact (IC) using transwell inserts. This confirms that direct tumour 
cell to stromal cell contact is not necessary for AML to induce increased IL-8 
expression by human BMSCs. 
 
 
Figure 3. 11 Bar graph comparing fold increase over control of IL-8 induction in 
AML/BMSC co-cultures in direct contact (DC) versus indirect contact (IC). 
AML cells (0.25x106) were co-cultured with primary BMSC either in DC or with indirect 
contact (transwell insert) for 24 h (n=5). RNA was extracted and IL-8 mRNA in the 
BMSC was assessed by real-time PCR. mRNA expression was normalised to 
GAPDH mRNA levels (n=5). 
 
3.8. Recombinant human MIF (rhMIF) induces IL-8 expression in AML 
derived BMSCs but not normal cell line BMSCs 
Since MIF has been shown to be over expressed in AML patients and is 
associated with poor outcome (300), and that MIF can induce IL-8 production 
by primary CLL (170), I hypothesised that the MIF from AML cells could be 
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increasing IL-8 in the BMSCs. To test this hypothesis, I stimulated BMSCs with 
100ng/mL of recombinant human MIF (rhMIF) (309, 310) and assayed for IL-
8 mRNA and protein expression over a period of 24 hours. I found that IL-8 
mRNA and protein increased (Figure 3.12) in response to rhMIF, 
demonstrating that MIF causes an increase in IL-8 expression by BMSCs.  
 
A.                                                                    B.  
                   
Figure 3. 12 Bar graph comparing fold increase over control of IL-8 expression 
in BMSCs in response to MIF stimulation, over 24 hours. 
(A) BMSCs from 5 patients were treated with rhMIF (100 ng/mL) for indicated times, 
and then extracted RNA was assessed for IL8 mRNA by qRT-PCR. mRNA 
expression was normalised to GAPDH mRNA levels. (B) BMSCs from 5 patients were 
treated with rhMIF (100 ng/mL) for indicated times, and then, media were assessed 
for IL8 protein expression by ELISA.  
 
Due to the number of experiments I needed to perform with patient BMSCs 
and AML together, with only limited availability of primary tissue, I attempted 
to mimic the effect of AML on BMSC by using a cell line known to be derived 
from BMSCs. The HS-5 cell line has been shown to support AML survival, 
proliferation and to protect AML cells from drug-induced apoptosis (66, 311), I 
therefore treated HS-5 with rhMIF. Figure 3.13A shows that MIF does not 
stimulate IL-8 mRNA expression in HS-5 cells. Moreover, when I cultured AML 
cells with HS-5, I observed no increase of IL-8 mRNA in BMSCs. (Figure 
3.13B). This suggests that the HS-5 cell line is not an ideal model for studying 
AML/BMSC interactions and this therefore, confirmed my understanding that 
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using primary AML with primary BMSCs is the only way to study the true nature 
of the AML microenvironment. 
A.                                                                        B. 
                        
  
Figure 3. 13 Bar graph comparing fold change in IL-8 mRNA expression in HS-
5 treated with rhMIF or co-cultured with AML.  
(A) HS-5 were treated with rhMIF (100 ng/ml) for the indicated times and then RNA 
extracted and assessed for IL-8 mRNA by qRT-PCR or (B) HS-5 were cultured alone 
or co-cultured with three different primary AML cells for 4 h. HS-5 RNA was extracted 
and IL-8 mRNA expression was analysed by qRT-PCR. IL-8 mRNA was normalised 
to GAPDH mRNA levels (n=3).  
 
3.9. Inhibition of AML-derived MIF downregulates IL-8 expression  
To confirm that MIF secreted from AML cells regulates IL-8 expression in 
BMSCs, I used ISO-1, a nontoxic inhibitor of MIF which functions by binding 
to bioactive MIF at its N-terminal tautomerase site (312). To perform these 
experiments, I cultured AML with BMSCs in the presence and absence of ISO-
1. I then extracted RNA from the BMSCs and analysed for IL-8 mRNA levels 
using qRT-PCR. Figure 3.14 shows that ISO-1 inhibited AML induced BMSC 
IL-8 mRNA expression. Taken together, this indicates that MIF secreted by 
AML cells induces IL-8 expression in BMSCs.  
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Figure 3. 14 Bar graph comparing IL-8 RNA expression levels in the absence 
(MIF) and presence (MIF+ISO-1) of the MIF inhibiting ISO-1.  
BMSCs were treated with rhMIF (100 ng/ml) and the MIF inhibitor ISO-1 (10 µM) for 
4 h then assessed for IL-8 mRNA expression (n=4). * denotes p < 0.05. 
 
3.10. Inhibition of MIF significantly reduces AML survival on BMSCs 
To determine the effect of MIF inhibition by ISO-1 on AML survival when 
cultured on BMSCs, I co-cultured AML cells on BMSC cells in the presence 
and absence of ISO-1 for 48h. AML survival was significantly reduced when 
cultured with BMSC in the presence of ISO-1 compared to control AML-BMSC 
co-cultures (Figure 3.15). I also included an AML mono-culture as a control.  
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Figure 3. 15 Scatter graph showing reduced AML survival in ISO-1 treated 
AML/BMSC co-cultures.   
BMSCs were pretreated with ISO-1 (10 µM) for 5 mins before the addition of primary 
AML cells from 10 patient samples for 48 h. AML blast number was assessed using 
a trypan blue exclusion hemocytometer-based counts (n=10). * denotes p < 0.05. 
 
3.11. Summary of the results presented in chapter 3 
MIF-induced stromal IL-8 (but not IL-6) is essential to human AML survival in 
vitro. This process is cell-cell contact independent. Demonstrating this, 
required experiments to be performed using primary BMSCs and not the HS5 
cell line. This was deduced as MIF stimulated IL-8 expression in primary 
BMSC but not HS-5 cell line. 
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4. Chapter 4: MIF induction of BMSC-derived IL-8 is mediated 
through CD74 and PKCβ signalling 
In this chapter I describe the signalling which occurs in BMSCs in response to 
MIF. Here I aim to identify the receptor located on the BMSC surface to which 
MIF binds and then investigate the downstream signalling molecules. 
4.1.  Identifying the receptor/s to which MIF binds and induces IL-8 in 
BMSCs 
Depending on the cellular context and the disease involved, MIF signalling is 
mediated by its receptors CXCR2 (IL-8 receptor, ILR8) (313), CXCR4 (SDF-1 
receptor) (314), and/or CD74 (158). BMSCs have been reported to express all 
three receptors (315-317). I used flow cytometry to measure the expression of 
CXCR2, CXCR4 and CD74 and of CD105 (as a positive BMSC marker to 
confirm stromal cell phenotype). Figure 4.1 shows that BMSCs are positive for 
CD105, CD74 and CXCR4 but that CXCR2 is not expressed at a level 
detectable by flow cytometry. 
 
 
Figure 4. 1 Representative flow cytometry analysis of cultured BMSCs stained 
with monoclonal antibodies against CD105, CD74, CXCR2 and CXCR4. 
The black line indicates isotype control and the red line indicates cells stained with 
anti-CD105-FITC, anti-CD74-FITC, anti-CXCR2-viobright-FITC and anti-CXCR4-PE. 
 
To determine the role of each receptor in mediating MIF response in BMSCs, 
I used specific inhibitors of CXCR2, CXCR4 and CD74 and measured IL-8 
mRNA expression. Figure 4.2 shows that the inhibition of CXCR2 using 
SB225002, CXCR4 using AMD3100 and of CD74 using an anti-CD74 blocking 
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antibody (aCD74 Ab) were all able to decrease MIF-induced IL-8 mRNA 
expression in BMSCs. These results suggest that all three receptors (CXCR2, 
CXCR4 and CD74) are involved to some degree in regulating MIF-induced IL-
8 expression in BMSCs.  
 
 
Figure 4. 2 Bar graph comparing MIF-induced IL-8 mRNA expression in BMSCs 
treated with the inhibitors of CD74, CXCR2 and CXCR4 receptors. 
BMSCs were pretreated with vehicle control (DMSO) or inhibitors for CD74 (αCD74 
Ab at 10 µg/ml), CXCR2 (SB225002 at 100 nM) and CXCR4 (AMD3100 at 100 nM) 
for 30 minutes before being stimulated with 100 ng/ml MIF for 4 h. RNA was extracted 
and assessed for IL-8 mRNA by qRT-PCR. mRNA expression was normalised to 
GAPDH mRNA levels (n=4). * denotes p < 0.05. 
 
4.2. The primary MIF receptor involved in mediating IL-8 expression is 
CD74 
To determine the key receptor that mediates MIF-induced IL-8 in BMSCs, I 
attempted to inhibit CXCR2 and CXCR4, which are G-protein coupled 
receptors (GPCRs), using pertussis toxin (PTX), an inhibitor of GPCR 
signalling produced by the bacterium Bordetella pertussis (318). PTX would 
not inhibit CD74, as it is not a GPCR, but rather the cell surface form of the 
Class II invariant chain (158). MIF binding to CD74 results in the serine 
phosphorylation of its short intracytoplasmic domain, and in modulation of the 
phosphorylation of its signalling co-receptor, CD44 (159). I found that PTX 
mediated Inhibition of CXCR2 and CXCR4 did not reduce MIF-induced IL-8 in 
111 
 
 
BMSCs (Figure 4.3). These data suggest that the primary receptor involved in 
MIF signalling in human AML is CD74.  
 
Figure 4. 3 MIF-induced IL-8 upregulation is mediated through CD74, as seen in 
this bar graph which shows IL-8 mRNA expression levels for untreated, MIF-
stimulated, PTX-treated, PTX-treated/MIF-stimulated BMSCs.   
BMSCs were pre-treated for 45 min with pertussis toxin (PTX) (50 ng/mL) then 
stimulated with MIF (100 ng/mL) for 4 h. RNA was then extracted and assessed for 
IL-8 mRNA by qRT-PCR. mRNA expression was normalised to GAPDH mRNA levels 
(n=4). 
 
To determine if CD74 is the main receptor to which MIF binds on BMSCs to 
induce IL-8, I used lentiviral mediated knockdown (KD) of CD74 in AML patient 
BMSCs. BMSCs were infected with lentvirus containing an shRNA that 
targeted the 3’UTR of CD74. After 72 hours of incubation, BMSCs were 
analysed for CD74 knockdown. Figure 4.4 shows that both, mRNA and protein 
expression of CD74, after infection with control KD or CD74 KD lentivirus, are 
significantly reduced, thus confirming the successful knockdown of CD74. 
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A.                                                                   B. 
                        
 
Figure 4. 4 CD74 protein levels in control versus knockdown BMSC samples, 
measured by qRT-PCR (A) and flow cytometry (B).   
BMSCs from 4 patient samples were incubated with control shRNA or CD74 shRNA 
for 72 h and analysed for CD74 mRNA expression by qRT-PCR, as shown by the bar 
graph (A), and for protein expression, as measured by flow cytometry in (B). * denotes 
p < 0.05. 
 
 
Next, I wanted to examine if CD74 knockdown inhibited MIF induced IL-8 
expression. Indeed, the data in Figure 4.5 confirms that the aforementioned 
inhibits MIF induced IL-8 mRNA expression in AML patient BMSCs. Together, 
these results demonstrate that MIF induces IL-8 in BMSCs via CD74.  
 
 
Figure 4. 5 Bar graph depicting IL-8 mRNA expression levels after CD74 
knockdown in BMSCs, which inhibited MIF induced IL-8 expression.   
BMSCs from 4 patient samples were infected with control shRNA or CD74 shRNA for 
72 h then treated with recombinant MIF and analyzed for IL-8 mRNA expression by 
qRT-PCR. * denotes p < 0.05. 
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4.3. Pharmacological inhibition of MIF signalling pathways 
I next investigated the signalling cascade in BMSCs downstream of AML and 
MIF induced activation. It has been shown that MIF binding to CD74 activates 
downstream signalling through PI3K/AKT and MAPK signalling pathways and 
promotes cell proliferation and survival (170, 319). Both AKT and MAPK 
pathways have also been described to be downstream of CXCR2 and CXCR4 
in AML and bladder cancer cells, respectively (79, 320). Additionally, Lutzny 
et. al. recently described activation of a PKC pathway in murine stromal cells 
co-cultured with CLL cells (201).  
In my experiments, I pre-treated BMSCs with LY294002 – a PI3K/AKT 
inhibitor, with PD098059 – a MAPK kinase (MEK) 1 inhibitor, or with Ro-31-
8220 – a pan PKC inhibitor. This was done to determine which pathway(s) 
regulate AML induced BMSC IL-8 mRNA induction. I found that Ro-31-8220, 
the PKC inhibitor could significantly inhibit IL-8 expression (Figure 4.6A). 
Contrarily, LY294002 and PD098059 had little or no effect. As a control, I 
examined AML cells that had been incubated with the BMSCs, which also 
demonstrated that IL-8 in AML cells is not inhibited by Ro-31-8220, LY294002 
or PD098059 when cultured with BMSC (Figure 4.6B). 
A.                                                                      B. 
                           
Figure 4. 6 Bar graphs showing that the pharmacological inhibition of PKC 
pathways, inhibit AML induced IL-8 expression levels in BMSCs.   
BMSCs were pre-treated with vehicle control (DMSO), Ro-31-8220 (1µM), PD98059 
(10 μM) and LY294002 (10 μM) and then incubated with primary AML cell for 4 h. 
AML cells were removed and RNA extracted from both BMSC (A) and AML cells (B) 
and assessed for IL-8 mRNA by qRT-PCR. mRNA expression was normalised to 
GAPDH mRNA levels (n=4). * denotes p < 0.05. 
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Next, I wanted to determine the effect of Ro-31-8220, LY294002 or PD098059 
on MIF induced IL-8 in BMSCs. To do this I pre-treated BMSCs with the 
respective drugs for 30 minutes and stimulated them with 100ng/mL of rhMIF 
for 4 hours. I found that Ro-31-8220 and PD098059 both inhibited MIF induced 
IL-8, whilst LY294002 had no effect (Figure 4.7). These results suggested that 
both MAPK and PKC signalling may be integral to the process of MIF induction 
of IL-8 in BMSCs.  
 
 
Figure 4. 7 Bar graph depicting IL-8 mRNA expression after pharmacological 
inhibition of MAPK and PKC signalling pathways, to examine its effects on MIF 
induced BMSC IL-8 mRNA expression.   
BMSCs were pre-treated with vehicle control (DMSO), Ro-31-8220 (250 nM), 
PD98059 (10 μM) and LY294002 (10 μM) and then incubated with 100ng/mL MIF for 
4 h. RNA was extracted from BMSCs and assessed for IL-8 mRNA by qRT-PCR. 
mRNA expression was normalised to GAPDH mRNA levels (n=4). * denotes p < 0.05. 
 
4.4. MAPK and AKT do not play a role in MIF-induced IL-8 in BMSCs 
To clarify whether PKC or MAPK or both are activated in response to MIF, I 
performed Western blot analysis on one BMSC sample for specific 
phosphorylation of AKT (at s473) and MAPK in response to stimulation with 
MIF for specified time points. I found that, MAPK and AKT were 
phosphorylated in the MIF treated samples compared to the control sample 
(Figure 4.8A). I next wanted to confirm this in the same sample as well as 
another three BMSC samples. Contrary to what I initially observed, there was 
no activation of MAPK or AKT in any of the BMSC cells I used (Figure 4.8B). 
It was unclear as to why the above results were obtained. Therefore, since the 
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AKT and MAPK inhibitors had limited effect on MIF induced IL-8 mRNA 
expression, I concluded that MAPK or AKT may not play a key role in BMSC 
response to MIF.  
 
A. 
 
B. 
 
Figure 4. 8 A western-blot image showing that pMAPK and pAKT are not 
activated in response to MIF in BMSCs.  
(A) BMSC#1 was activated with rhMIF (100ng/ml) for 0, 2, 5, 10, 15 and 30 minutes. 
Protein was extracted and Western blotting was performed for pAKT, total AKT, 
pMAPK and total MAPK. Western blots were reprobed for B-actin to confirm equal 
sample loading, (B) Four different BMSCs were activated with rhMIF (100 ng/ml) for 
various times. Protein was extracted and Western blotting performed. Blots were 
probed for pAKT and pMAPK as well as total AKT and total MAPK. Blots were then 
re-probed for GAPDH to show equal sample loading. 
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4.5. PKCβ is activated in response to MIF in BMSCs 
Since Ro-31-8220 could inhibit MIF induced IL-8 mRNA expression in BMSCs, 
and PKC exists in multiple isoforms, I next wanted to determine which PKC 
isoform is activated in response to MIF in BMSCs. To do this I performed 
Western blot analysis on BMSCs for specific phosphorylation of PKC isoforms 
in response to MIF activation. I activated BMSCs with pre-conditioned AML 
cells for 15 minutes or MIF (100ng/ml) over various time points (0, 5 and 15 
minutes). Figure 4.9 shows that MIF and AML both induce phosphorylation of 
PKCα/βII and PKCβ in BMSCs.  
 
Figure 4. 9 A western-blot image showing MIF activates PKCα/βII and PKCβ in 
BMSCs.  
BMSCs were cultured with preconditioned AML for 15 minutes or rhMIF (100 ng/mL) 
for various times. Protein was extracted and Western blotting performed. Blots were 
probed for pPKCα/βII, pPKCβ, PKD/PKCμ, PKCδ and PKCδ/θ. Blots were then re-
probed for βactin to show equal sample loading. 
 
4.6. MIF-induced IL-8 in BMSCs is signalled through PKCβ 
As both pPKCα/βII and pPKCβ protein in BMSCs showed an increase in signal 
when treated with either AML or MIF, I wished to determine which isoform was 
responsible for MIF induced IL-8 expression. To do this I used isoform specific 
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inhibitors: Go6976 to inhibit PKCα/β and Enzastaurin to inhibit PKCβ, to block 
MIF-induced IL-8 expression in BMSCs. Both inhibitors showed similar levels 
of inhibition of MIF-induced IL-8 up-regulation (Figure 4.10). Together these 
results support the view that MIF-induced IL-8 expression in AML patient 
BMSCs requires PKCβ. 
 
 
Figure 4. 10 Bar graph comparing IL-8 mRNA expression levels in BMSCs 
treated with inhibitors to assess the effect of pPKCα/βII and pPKCβ on MIF-
induced IL-8 expression.   
BMSCs were treated with vehicle control (DMSO), Go6976 (1 μM) or enzastaurin (1 
μM) for 30 minutes before treatment with rhMIF (100 ng/ml) for 4 h. RNA was 
extracted and analysed for IL-8 mRNA expression by RT- PCR. * denotes p < 0.05. 
 
4.7. Knockdown of PKCβ inhibits MIF-induced IL-8 expression in 
BMSCs 
To confirm that PKCβ is required for MIF-induced IL-8 expression in BMSCs, 
I employed shRNA knockdown of the PKCβ mRNA and protein. To do this I 
infected BMSCs with control shRNA, or shRNA with a lentivirus targeting 
PKCβ RNA coding sequence. Figure 4.11 shows that shRNA inhibits PKCβ 
mRNA and protein expression. 
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A.                                                                               B. 
                       
 
Figure 4. 11 Results depicting changes in PKCβ expression after knockdown in 
BMSCs.   
BMSCs were infected with lentivirus containing control or PKCβ shRNA for 72 h and 
then analysed for (A) PKCβ mRNA using qRT-PCR and (B) protein expression, where 
the western blots were re-probed with β-actin to show equal sample loading, (n=2). * 
denotes p < 0.05. 
 
Next, I wanted to determine if the knockdown of PKCβ would inhibit MIF 
induced IL-8 expression. Figure 4.12 shows that PKCβ shRNA, indeed inhibits 
MIF-induced IL-8 mRNA and protein expression into culture supernatants of 
BMSCs, thus confirming that PKCβ influences MIF-induced IL-8 up-regulation 
in BMSCs of AML patients. 
A.                                                                           B. 
                     
 
Figure 4. 12 Bar graphs representing IL-8 mRNA expression levels in BMSCs, 
where PKCβ was knockdown. PKCβ knockdown inhibits MIF-induced IL-8 
expression in BMSCs.   
BMSCs were infected with lentivirus containing control shRNA, or PKCβ shRNA for 
72 h, followed by treatment with recombinant MIF. They were then analysed for IL-8 
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mRNA using qRT-PCR (A), and for IL-8 protein by ELISA (B) (n=3). * denotes p < 
0.05. 
4.8. Targeting the MIF-PKCβ-IL-8 axis disrupts BMSC induced 
protection of primary human AML cells 
To examine the effect of blocking IL-8 on BMSC-induced protection and 
survival of primary AML cells, I co-cultured primary AML cells with BMSCs 
(either control-KD or IL-8-KD). Firstly, I used lentivirus to deliver shRNA, 
targeted to knockdown IL-8. Figure 4.13A and 4.13B show that IL-8 mRNA 
and protein expression was inhibited in BMSCs after transduction of with the 
IL-8 knockdown virus. Next, I stimulated control-KD and IL-8-KD BMSCs with 
100 ng/ml rhMIF for four hours and found that the knockdown of IL-8 inhibits 
MIF induced IL-8 mRNA and protein expression in BMSC (Figure 4.13C).  
 
A.                                           B.                                    C. 
  
 
Figure 4. 13 Bar graphs showing IL-8 expression levels, following the 
knockdown of IL-8 in AML derived BMSCs.   
BMSCs were infected with lentivirus containing control shRNA or IL-8 shRNA for 72 
h. (A) RNA was extracted and analyzed for IL-8 mRNA expression by qRT-PCR. (B) 
Media was also taken and analysed for IL-8 protein expression by ELISA. (C) BMSCs 
were then treated with rhMIF (100ng/ml) for 4 hours. RNA was extracted and 
analysed for IL-8 mRNA expression by qRT-PCR, (n=6). * denotes p < 0.05. 
 
Next, I sought to determine the effect of IL-8 knockdown in BMSCs, on AML 
survival in co-cultures. To do this, I infected BMSCs with control KD and IL-8 
KD lentivirus and then cultured AML on these for 48 hours. Figure 4.14A 
shows that the knockdown of IL-8 in BMSCs significantly inhibits AML survival 
when in co-culture, compared to control KD BMSCs. I also used SB225002 to 
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inhibit IL-8 in culture. Figure 4.14B shows that AML survival is reduced in the 
cultures treated with SB225002.  
 
A.                                                           B. 
                    
Figure 4. 14 Results depicting that the IL-8 inhibition in BMSCs reverses AML 
survival in co-cultures.   
A) Bar graph showing AML blast numbers in co-cultures with control versus IL-8 KD 
BMSCs. BMSCs were infected with lentivirus containing control shRNA or IL-8 shRNA 
for 72 h. BMSCs were then co-cultured with AML cells from seven samples for 48 h. 
AML blast number was assessed using a trypan blue exclusion hemocytometer-
based counts (n=7). (B) Scatter graph depicting AML blast numbers. BMSCs were 
pre-treated with SB225002 (100 nM) for 30 minutes before the addition of primary 
AML cells from 10 samples for 48 hours. AML blast number was assessed using a 
trypan blue exclusion hemocytometer-based counts. * denotes p < 0.05. 
 
4.9. Summary of results chapter 4 
Altogether, these results identify a novel pro-tumoural regulatory pathway in 
the AML microenvironment, whereby AML derived MIF binds to receptors on 
BMSCs, and primarily through surface CD74 induced stromal cell production 
of IL-8 via a PKCβ dependent pathway. The schematic in Figure 4.15 
illustrates my proposed mechanism for the AML derived MIF stimulation of 
stromal IL-8.  
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Figure 4.15. Schematic of the proposed MIF/PKCB/IL-8 survival pathway in 
AML.  
In the AML BMM, AML-derived MIF stimulated BMSC expression of IL-8, through 
binding of cell surface CD74 and subsequent activation of PKCβ in the BMSC 
compartment.  
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5. Chapter 5: Hypoxia regulates AML-derived MIF 
 
In the previous chapter I showed that AML cells constitutively express high 
levels of macrophage migration inhibitory factor (MIF) which drives IL-8 
expression in BMSCs, which in turn supports AML cell survival and 
proliferation.  
The BMM is hypoxic and targeting hypoxia inducible genes has been shown 
to eliminate cancer stem cells in haematological malignancies (250). HIF1-
α expression in AML patient samples has been found to be associated with 
poor prognosis (244). Moreover, targeting HIF1α in AML cancer stem cells 
abrogated their colony forming activity (250). Recent data showed that 
HIF2α silencing impairs long term engraftment of HSC and inhibits 
proliferation of primary AML in vitro (251). Another study has shown that HIF2α 
is high in subsets of both human and mouse AML cells, and that 
overexpression of HIF2α accelerated disease progression in AML mouse 
models. However, it also highlights that patients with high HIF2α expression 
levels trend toward disease free survival (252). Together these data describe 
a complex interplay between hypoxia regulated transcription factors HIF1α 
and HIF2α and their regulatory role in normal HSCs and AML cells.  
Hypoxia has been identified as a potent inducer of the pro-inflammatory 
cytokine MIF in inflammatory diseases (321, 322). Hypoxia-induced MIF 
expression is dependent upon a hypoxia response element (HRE) in the 
5'UTR of the MIF gene (323). Specifically, a single nucleotide polymorphism 
(SNP) mapping to a functional HRE in the MIF locus, prevents induction of MIF 
by hypoxia (324). Consequently, these studies lead me to hypothesise a role 
for hypoxia in regulating MIF survival signals in AML.  
In the work presented in this chapter, I aim to determine if there is a connection 
between the hypoxic BMM and MIF in regulating AML survival. Then, I further 
examine the role of HIF1α and HIF2α in this response, and evaluate the 
functional consequences and potential therapeutic effect of inhibiting such a 
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pathway in vivo, in AML patient-derived xenograft models. AML patient 
samples used in this study are shown in table 5.1 below.  
Table 5. 1 AML patient sample characteristics used in chapter 5. 
 
 
5.1. AML cells derived from the bone marrow express higher levels of 
MIF compared to cells in the systemic circulation and spleen 
To determine whether high and constitutive expression of MIF in AML cells is 
a function of the BMM, I examined if the expression levels of MIF in AML cells 
from an AML BM sample would be lower compared to one from the peripheral 
blood (PB). This stage was threefold:  
(i) In silico: As a proof of concept, using a publicly available RNA 
sequencing data set (GEO accession number GSE49642) (325) for a 
panel of 43 AML patients (comprising of 22 unmatched AML samples 
from the PB and 21 AML samples obtained from BM aspirate), and with 
the help of my colleague Manar Shafat, a differential expression 
analysis of MIF in this data set was performed (described in section 
2.6). The analysis showed that MIF gene expression was significantly 
higher in AML samples from the BM compared to those from the PB 
(Figure 5.1A).  
 
(ii) In vitro: I obtained five patient matched primary AML samples (both BM 
and PB) from the haematology department at the NNUH and freshly 
extracted RNA from these samples. It was crucial that this step was 
performed as soon as the samples were obtained from the hospital, to 
avoid any changes in gene expression of these cells once they were 
AML# Age Sex WHO calssification Cytogenetics
AML#21 65 male AML with maturation Trisomy 13
AML#22 37 male AML without maturation Normal
AML#23 59 male AML with maturation 46,XY,t(8;21)(q22;q22)
AML#24 88 male AML with maturation Trisomy 8
AML#25 45 male AML with maturation Normal
AML#26 74 male AML with minimal differentiation 47 XY +13
AML#27 69 female AML with minimal differentiation failed
AML#28 59 male Acute monoblastic and monocytic leukaemia 46,XY, +21
AML#29 66 male AML with minimal differentiation  inv(16)(p13q22) and +8
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extracted from the BM/PB, and risk re-oxygenation. Samples were, 
therefore, transported to the research lab immediately after they were 
taken. I next performed cDNA synthesis and carried out qRT-PCR for 
MIF and GLUT1 expression. GLUT1 is a common target gene of HIF1α 
and HIF2α  (326, 327) and serves as a positive control for hypoxia in 
this model. I found that AML cells from the BM expressed significantly 
higher levels of MIF and GLUT1 than those taken from the PB (Figure 
5.1B).  
 
A.                 
   
B.    
     
 
Figure 5. 1 Scatter graph showing that BM AML cells express significantly 
higher MIF levels than circulating AML cells.   
(A) MIF gene expression (expressed in log2 RPKM values) was obtained from 
GSE49642 for 22 peripheral blood (PB) and 21 bone marrow (BM) AML patient 
samples. p-value was obtained by Wilcoxon rank-sum test. Line denotes the median 
value. (B) RNA was extracted from AML originating from the BM and PB of matched 
patients. MIF and GLUT1 mRNA expression was determined by qRT-PCR and 
normalised to B-actin. p-value was obtained by Wilcoxon rank-sum test. Line denotes 
the median value. 
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(iii) In vivo: To replicate the in silico and in vitro results in vivo, I used a 
patient-derived xenograft (PDX) model that has been set up by 
members of our research group. In this model, 9 primary AML patient 
BM samples were injected into female NSG mice and allowed to engraft 
in their BM and to infiltrate the spleen. Animals were then sacrificed 
once they met pre-defined severity end points. The experimental design 
of this in vivo model is depicted in Figure 5.2A. To determine if AML 
cells were engrafted in the BM and spleen of these animals, I isolated 
total cells from both organs and used a fraction of these cells to 
determine engraftment, by measuring human CD33 and CD45 levels in 
these samples. The second fraction was kept for RNA analysis. Figure 
5.2B confirms that the primary AML successfully engrafted the BM and 
spleen of NSG mice (engraftment presented as % of CD33-positive 
CD45-positive cells/total number of cells. Samples with values above 
1% were considered to have been successfully engrafted). 
A. 
 
B.  
 
Figure 5. 2 Experimental plan of the patient-derived xenograft (PDX) model, and 
results that indicated successful engraftment. 
(A) 2x106 primary AML cells (from the BM of 7 AML patients) were injected into the 
tail-vein of NSG mice. At the end of the experiment, AML cells were isolated from the 
BM and spleen for RNA analysis (B) Engraftment was measured using flow cytometry 
after double staining with human CD33 and CD45, the dot plot presents each AML 
engraftment into NSG mice and is shown for BM and spleen. 
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I next extracted RNA from the second fraction of cells and used specific qRT-
PCR primers to analyse human MIF and GLUT1 gene expression levels in 
AML cells engrafted in the BM, and in AML cells engrafted in the spleen. Figure 
5.3A shows that MIF had a lower deltaCT (dCT) value in AML cells from the 
BM, compared to those from the spleen (the lower the dCT value, the higher 
the gene expression level). Furthermore, GLUT1 expression was significantly 
higher in samples from the BM compared to those from the spleen (Figure 
5.3B). 
 
A.                                                               B.  
                     
Figure 5. 3 Scatter graphs comparing MIF and GLUT1 RNA expression levels in 
the BM and spleen of the PDX animals.   
RNA was extracted from AML cells isolated from the BM and spleen as explained in 
Figure 5.2. RNA was analysed for (A) MIF mRNA and (B) GLUT1 mRNA using human 
specific primers. mRNA differences are presented as delta cycle threshold (dCT), 
normalised to human B-actin.  
 
5.2. MIF is part of a hypoxic gene signature in AML cells isolated from 
the BM, but not those isolated from the PB  
As the BM has been shown to be hypoxic (224-227) and as hypoxia has been 
shown to regulate the expression of MIF in various cells (321, 326, 328), I 
hypothesised that hypoxia was responsible for the higher expression of MIF in 
AML cells located in the BM. In 2014, Wierenga and colleagues set up a study 
to identify the downstream molecular mechanisms of hypoxia in regulating 
HSC function. They were able to identify common and unique hypoxia, HIF1α 
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and HIF2α gene signatures through exposure of CD34+ cord blood cells to 
hypoxic conditions, and through the overexpression of HIF1α and HIF2α in 
CD34+ cord blood cells (293). Using the hypoxia specific gene list that they 
generated and with the help of my colleague Manar Shafat, I determined the 
differential expression of these genes in the data set used in Figure 5.1A. The 
aim here was to (i) confirm if AML cells from the BM would be enriched for 
hypoxia related genes compared to AML cells from the PB, and (ii) whether 
MIF is part of this hypoxic signature.  
The analysis generated three lists of genes that are differentially expressed in 
the BM compared to the data set used in Figure 5.1A. The analysis revealed 
that a set of hypoxia-related genes were preferentially expressed in AML cells 
in the BM, compared to the PB, with MIF being amongst a significantly 
enriched group of genes.  
5.3. Hypoxia induces MIF in primary AML cells 
Next, I wanted to determine whether hypoxic conditions could induce 
expression of MIF in AML cells, in vitro. I established hypoxic culture 
conditions in the OCI-AML3 cell line and AML cells, either via treatment 
with hypoxia-mimicking agents, cobalt chloride (CoCl2) and desferrioxamine 
(DFO) for 4 hours, or by culturing the cells in a hypoxic chamber (1% O2) for 
24h. I then assayed for MIF mRNA using qRT-PCR, and for protein secretion 
using an MIF specific ELISA. Figure 5.4 shows that CoCl2 treatment and 1% 
O2 significantly induced MIF mRNA expression, while only DFO and 1% O2 
significantly induced MIF protein secretion in the OCI-AML3 cell line and 
primary AML samples. 
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A.                                                               B. 
 
 
Figure 5. 4 Bar graphs depicting MIF mRNA and protein expression levels in 
AML cells following culture under hypoxic conditions in vitro.  
OCI-AML3 and primary AML cells (n=3) were either treated with CoCl2 (100uM) or 
DFO (150uM) for 4 hours, or cultured under hypoxic conditions for 24 hours, (A) RNA 
was extracted and MIF mRNA expression was determined with qRT-PCR. (B) Media 
was collected from the respective conditions described in (A) and MIF protein 
secretion was determined by target-specific ELISA, (n=4). * denotes p < 0.05. 
 
5.4. HIF1α is a candidate regulator of MIF expression in Primary AML 
cells 
Next, I wanted to determine the contribution of HIF1α or HIF2α in regulating 
the expression of MIF in the BM. The differential expression analysis described 
in section 5.2 for hypoxia, was also performed with HIF1α or HIF2α gene lists 
to determine the significantly upregulated HIF1α and HIF2α genes in AML BM 
samples compared to AML PB samples (GEO accession number GSE49642). 
The analysis showed that MIF expression is part of the HIF1α signature, but 
not of HIF2α. Based on these findings, I hypothesise that HIF1α plays a 
significant role in upregulating MIF in primary AML.  
5.5. HIF1α, but not HIF2α is stabilised and induces MIF in primary AML 
cells in response to hypoxia 
To further characterise the role of HIF1α and HIF2α in primary AML cells, I 
used western blotting to assay for HIF1α and HIF2α protein expression in AML 
cells cultured under normoxic and hypoxic conditions (1% O2), using a hypoxic 
chamber. It has been previously reported that under prolonged hypoxia, HIF1α 
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protein degrades, while HIF2α exhibits minimal change (329), Hence, I began 
with a short incubation time of 4 h, to detect changes in HIF1α and HIF2α 
levels. I found that HIF1α was stabilised after 4h under hypoxic conditions in 
the OCI-AML3 cell line and in three primary AML blast samples, but HIF2α 
was undetectable at 4 hours, and detectable but not stabilised upon 12 h of 
hypoxia (figure 5.5). Moreover, the Western blots showed that HIF2α was 
expressed under normoxia in all the samples tested, as revealed by the 
occurrence of multiple bands at 90 – 120 kD in the western blot showed. Other 
studies have observed detection of multiple bands of HIF2α protein (330, 331).  
 
 
Figure 5. 5 Western blot demonstrating the stabilisation of HIF1α but not 
HIF2α in AML cells under hypoxic culture conditions.  
OCI-AML3 and primary AML cells were cultured under hypoxic conditions for 4 hours 
to detect HIF1α, and for 12 hours to detect HIF2α. Protein was then extracted from 
the cells and Western blotting was performed. 
 
5.6. MIF is not induced in normal non-leukaemic CD34+ cells 
Leukaemic cells and normal HSCs have been shown to co-exist within one 
compartment in the BM of AML patients (332). Hence, it is important to 
determine the effect of hypoxia on MIF expression in normal CD34+ cells. I 
obtained normal CD34+ cells from peripheral blood venesections, from 
patients without AML (from patients with genetic haemachromatosis, 
undergoing therapeutic venesection, but with non-raised ferritin levels). Firstly, 
I determined the expression of MIF in CD34+ cells compared to AMLs. Figure 
5.6 shows that at the mRNA level CD34+ cells express significantly higher 
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levels of MIF mRNA compared to AML cells, however, on the protein level, 
CD34+ cells secrete less MIF protein than AML cells as confirmed by ELISA.  
 
A.                                                                 B.  
                                  
Figure 5. 6 Bar graphs depicting differences in the expression of MIF, mRNA 
and protein, in CD34+ cells versus AML cells.  
0.25x106 AML or non-malignant CD34+ cells were cultured under normal culture 
conditions for 24h. (A) RNA was extracted and MIF mRNA expression was 
determined with qRT-PCR. (B) Culture media was assayed for MIF cytokine 
secretion, (AML, n=4, CD34+, n=5). * denotes p < 0.05. 
 
Next, I cultured CD34+ cells under normoxic or hypoxic conditions using a 
hypoxia chamber for 24h. Figure 5.7 shows that MIF mRNA expression and 
protein secretion was not induced in non-malignant CD34+ cells under 
hypoxia. This finding demonstrates that hypoxic regulation of MIF is a tumour 
specific event.  
 
A.                                                                    B.  
    
Figure 5. 7 Bar graphs depicting the expression of MIF mRNA and protein in 
CD34+ cells under normoxic and hypoxic conditions. 
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Non-malignant CD34+ cells were cultured under normoxic and hypoxic conditions for 
24 hours. (A) RNA was extracted and MIF mRNA expression was determined with 
qRT-PCR (B) culture media was assayed for MIF cytokine secretion, (n= 5). Minor 
differences in the MIF expression levels denote that hypoxia does not induce MIF 
expression in normal CD34+ cells.  
 
5.7. Silencing of HIF1α, but not of HIF2α, significantly reduces MIF 
expression in primary AML cells 
To further characterise the role of HIF1α in regulating MIF, and to confirm the 
specificity of its response to HIF1α versus HIF2α, I used lentiviral-mediated 
knockdown (KD) of HIF1α or HIF2α in AML patient cells. Lentiviral vectors 
provide a tool to express short hairpin RNA (shRNA) to induce stable and long-
term gene silencing in both dividing and non-dividing cells (333). Figure 5.8A 
confirms the reduced mRNA expression of HIF1α and HIF2α after infection 
with HIF1α-KD and HIF2α-KD lentivirus. Furthermore, Figure 5.8B shows a 
representative western blot of reduced HIF1α or HIF2α stabilisation under 
hypoxic conditions in KD cells when compared to control-KD cells. These 
results confirm successful knockdown of HIF1α or HIF2α in AML cells.  
A.                                                    B.  
                      
Figure 5. 8 HIF1α or HIF2α lentiviral knockdown (KD) in primary AML cells 
AML cells were infected with lentivirus against HIF1α or HIF2α for 72h, (A) lentiviral 
knockdown (KD) in AML cells was determined by qRT-PCR for mRNA expression (B) 
HIF1α KD, HIF2α KD or control-KD AML cells were cultured under hypoxic conditions 
for 4 and 12 hours to detect HIF1α KD and HIF2α KD respectively, then western 
blotting performed for protein expression (n=4). 
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Next, I wanted to determine the effect of silencing HIF1α or HIF2α on MIF 
expression in AML cells. I cultured HIF1α KD, HIF2α KD or control ShE-KD 
cells under normoxic conditions and assayed for basal expression of MIF 
mRNA and protein. I found that basal MIF mRNA expression was reduced in 
both HIF1α KD and HIF2α KD AML cells (Figure 5.9A). However, MIF protein 
secretion was only significantly reduced in HIF1α KD AML cells, but not in 
HIF2α KD AML cells (Figure 5.9B). Moreover, when HIF1α KD cells were 
cultured under hypoxic conditions for 24h, the MIF induction under hypoxia 
was significantly inhibited (figure 5.9C). I could also visually observe this in 
culture, as control (ShE) and HIF2α KD cells continued to grow and survive, 
while HIF1α KD cell counts remained low over culture periods. Specifically, at 
5 days of culture, the HIF1α KD AML blast cells reduced leukaemic survival 
by 65% compared to control cells while HIF2α KD had no impact on cell 
survival (Figure 5.9D). Together, these results demonstrate that HIF1α 
regulates MIF secretion in AML cells under hypoxic conditions.  
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A.                                                              B.  
                      
C.                                                              D. 
              
Figure 5. 9 Bar graphs showing the differences in basal MIF expression in 
HIF1α or HIF2α lentiviral knockdown (KD) primary AML cells.  
(A) RNA was extracted from cultured AML HIF1α or HIF2α-KD, or control-KD cells, 
and MIF mRNA expression was determined with qRT-PCR. (B) Protein expression in 
culture media from the cells in A was determined by ELISA (C) HIF1α KD and control-
KD cells were cultured under normoxic or hypoxic conditions for 24 h, MIF protein 
secretion was then evaluated using ELISA (D) Control-KD, HIF1α or HIF2α KD AML 
cells were cultured for 5 days post-infection, and cell survival was measured with the 
CellTiter-Glo Luminescent Cell Viability Assay, (n=4). * denotes p < 0.05. 
 
5.8. MIF functions to promote AML tumour survival in vitro 
To understand the importance of MIF for the survival of AML cells in vitro, I 
carried out lentiviral-mediated knockdown of MIF in AML cells. I first confirmed 
the reduced mRNA and protein expression of MIF, prior to functional analysis 
of the cells (Figures 5.10A and 5.10B). Next, to determine the effect of MIF KD 
on cell survival, I cultured the cells under normal conditions for 5 days post 
infection and found that MIF-KD significantly reduced survival of OCI-AML3 
cells and of primary AML cells in vitro (figure 5.10C); it also compromised the 
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leukaemic colony-forming ability of primary AML cells in methylcellulose media 
assays (Figure 5.10D).  
 
A.                           B.                               C.                          D. 
    
Figure 5. 10 Figure 5.12 Bar graphs showing that lentiviral Knockdown of MIF 
in AML cells reduces cell survival and colony formation.  
OCI-AML3 cells and primary AML cells (n=3) were infected with Lentivirus against the 
MIF gene; the successful knockdown of MIF was confirmed by (A) mRNA expression 
analysis with qRT-PCR, and (B) secreted MIF protein analysis using ELISA. (C) ShE-
KD and MIF-KD cells were cultured in basal media for 5 days post-infection; cell 
survival was measured using the CellTiter-Glo Luminescent Cell Viability Assay. (D) 
Colony-forming assays of ShE-KD and MIF-KD cells were performed in 
methylcellulose media. * denotes p < 0.05. 
 
To determine if the reduced cell survival was due to an increase in apoptosis, 
I stained MIF KD AML cells with Annexin V and performed flow cytometry. 
Figure 5.11 shows that knocking down MIF in AML cells induced apoptosis, as 
evidenced by an increase in the positive expression of Annexin V, which can 
be seen in Figure 5.11 below (percentage of cells in the bottom right quadrant 
increased from circa 10% to 30% AV positive cells). 
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A.                                                                       B.  
  
Figure 5. 11 Scatter plots depicting the apoptosis of AML cells, driven by MIF 
knockdown.  
Apoptosis assays of ShE-KD and MIF-KD cells were performed using annexin V (AV) 
and propidium iodide (PI) (A) representative scatter plot of AV PI staining of control 
ShE-KD and MIF-KD AML cells (n=5) after 5 days post lentiviral infection. Bottom 
right quadrant represents apoptotic cells (B) Column scatter graph showing % PI/AV 
positive cells of control ShE-KD and MIF-KD AML cells. P value indicated on the 
figure.  
 
5.9. The leukaemic cell HIF1α-MIF axis functions to promote tumour 
proliferation in vivo 
Next, I wanted to determine the role of HIF1α-regulated MIF in AML 
progression in vivo. To track AML disease progression in vivo, I transduced 
OCI-AML3 cells with a luciferase construct that is detectible by 
bioluminescence (BLI), upon injecting the animals with luciferin. Successful 
infection of OCI-AML3 with the luciferase construct was determined by qRT-
PCR and flow cytometry. These cells will be referred to as OCI-AML3-luc. 
Next, I infected OCI-AML3-luc cells with control lentivirus (ShE-KD) or HIF1α-
KD or MIF-KD lentivirus. NSG mice (6-8 weeks) were injected with 0.5x106 
OCI-AML3-luc cells from ShE-KD, HIF1α-KD or MIF-KD cultures. Animals 
were imaged at day 21 and 28 post-injection. The time points were chosen 
based on experience gained from experimentation with previous AML models 
in our research group. I found that at both time points mice transplanted with 
HIF1α-KD and MIF-KD cells had lower BLI detection, and thus, lower tumour 
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burden compared to control ShE-KD transplant animals (Figures 5.12A and 
5.12B).  
 
A.                                                                                     B.  
 
 
Figure 5. 12 In vivo bioluminescence images depicting disease progression in 
HIF1α and MIF KD AML xenograft model.  
0.5x106 control-KD (ShE) OCI-AML3-luc and HIF1α-KD or MIF-KD OCI-AML3-luc 
cells were injected into NSG mice (n=4 in each group). NSG mice were monitored for 
disease progression using bioluminescence and sacrificed upon signs of disease. (A) 
Bioluminescence images of recipient mice, with control-KD (ShE) and HIF1α-KD (HF) 
OCI-AML3-luc cells on day 21 and day 28 respectively. (B) The mean 
bioluminescence intensity (BLI) at day 28 of each image was determined with Image 
J software. P value indicated on the figure.  
 
Animals were sacrificed at pre-defined severity end points. I then determined 
AML cell engraftment in the BM by using flow cytometry, by determining 
human CD33 and CD45 expression (Figure 5.13A). Finally, I found that NSG 
mice that were engrafted with HIF1α-KD or MIF-KD OCI-AML3-luc cells had 
significantly increased survival compared to control animals as evident from 
the Kaplan-Meier survival curves shown in Figure 5.13B. 
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A.                                                                       B. 
             
Figure 5. 13 Results summarizing that the inhibition of AML HIF1α and MIF 
significantly increases survival of AML derived xenograft models. 
(A) Column scatter graph showing engraftment of OCI-AML3-Luc cells, engraftment 
was measured using human CD33 and CD45 expression. In the dot plot each AML 
engraftment into NSG mice is shown for control-KD (ShE), HIF1α-KD and MIF-KD 
cells (B) Kaplan-Meier survival curves for NSG mice injected with OCL-AML3-luc 
HIF1α-KD cells or OCI-AML3-luc control-KD cells.  
  
5.10. Pharmacological inhibition of MIF in vivo increases survival of 
AML xenograft models.  
To evaluate the consequences of pharmacological inhibition of MIF in human 
AML cells on disease progression, I used an AML PDX model, hereby mice 
were injected with cells from one primary AML sample. The experiment mainly 
aimed to evaluate the effect of ISO-1 (a specific MIF inhibitor, utilised in 
experiments presented in chapter 3 and chapter 5) on animal survival. 
However, since MIF has been reported to be a ligand of CXCR4 (334), and its 
inhibition hinders the migration of lung and prostate cancer cells (165, 335), I 
hypothesised that the inhibition of MIF with ISO-1 might affect the retention 
and mobilisation of AML cells to the PB in a similar manner to the inhibition of 
the SDF-1/CXCR4 axis by AMD3100 (336).  
At day 17 post injection of AML cells, mice were imaged to confirm the 
establishment of AML tumour in the BM. Animals with established tumour were 
randomly assigned to be treated with ISO-1 for 7 days (10mg/kg/day, IP) or 
vehicle control (Figure 5.14A). On the first day of treatment, 50uL of PB were 
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collected from the tail-veins of the animals at 4, 8 and 24 hours. Total cells 
were isolated by centrifugation and double stained for human CD33 and CD45. 
I found that there was no significant difference in the percentage of PB cells 
positive for human CD33 and CD45, between treated and untreated animals 
at all three time points. This suggested that the ISO-1, at least at the chosen 
dose, did not affect AML mobilisation from the BM to the PB. Moreover, the 
percentage of human CD33 and CD45 positive cells declined in both, treated 
and untreated animals (figure 5.14B). However, the decline was not 
statistically significant, and could be attributed to more cells infiltrating the 
spleen, and less cells circulating in the PB, as evident from the spleen 
engraftment data in figure 5.14C. Figure 5.16C shows that AML cells were 
successfully engrafted, as confirmed by positive human CD33 and CD45 
expression. Finally, I found that treatment with ISO-1 for 7 days significantly 
improved the survival rate of the AML PDX animals, compared to the treatment 
control (Figure 5.14D). 
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A.                                                        B. 
  
C.                                                              D.  
   
Figure 5. 14 Summarised results of experiments showing that the 
pharmacological inhibition of MIF in an AML patient derived xenograft model 
(PDX) does not affect AML mobilisation, but significantly increases animal 
survival.  
(A) Representative diagram of the PDX model showing ISO-1 treatment timeline. (B) 
Percent human CD33 and CD45 positive cells in the PB of control and in ISO-1 
treated animals at 4, 8 and 24 hours post ISO-1 or vehicle treatment. (C) Column 
scatter graph showing engraftment of primary AML cells. Engraftment was measured 
using flow cytometry to detect human CD33 and CD45 expression. In the dot plot 
each AML engraftment into NSG mice is shown for the BM and spleen for either 
control or treated animals. (D) Kaplan-Meier survival curves for NSG mice treated 
with either vehicle control or ISO-1.  
 
5.11. Summary of results chapter 5  
In this chapter, I demonstrated that hypoxia, acting through HIF1α, is 
responsible for the up-regulation of MIF in primary AML cells, and their 
proliferation and survival in the tumour microenvironment. I found that AML 
cells from the BM have increased levels of MIF compared to AML cells from 
the PB or spleen. I found that MIF is up-regulated under hypoxic conditions at 
both, the transcriptional and protein levels in AML, but not in normal CD34+ 
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cells. Functionally, it can be deduced that the hypoxia/HIF1α/MIF axis plays 
an important role in tumour survival and in proliferation of AML within the BM 
microenvironment in vivo, as inhibition of this axis improved animal survival in 
AML-derived xenograft models. 
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6. Chapter 6: AML cells induce senescence in BMSCs 
through the upregulation of p16 
 
As reviewed in section 1.6, recent investigations into the role of senescence 
in tumorigenesis have shown that acute senescence contributes to the 
prevention of cancer. However, more chronic forms of senescence promote 
tumour development and progression through the senescence associated 
secretory profile (SASP). AML is primarily a disease of old age and is mainly 
managed through chemotherapy. Moreover, chemotherapy has been shown 
to induce senescence that persists after therapy is discontinued (282), and 
recently, BMSCs from MDS and AML patients have been shown to be 
senescent (337). These findings make a strong argument to hypothesise that 
a senescent BM microenvironment may be essential for the development of 
AML and its relapse after chemotherapy.  
In this chapter I present data investigating a novel aspect of AML remodelling 
of BMSCs, namely AML-induced senescence in BMSCs. Table 6.1 shows the 
characteristics of the AML samples used in this study.  
Table 6. 1 AML patient sample characteristics used in chapter 6.  
 
 
6.1. Proteome profile arrays from AML-BMSC co-cultures show an 
upregulation of SASP related factors 
From the cytokine array data of primary AML, primary BMSCs and AML/BMSC 
co-cultures that were described in chapter 3 (section 3.3), I found that six 
cytokines were significantly up-regulated in the AML/BMSC co-cultures 
(Figure 3.5). Further analysis showed that four of these (IL-6, IL-8, MIP-1a and 
MIP-3a) were shown to be associated with SASP in studies conducted on age-
AML# Age Sex WHO calssification Cytogenetics
AML#25 45 male AML with maturation Normal
AML#26 74 male AML with minimal differentiation 47 XY +13
AML#27 69 female AML with minimal differentiation failed
AML#28 59 male Acute monoblastic and monocytic leukaemia 46,XY, +21
AML#29 66 male AML with minimal differentiation  inv(16)(p13q22) and +8
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related diseases, including cancer (274, 338). In the analysis in Figure 3.5, I 
aimed to account for AML derived cytokines by subtracting the data from the 
AML cultures from the AML/BMSC co-cultures. Moreover, and as I have 
previously shown, BMSCs express high levels of IL-8 and IL-6 (Figure 3.8 and 
Figure 3.10). This led me to hypothesise that AML cells may be inducing 
BMSCs to become senescent, and to secrete SASP related factors that 
promote AML survival in the tumour microenvironment.  
6.2. BMSCs from late passages become senescent in culture 
In section 3.1, I reported that after 6-8 weeks of passaging BMSCs, cell 
proliferation started to slow down, and that their morphology changed from a 
fibroblastic, spindly shape to a flatter, rounder shape with cell-free gaps. This 
morphological phenotype has been reported to be an attribute of senescent 
cells (339, 340). Since the aim of the work reported in this chapter is to 
determine if primary AML cells induce senescence in BMSCs in vitro, I had to 
ensure that the BMSCs used were not senescent. Thus, before performing 
any co-cultures, in addition to observing morphology and taking note of growth 
rate, I checked for β-Galactosidase staining in the BMSCs. Figure 6.1 presents 
images of BMSCs that have undergone senescence in culture and are positive 
for β-Galactosidase staining. Therefore, I deemed theme unsuitable for use in 
my co-culture studies. The BMSCs that I used in the following experiment were 
passaged 2-4 times, and only BMSCs that did not stain for β-Galactosidase 
were employed.  
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Figure 6. 1 Light micrographs of senescent patient-derived BMSCs.  
Late passage BMCSs were plated in 35mm dishes close to confluence and β-
Galactosidase staining was performed. A blue stain indicated senescent BMSCs 
(n=3).  
 
6.3. AML cells increase senescence associated β-Galactosidase 
staining in patient derived BMSCs 
To determine if primary AML cells induce senescence in patient derived 
BMSCs in vitro, I cultured non-senescent BMSCs alone or in co-culture with 
primary AML cells for 6 days, and assayed for β-Galactosidase staining. As a 
positive control for senescence, I included a culture of BMSCs treated with 
0.05uM daunorubicin (DNR). I performed this experiment on 3 different 
BMSCs, using 3 different primary AML samples. Before staining, I aimed to 
remove the AML cells off the BMSCs, however, some AML samples were 
highly adhesive to the BMSCs and were not completely removed. I found that 
DNR and AML cells, both, induce a change in the general morphology of 
BMSCs, and increase β-Galactosidase staining; in particular, the blue stain is 
darker in the BMSCs in close proximity to the AML cells (Figure 6.2). These 
observations suggest that AML cells could be inducing senescence in BMSCs 
in vitro.  
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Figure 6. 2 Light micrograph images showing that primary AML cells induce 
β-Galactosidase staining in primary BMSCs. 
BMSCs were treated with 0.05uM daunorubicin (DNR) or co-cultured with 0.5x106 
primary AML cells for 6 days, AML cells were removed and β-Galactosidase staining 
performed. The blue staining indicates senescent BMSCs (n=3). 
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6.4. AML cells induce p21 and p16 mRNA in BMSCs.  
Studies have shown that the contributions of the p53–p21 and the p16Ink4a–
RB effector pathways, to the initial growth arrest in cells can vary depending 
on the type of stress (338). However, it is thought that the p53/p21 pathway 
establishes growth arrest. On the other hand, the pRB/p16 pathway reinforces 
the irreversibility of senescent cells by inhibiting cell cycle progression, and is 
important for the full senescence of stromal cells (341). To determine the 
contribution of each of the effector pathways to AML-induced senescence in 
BMSCs, I co-cultured primary BMSCs with primary AML cells in transwell 
inserts for 6 days. This allowed me to prevent AML adhesion to BMSCs, and 
AML contamination to the BMSC compartment. I found that primary AML cells 
induced p21 and p16 mRNA expression in BMSCs (Figure 6.3). At this point, 
I decided to focus on investigating the role of p16 in AML-induced senescence, 
as the p16 axis is permanently activated under persistent stress stimuli.  
 
Figure 6. 3 Bar graphs showing that primary AML cells increase p21 and p16 
mRNA expression in primary BMSCs.  
BMSCs were co-cultured with 0.5x106 primary AML cells for 6 days using a transwell 
insert. mRNA was extracted and qRT-PCR was performed using p21 and p16 
primers. mRNA expression is normalised to β-actin (n=3). * denotes p < 0.05. 
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6.5. Knockdown of p16 in BMSCs inhibits AML induced p16 expression 
in BMSCs. 
To decipher the contribution of BMSC p16 towards AML cell survival in co-
culture, I used lentiviral-mediated knockdown of p16 in primary BMSCs. Figure 
6.4A confirms reduced p16 mRNA in BMSCs 72-hours post infection. To 
confirm knockdown at a protein level, and to determine if this knockdown is 
consistent with the well-defined AML-induced p16 activation in BMSCs, I 
carried out a western blot on BMSCs with p16 knockdown (p16 KD) and 
control (ShE), that were co-cultured with AMLs. I found that p16 knockdown in 
BMSCs inhibited AML induced p16 expression in BMSCs (Figure 6.4B). This 
also confirmed successful knockdown of p16 in primary BMSCs. 
A.                                                     B.  
     
Figure 6. 4 Results from experiments that reveal that the knockdown of p16 in 
BMSCs inhibits AML induced p16 expression.  
Control (ShE) or p16 KD BMSCs were co-cultured with 0.5x106 primary AML cells for 
6 days using a traswell insert. (A) mRNA was extracted and qRT-PCR performed 
using p16 primers, mRNA expression is normalised to β-actin (n=3) and (B) protein 
was extracted from BMSCs and western blotting was performed for p16 expression 
(n =2). 
 
6.6.  p16 deficient BMSCs have reduced ability to support AML survival 
in vitro 
I co-cultured AML cells from 5 primary AML patients on five different BMSCs 
that had either been infected with ShE control lentivirus or with p16-KD 
lentivirus. I found that AML cells co-cultured with p16-KD BMSCs had 
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significantly reduced survival compared to AML cells co-cultured with ShE-
control BMSCs (Figure 6.5).  
 
Figure 6. 5 Dot plot depicting the survival of AML cells co-cultured with p16 
deficient BMSCs.  
AML cells (0.25x106) were co-cultured with control (ShE) or p16 KD primary BMSCs 
in 12 well plate for 6 days (n=5). AML blast number was assessed using trypan blue 
exclusion hemocytometer-based counts. * denotes p < 0.05. 
 
6.7.  In vivo modelling of the senescent BM phenotype using the p16-
3MR mouse model 
A number of murine models have been developed to study p16 driven 
senescence in vivo (265). Of importance to this work is the p16-3MR 
senescence reporter mouse, developed by our collaborator Dr J Campisi 
(262). Dr Campisi’s research team developed a transgenic mouse model to 
label and eliminate cells undergoing p16 driven senescence. In this model, the 
p16 senescence-sensitive promoter drives expression of 3MR, a fusion protein 
that is composed of renilla luciferase (renLuc) and monomeric red fluorescent 
protein (RFP) reporters, and of herpes simplex virus-1 thymidine kinase (HSV-
TK), which converts ganciclovir (GCV) into an apoptosis inducer in cells where 
the p16 promotor is activated.  
The luciferase reporter allows the visualisation of senescent cells from live 
p16-3MR, using bioluminescence; RFP permits the identification and isolation 
of senescent cells by flow cytometry; HSV-TK facilitates the depletion of 
senescent cells in vivo (Figure 6.6). Eventually, our group would use the p16-
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3MR mouse model, and engraft MN1 transduced lineage depleted murine 
mononuclear cells to generate AML in vivo. The initial step to realise this would 
be to determine if MN1 cells would induce p16 expression in murine BMSCs 
derived from young, 6 to 8 weeks old p16-3MR mice, in vitro.  
 
Figure 6. 6 Schematic of the p16-3MR transgene.  
(A) The tri-modal reporter is under the control of the p16 promoter, which allows the 
visualisation/tracking, isolation and selective depletion of senescent cells in vivo, due 
to the renilla luciferase (renLuc), monomeric red fluorescent protein (mRFP), and 
Herpes simplex virus thymidine kinase (HSV-TK) proteins, respectively. (B) A 
diagram explaining the mechanism by which Gancyclovir (GCV) is phosphorylated by 
HSV-TK. This forms a purine analogue that inhibits DNA polymerase and causes 
chain termination and apoptosis of the affected senescent cells.  
 
6.8. Isolation and culturing of p16-3MR BMSCs 
Once total BM cells from the femurs and tibias of animals were isolated, as 
described in the methods section 2.5.5, I suspended the cells in DMEM 
supplemented with 10% FCS and pen-strep, and cultured them in a T-75 flask. 
The cells were allowed to adhere for 48 hours in normal culture conditions. At 
72-hours, I discarded cells that did not adhere, as this was indicative of dead 
or dying cells, and added 12-15mL fresh growth media. I found that adherent 
BMSCs could be observed at week 1, and gradually become confluent over 2 
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weeks (Figure 6.7). I found that replacing media with fresh media every third 
day is essential to preserve the replicative capacity of cells, and to prevent 
culture-stress or contact inhibition growth arrest. When needed, I trypsinised 
the cells and plated them into 12 well plates for further experimentation.  
 
 
Figure 6. 7 Light microscopy images from the In vitro cultures of p16-3MR 
derived BMSCs.  
Representative images of two samples of p16-3MR BMSCs in culture at specified 
days, post isolation.  
 
6.9. MN1 AML cells induce p16 expression in p16-3MR derived BMSCs 
After successful expansion of the p16-3MR BMSCs, I wished to determine if 
murine AML MN1 cells, could induce p16 expression in p16-3MR BMSCs. 
Thus, I co-cultured MN1 cells with p16-3MR BMSCs in either direct contact 
(DC) or in transwell inserts (TW) for 7 days. Media was replaced on day 3. 
Using western blotting, I determined p16 protein expression in p16-3MR 
BMSCs. Figure 6.8 shows that MN1 cells induced p16 protein expression in 
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p16-3MR BMSCs. These preliminary results provide the scientific rationale for 
an initial in vivo syngeneic MN1 – p16-3MR senescence model.  
 
 
Figure 6. 8 Western-blots showing that MN1 AML cells induce p16 expression 
in p16-3MR derived BMSCs in vitro.  
1x105 P16-3MR derived BMSCs were cultured with 0.5x106 murine MN1 AML cells 
for 7 days, and p16 expression determined by western blotting. Blots were then re-
probed for β-actin as a control (n=1).  
 
6.10. Summary of chapter 6 
In summary, the results presented in this chapter show that AML cells induce 
a senescent phenotype in BMSCs, accompanied by an upregulation of p16. 
Knockdown of p16 in BMSCs leads to reduced AML survival in co-culture. 
Further replication of these results, as well as in vivo validation of the MN1 
AML – p16-3MR senescence model are required. These are planned by the 
team in Norwich and potentially as part of my first post-doc. The new project 
will potentially use this model, amongst others, to further investigate the role 
of senescence and ageing in the initiation and progression of AML.  
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7. Chapter 7: discussion and conclusions  
 
7.1. AML-derived MIF stimulates BMSC IL-8 expression through PKCβ 
and is essential for AML survival 
In chapter 3, I have identified MIF as an AML-derived cytokine that alters the 
cytokine expression profile of primary BMSCs in vitro, specifically through the 
upregulation of the pro-survival chemokine, IL-8. I have shown that MIF is not 
just highly expressed by AML cells, but that it also stimulates IL-8 expression 
in primary AML-derived BMSCs. This upregulation of IL-8 in the BMSCs, 
induced by MIF, is not seen in normal BMSCs, suggesting a malignancy 
exclusive phenomenon. Inhibition of either MIF or IL-8 in the leukaemic setting 
significantly reduces AML survival in vitro. 
7.1.1. Modelling the AML microenvironment using primary AML BMSCs 
Previous studies have also reported both, human and murine BMSC’s ability 
to support AMLs in co-cultures (70, 131, 299, 342). A caveat in these findings, 
however, is that the BMSCs used in the reported studies were primarily 
healthy, non-malignancy-derived BMSCs; thus, they may not ideally represent 
a malignancy-associated secretory profile. All cytokine arrays and analyses 
presented in this work were derived from six primary AML BM samples, 
thereby representing more closely the malignancy-associated secretory 
profile. 
 
Additionally, upon karyotyping, three of the six primary samples revealed a 
normal karyotype. The karyotypes for the other three BMSCs could not be 
determined, as the samples failed to yield analysable metaphases. This issue 
has been reported by other studies as well (343). My findings contrast those 
of Huang et. al., who found that three out of four BMSCs from AML patients 
were cytogenetically abnormal (295). Nevertheless, the sample numbers in 
both our series are too small to be statistically sufficient, and so the real 
incidence of cytogenetic abnormalities in the BMSCs of AML patients remains 
uncertain.  
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7.1.2. AML-induced alternations in BMSC secretory profiles  
The cytokine array data were produced from 24-hour co-culture systems. A 
limitation to this end-point assay, is that it does not account for real-time 
events, such as autocrine and paracrine responses in all three culture 
conditions (AML only, BMSC only and AML/BMSC co-cultures). Hence, it is 
possible that the contribution of some cytokines might have been overlooked 
due to these effects. 
The cytokine profile of the six BMSC and AML co-cultures showed an 
upregulation of LIF, endoglin, MIP-3α, MIP-3β, MIP-1α/β, IL-6 and IL-8 in their 
culture media. IL-8 mRNA was upregulated 50 to 57-fold. These changes in 
AML-induced mRNA and protein expression in BMSCs have been reported by 
other studies, including Civini et. al., where TF-1 and K562 AML cell lines were 
co-cultured with healthy BMSCs, thus showing a varied increase in BMSC 
mRNA expression of IL-8 in the co-cultures (344). In my research, I show a 
consistent increase in all BMSC IL-8 mRNA expression from co-cultures. This 
strongly suggests that cell lines may not be an accurate representative of the 
responses seen with primary tissue.  
In a recent study, Reikvam and colleagues investigated the secretory profile 
of AML co-cultured with healthy BMSCs and observed a constitutive secretion 
of IL-8, IL-6 and VEGF amongst other cytokines from BMSCs (68). Their 
findings are partially consistent with my findings. However, when I co-cultured 
AML cells with HS-5, a normal BMSC cell line, I did not observe an 
upregulation of IL-8 mRNA. Moreover, the HS-5 cell line has been reported to 
support AML survival and to protect AML cells from spontaneous drug 
induced-apoptosis through direct contact (66, 311). Taken together, this 
indicates that the change in secretory profile is unique to AML-derived BMSCs, 
and also, that the HS-5-induced protection may be independent of the MIF-IL8 
axis.  
Ryningen et al. co-cultured fibroblast cell lines and one healthy primary 
BMSCs with AML cells and observed an upregulation of IL-8 secretion in the 
co-cultures. They hypothesised that the overall increase in IL-8 is due to 
153 
 
 
fibroblast and BMSC-induced changes in AML cells, causing an increase in 
their constitutive release of IL-8 (131). Moreover, Huang et. al. reported that 
the canonical IL-8 pathway was upregulated in AML cells compared to BMSCs 
(295). These studies neither reported BMSCs as the main source of IL-8 in the 
co-cultures, nor did they use primary AML-derived BMSCs; however, they 
indicated that IL-8 played an important role in the AML microenvironment. 
Furthermore, Huang et. al. also reported that BMSCs derived from AML 
patients differ from those of healthy donors, mainly in terms of monocyte 
chemoattractant protein-1 (MCP-1) levels. Hence, it is not unreasonable to 
suggest that healthy BMSCs and AML-derived BMSCs differ in their secretory 
profiles when cultured with AMLs. However, due to lack of healthy primary 
BMSCs in my study, I was unable to make any definitive conclusions as to 
how normal BMSCs differ from AML-derived BMSCs in my co-culture model.  
7.1.3. Characteristic primary AML cytokines, an emerging role for MIF 
In monoculture, I found that AMLs secrete high levels of myeloperoxidase, 
MMP9, osteopontin, IL-8, thrombospondin, MIF and serpine1. Interestingly, 
myeloperoxidase is a widely accepted gold standard marker for AML 
diagnosis. It is indicative of a myeloid lineage commitment and is associated 
with favourable prognosis (345). Furthermore, MMPs and osteopontin have 
been shown to be expressed by AML cells and to be associated with poor 
patient prognosis (346, 347). The MMP network is thought to cross-talk with 
other chemokine networks in AML to promote disease progression (348). 
Finally, serpine1 is also known to be secreted by AML cells and plays a role in 
pro-tumoural angiogenesis (349).  
In a recent study investigating the expression of a panel of hypoxia-regulated 
genes in AML and MDS patients, Falantes et. al. showed that MIF was highly 
expressed by a cohort of AML patients compared to those of the MDS cohort. 
Further analysis showed that MIF gene expression correlated with poor patient 
outcomes (300). MIF has also been shown to be overexpressed in other 
haematological malignancies, such as CLL. Binsky et. al. demonstrated that 
CLL cells overexpress the MIF receptor, CD74, and are responsive to 
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recombinant human MIF. Moreover, treatment with ISO-1 inhibited IL-8 mRNA 
and protein expression in CLL cells (170). Nonetheless, MIF protein secretion 
was not determined in this study. They concluded that MIF was secreted by 
CLL cells based on reduced IL-8 levels (which is in line with my findings), and 
furthermore, based on lower antiapoptotic BCL-2 mRNA expression when the 
cells were treated with ISO-1, thereby resulting in reduced cell survival and 
increased cell apoptosis.  
While Binsky and colleagues identified MIF to activate a CLL autocrine loop, 
my findings suggest that MIF activates a paracrine pathway in BMSCs, 
subsequently altering the microenvironment in a pro-tumoural manner. Unlike 
Binsky et. al.’s work, I have not investigated the effect of exogenous MIF or IL-
8 on AML expression of MIF, IL8 or CD74. However, CD74 has been shown 
to be expressed on the cell surface and in the cytoplasm of primary AML cells 
and AML cell lines (350), and to be associated with a poor outcome in younger 
AML patients (351). These studies make it reasonable to hypothesise that MIF 
might have an autocrine effect on the malignant cells as well as BMSCs and 
warrants further investigation of MIF receptor expression and function in the 
AML cells.  
I found that the inhibition of MIF using ISO-1 significantly reduced AML survival 
in co-culture. These results support previous findings that indicated reduced 
CLL survival following functional MIF inhibition, when cultured on a 
macrophage feeder layer (166). Interestingly, in an vivo model of breast 
cancer, MIF have been shown to promote tumour growth and pulmonary 
metastasis by inducing a highly immune suppressive subpopulation of 
myeloid-derived suppressor cells (MDSCs) (352). 
Recently, in a similar breast cancer mouse model, MIF was found to decrease 
the number of intra-tumoural CD8+ T cells, and to inhibit their ability to produce 
the cytokine IFN-gamma, resulting in inhibition of the immune function of these 
cells (353). From these studies and my findings, it is possible to deduce that 
MIF may have a broader effect on cellular components of the BMM, including 
immune cells and BMSCs 
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MIF protein is roughly 30% homologous with the related protein, D-
dopachrome tautomerase (D-DT), also referred to as MIF-2 (354). MIF and D-
DT genes are located on the same chromosome in both human and mouse 
and are ~ 80 kb apart (355, 356). D-DT expression has been detected in a 
number of human organs, however, a comparison of enzymatic activity of the 
two proteins showed that human MIF is about 10-times more active than the 
human D-DT protein (356). Both MIF and D-DT have been shown to have 
overlapping functions in solid tumours, for instance, in a study on renal clear-
cell carcinoma, D-DT and MIF showed additive protumourigenic effects (357), 
similar findings were shown in a model of non-small cell lung carcinoma (358). 
However, there is no data on the expression or role of D-DT in haematological 
malignancies. Taken together, it is plausible that D-DT, if expressed in 
leukemic cells, might play an independent or cooperative role with MIF in AML 
cells.  
My findings only identified MIF-driven survival signals in AML 
microenvironment. The homology in protein structure and similar activity of 
MIF and D-DT, could present an issue of specificity of the assays used to 
detect MIF and MIF-derived responses. In my study, MIF RT-PCR primers and 
MIF ELISA kits were not tested for cross-reactivity with D-DT. Although the 
ELISA assay used to detect MIF protein was validated by the suppliers to be 
MIF specific, ideally, recombinant human D-DT could have been used to 
determine any detection of D-DT. To rule out detection of D-DT using MIF RT-
PCR primers, the PCR transcript can be sequenced to determine the 
specificity of the product and primers used.  Most importantly, these measures 
are valid if mRNA and protein expression of D-DT were detected in AML cells 
used in the study.  
7.1.4. Clinical investigations of MIF inhibitors  
Recently MIF has been shown to exist in two immunologically distinct redox-
dependent isoforms, known as oxidised MIF (oxMIF) and reduced MIF 
(redMIF), total MIF was defined as the sum of oxMIF and redMIF, oxMIF is 
believed to be disease-associated (359). In solid tumours, oxMIF inhibition 
156 
 
 
sensitised human cancer cell lines to cytotoxic drugs (360). In my experiments, 
I assayed for total MIF cytokine secretion. In early phase trials of colorectal 
cancer and selected solid tumours, a novel oxMIF inhibitor (imalumab) was 
found to be effective and well tolerated (361, 362). Therefore, it would be 
interesting to identify the relative abundance of the two MIF isoforms in AML 
patient samples and to evaluate the efficacy of imalumab in in vitro and in vivo 
models of AML. This could help evaluate the plausibility of an MIF inhibitor trial 
in patients with AML.  
7.1.5. PKCβ targeting in leukaemic cells 
In chapter 4, I demonstrated that MIF binding of CD74 on the surface of 
BMSCs activated PKCβ signalling, and that the knockdown of PKCβ in BMSCs 
significantly reduced AML survival in co-culture. PKC signalling has been 
shown to be altered in cancer cells (363). Members of the PKC family have 
been implicated in haematological malignancies. In line with what I have 
shown in AML cells, inhibition of PKCβ with enzastaurin has been shown to 
abrogate the protective effect of BMSCs on MM cell lines (364). PKCβII is over 
expressed in CLL cells and is downstream of the B cell receptor (365).  
El Gamal et al demonstrated that PKC inhibition in CLL promotes apoptosis, 
inhibits proliferation, and abrogates microenvironment mediated protection of 
CLL cells (366). In their study, microenvironmental protection was simulated 
using a cytokine cocktail which mimicked the cytokines shown to be essential 
for CLL survival, whereas in my model, I aimed to mimic the microenvironment 
by co-culturing AML cells with BMSCs. Additionally, activation of PKCβII in a 
murine stromal cell line EL08-1D2 was shown to be essential for the survival 
of leukaemic cells from CLL, ALL and MCL patients (28). Taken together, it is 
postulated that PKCβ is commonly activated in haematological malignancies, 
which supports my hypothesis of its importance in the leukaemic 
microenvironment. 
7.1.6. IL-8 as a key cytokine for AML survival 
In 1993, Tobler et. al. described the constitutive expression of IL-8 and its 
receptor in AML (136). More recently, Schinke et. al. reported that IL-8 is 
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overexpressed in primary AML samples compared to normal HSCs. Inhibition 
of the IL-8 receptor CXCR2 selectively decreased proliferation and cell cycle 
arrest of AML cells (140). In line with these studies, I found that the inhibition 
of CXCR2, or the knockdown of IL-8 in BMSCs reduced AML survival in co-
culture. Elaborating on the role of IL-8 in the AML microenvironment, AML cells 
have been shown to have a higher low-density lipoprotein (LDL) uptake 
compared to normal mononuclear blood cells, which in turn resulted in higher 
cellular cholesterol levels. Cellular cholesterol is essential for membrane 
protein structure and function, and so the inhibition of this uptake sensitised 
AML cells to chemotherapy in clinical trials (367, 368). Very recently, Bhuiyan 
et. al. reported that autocrine and paracrine IL-8 (and IL-6) stimulated LDL 
uptake in AML cells, thereby increasing AML cellular levels of cholesterol 
(369). Taken together, these studies further support the broader role of IL-8 in 
the survival of AML cells.  
7.1.7. In vivo modelling of IL-8 may be challenging 
Because mice lack a direct homologue of IL-8, MIF stimulation of human IL-8 
could not be demonstrated in vivo. An accepted homologue of IL-8 is murine 
MIP-2 (370). HSCs have been shown to respond to murine MIP-2 (371), 
however, to this date, leukaemic cell response to murine MIP-2 has not been 
reported. An alternative model could be a syngeneic murine model in which 
murine AML cells overexpress MIF. However, since IL-8 upregulation is the 
ultimate effect of AML-derived MIF, it is also imperative to evaluate the effect 
of MIF-deletion in AML cells on animal survival. I have presented these results 
in chapter 5, where AML-derived MIF inhibition resulted in reduced tumour 
burden and significantly increased animal survival.  
In summary, I have described how AML stimulates the production of IL-8 from 
BMSCs and using pharmacological and lentiviral intervention, inhibiting this 
process significantly reduces AML survival in vitro.  
7.2. Hypoxia regulates MIF expression through HIF1a  
In the previous section I discussed the importance of MIF as a mediator of 
AML survival. In chapter 5, I reported that hypoxia, acting through HIF1α, is 
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responsible for the up-regulation of MIF, and the subsequent proliferation and 
survival of AML in the tumour microenvironment.  
Hypoxia has as broader malignant phenotype in the proliferation of solid 
tumour cells in studies of breast, prostate, ovarian and pancreatic cancers 
(372-374). Under normal physiological conditions, the BM is a known hypoxic 
environment. Fiegl et. al. have established that the AML BM is also hypoxic 
(240). Furthermore, tumour-specific transcriptional programs in AML patient 
samples included an up-regulation of the hypoxic response genetic signature 
(375).  
7.2.1. AML emerges as a hypoxia driven malignancy  
In a study evaluating the effectiveness of hypoxia-activated pro-drug TH-302, 
Benito et al report that BM and PB AML samples exhibited a greater hypoxic 
signature than those of healthy controls. This suggests that AML cells retain a 
hypoxia-induced gene signature even after they exit the hypoxic BM (246). 
However, the study does not report a direct comparison of hypoxic signatures 
between AML PB samples and normal PB samples. Moreover, it has been 
reported that AML PB CD34+ cells are functionally different from those in the 
BM. Cheung et. al. identified 9 genes whose expression was significantly 
higher in BM CD34+ cells compared to PB CD34+ cells (376). Among these 
genes, MCL-1 and DUSP1 have been shown to be HIF1α target genes (377, 
378).  
In line with these studies and, using bioinformatic analysis, I reported that AML 
samples from the BM are enriched in hypoxia regulated genes compared to 
samples from the PB (section 5.2). I further confirmed this in vitro, using five 
primary AML samples, in which hypoxia regulated GLUT1 and MIF were 
higher in BM AML cells than in the PB. I found that hypoxia did not induce MIF 
expression in normal peripheral CD34+ cells. However, normal CD34+ in this 
experiment were derived from healthy donors and may be intrinsically different 
from AML PB CD34+ cells. Whether PB AML cells are different from healthy 
PB CD34+ cells warrants further investigation. In summary, these findings 
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suggest that hypoxia is key to AML pathogenenesis and, most importantly, it 
is a tumour-specific feature.  
I report above in chapter 5 that the upregulation of MIF is a functional 
consequence of the hypoxic microenvironment. Interestingly, others have 
shown in their studies that it was hypoxia that regulated MIF expression in 
endothelial cells and vascular smooth muscle cells (321, 328). MIF was shown 
to be up-regulated by hypoxia in several tumour cell types in vitro including in 
breast carcinoma cells (323). Interestingly, CLL cells are highly dependent on 
MIF for their survival (166) and have been shown to constitutively express 
HIF1α under normoxic conditions (379). Hence, the inhibition of HIF1α or MIF 
interactions have been suggested as a plausible therapeutic approach for CLL 
(380). Following these, I demonstrated that by silencing HIF1α, using a 
lentivirus-mediated knockdown in both primary AML and in the OCI-AML3 cell 
line, the expression of MIF is regulated by hypoxia driven HIF1α.  
7.2.2. The role of HIFs in AML remains to be delineated  
In my studies, the knockdown of HIF1α in primary AML cells significantly 
reduced their proliferation in culture, and significantly increased the survival of 
NSG mice injected with HIF1α-KD OCI-AML3luc cells. Previously published 
results using a syngeneic murine AML model showed that genetic deletion 
of HIF1α had no effect on mouse AML maintenance, and may accelerate 
disease development (248). In another study by the same group, it was shown 
that the loss of HIF1α accelerated murine FLT3-ITD induced 
myeloproliferation (381). This observation appears contrary to my own data, 
where I found that the loss of HIF1α reduced the number of AML cells, 
compared to controls (section 5.7, Figure 5.11D).  
However, other studies have shown that deleting HIF1α in a subset of primary 
AML LSCs led to a decrease in their sensitivity to HIF1α inhibition. Wang et. 
al. demonstrated an important role for HIF1α in the in vitro colony-forming 
activity of their 7 clinical AML samples, where the experiments employed 
echinomycin as a HIF1α inhibitor (326). This was also demonstrated in another 
study using AML cell lines to study the effect of HIF1α in AML (382). However, 
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since echinomycin blocks HIF1α transcriptional activity by binding to DNA via 
bi-functional intercalation into the hypoxia response element, this would also 
compromise HIF2α transcriptional activity (216). Vukovic et. al. revealed that 
HIF-1α and HIF2α are not required for leukaemia stem cell maintenance and 
AML propagation, but that they acted synergistically to suppress leukaemia 
development in mice. In their models, the knockout of HIF2α or the 
pharmacological inhibition of the HIF pathway in human AML cells had no 
impact on their survival and proliferation under hypoxic conditions (253).  
In my experiments, I showed that HIF2α is detectable under normoxic 
conditions in AML patient samples and in the OCI-AML3 cell line. Interestingly, 
I observed that the HIF2α protein, unlike HIF1α, is not increased under hypoxic 
conditions, while I found that HIF1α is only stabilised under hypoxic conditions. 
In AML cell lines (HL60 and THP-1), HIF1α has been shown to be 
constitutively expressed under normoxic conditions (383). More recently, it has 
been shown that in primary and cell line CML cells HIF1α is stabilised under 
normoxic conditions (384). The discrepancy in the status of HIF1α, in primary 
and cell line AML models, indicate that they are intrinsically different from one 
another. Hence, observations in cell lines cannot always be generalised to the 
primary disease.  
I demonstrated that specific KD of HIF1α but not HIF2α prevented MIF 
induction under hypoxic conditions. Taken together, these results suggest that 
HIF1α, but not HIF2α, is responsible for driving MIF expression in my AML 
samples. In my in vivo studies, HIF1α-KD AML cells took longer to engraft, 
compared to the control-KD cells for which animal survival was longer. 
Therefore, this suggests that human AML benefits from the hypoxia present 
within the bone marrow microenvironment. 
Previously published studies demonstrated that the overexpression of HIF2α 
accelerate myeloid leukaemia in mice. Conversely, HIF2α-KD in leukaemic 
cell lines prolonged the survival of transplanted mice (252). Rouault-Pierre and 
colleagues show that cells from primary AML samples were dependent on the 
level of HIF2α for their survival, and were protected from apoptosis induced by 
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ER stress (251). This is in contrast to my results, where I found that the 
knockdown of HIF2α in primary AML cells did not lower the survival of AML 
cells in culture, and it had a minimal effect on MIF secretion by the cells. 
7.2.3. In vivo modelling of the role of MIF in AML BMM 
I found that knocking down MIF significantly reduces AML survival and colony 
forming ability. Moreover, animals transplanted with AML cells following MIF-
KD had significantly improved survival compared to controls. This is in 
agreement with observations in MM, where MIF-KD in MM cells did not form 
tumours in bone of MM mouse models, whereas control KD cells caused 
tumours in the bone (385), thereby, suggesting a role for MIF in the 
microenvironment of AML and MM likewise. Moreover, I found that MIF-KD 
induced apoptosis in AML cells. Recently, the presence of MIF-KD in cervical 
adenocarcinoma cells was shown to induce apoptosis and to inhibit cell 
proliferation, via the upregulation of proapoptotic proteins and the 
downregulation of antiapoptotic proteins of the Bcl-2 family (386). MIF can also 
induce apoptosis by inhibiting wildtype p35 activity, as demonstrated in lung 
adenocarcinoma cells (154). The mechanism by which MIF induces apoptosis 
in AML cells remains to be investigated.  
In the CI-AML3luc mouse models, MIF-KD mice had less tumour burden than 
the HIF1α-KD mice. Moreover, survival was slightly more improved for the 
MIF-KD mice (section 5.9). This may be due to indirect protein interactions, by 
which MIF may regulate HIF1α function, as deduced from a study in which the 
overexpression of MIF in selected cell lines enhanced HIF1α activation under 
hypoxia, and was dependent on wildtype p53 (387). In my experiments, I did 
not investigate whether MIF regulates HIF1α function in the AML cells. It would 
be interesting to determine the effect of exogenous MIF on HIF1α activity in 
MIF-KD cells. Furthermore, in case this interaction is dependent on wildtype 
p53, this mechanism might be attenuated in p53 mutant AML. In conclusion, 
the functional interactions of MIF and HIF1α in AML remain to be elucidated. 
Finally, in the primary AML PDX used in my studies, MIF gene silencing with 
shRNA provided better survival differences than using the pharmacological 
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inhibitor, ISO-1, which only extended survival by less than 10 days. A possible 
explanation for this could be that the ISO-1 dosage was suboptimal. In fact, in 
a study using ISO-1 to inhibit MIF function in a model of sepsis, doses of up to 
35 mg/kg/day were used (388), while the dose used in my studies was only 
10mg/kg/day. I postulate that a higher dose could have improved survival and 
improved AML cell mobilisation to the PB. 
In conclusion, my study presents a mechanism linking hypoxia to a chemokine 
factor, inducing a pro-tumoural signalling pathway in the AML 
microenvironment. In doing so I establish a potential strategy to target AML. 
7.3. AML induces senescence in BMSC through upregulation of p16  
In chapter 6, I presented novel data that identified the BMM as a progressively 
senescent one which enhances the survival of AML within the BM. I also 
showed that the senescence of BMSCs in the environment is induced by AML 
cells and is brought about through the cyclin-dependant kinase inhibitor, p16. 
Finally, BMSCs from the p16-3MR mice were successfully cultured and p16 
expression was determined in co-cultures with murine MN1 AML cells. 
Knockdown of p16 in BMSCs reduced AML survival in co-cultures; as a result, 
in vivo experiments with the p16-3MR animal model will be optimised for 
further senescence studies in AML. 
7.3.1. An ageing-induced malignant environment   
AML is a disease of the older population (27) and senescent cells have been 
shown to naturally accumulate with age (265). Moreover, it has been shown 
that, senescent fibroblasts stimulate the growth of neighbouring pre-neoplastic 
epithelial cells, in co-culture experiments of prostate cancer and in in vivo 
models of lung cancer (389, 390). These studies suggest that as aging cells 
accumulate, they create an environment which is favourable to cancer cell 
survival. Interestingly, it has also been shown that cancer cells can induce 
normal cells to become senescent. In an vivo model of p16 driven senescence, 
imaging revealed p16 expression in the emerging neoplasm and surrounding 
stromal cells (391). This is in line with my observation that AML cells induce 
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p16 expression in BMSCs. However, I did not study p16 expression in the 
malignant compartment.  
7.3.2. Senescence in AML cells 
Müller-Tidow et. al. investigated the expression levels of cell cycle genes in 
primary AML patient cells and found that average expression levels 
of p16 (and tumour suppressor p14) were higher in AML samples, compared 
to control samples. However, the median age for the AML cohort in this study 
was 52 years and the control group included only six samples (392). In a more 
recent study, p16 mRNA was shown to be downregulated in AML cells with 
increasing age (393). Considering the differing outcomes of these studies, an 
interpretation of the significance of p16 expression in the AML compartment 
can only be accurate if the patient ages are comparable.  
7.3.3. In vitro markers and inducers of senescence  
Since it was first described in 1995 by Professor Campisi’s research group, β-
galactosidase (β-gal) staining has been widely used for detecting senescence. 
Senescent cells are identified by their failure to synthesise DNA. Nonetheless, 
this is also characteristic of quiescent and differentiated cells. The β-gal 
staining assay has the following advantages: i) it is easy to detect, ii) it has 
been shown to be independent of DNA synthesis in senescent cells, and iii) it 
generally differentiates senescent cells from quiescent cells (394, 395). 
Hence, it was ideal for detecting AML-induced senescence in my co-culture 
model.  
I found that BMSC from late passages become senescent in culture. This is 
not surprising as cultured primary BMSCs have been shown to undergo 
senescence (396, 397). Moreover, AML-derived BMSCs may be intrinsically 
different from normal BMSCs in terms of the rate at which they undergo 
senescence. Kim et. al. reported that AML derived BMSCs had lower 
proliferative activity than that of the controls due to increased senescence 
(343). Hence, in my study, the lack of normal BMSCs and the small sample 
size of AML-BMSCs may be a limiting factor in the interpretation of data. More 
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definite conclusions may be made from a bigger sample size, and including a 
comparison with normal BMSCs. 
In my culture model, I used daunorubicin as a positive control to induce 
senescence in BMSCs. It is the immediate precursor of the more widely used 
doxorubicin (398). Doxorubicin and daunorubicin are both anthracyclins with 
the same mechanism of action (399), and they have been sown to induce a 
senescent-like phenotype in vitro and in vivo (282, 400). Additionally, 
daunorubicin is a critical component of standard induction chemotherapy in 
AML patients (401). It would be interesting to investigate whether the effect of 
daunorubicin and AML are synergistic on BMSC senescence, and how it can 
be eliminated.  
Alhtough SASP factors have been shown to develop slowly over time, not all 
of them are secreted at the same time (261). I have reported that AML cells 
induced SASP-related factors in 24-hour co-cultures. I then performed β-gal 
staining in BMSCs after 6 days of co-culture, however, I did not check for 
SASP factors at 6 days. It is possible that AML-derived BMSCs may be pre-
conditioned to developing an SASP at an earlier time point once they are 
cultured in vitro. Ideally, AML-BMSCs should be compared to healthy, age 
matched BMSCs to allow identification of intrinsic differences between 
malignant and healthy BSMCs.  
7.3.4. In vivo modelling of the senescent BMM in AML  
In efforts to optimise the p16-3MR model to study AML BM senescence, I 
showed that murine AML cells, overexpressing the MN1 AML oncogene 
induced p16 protein expression in p16-3MR-derived murine BMSCs after 7 
days of co-culture. Ideally, additional confirmatory experiments need to be 
performed to confirm this result and to optimise the AML p16-3MR mouse 
model.  These include, determining luciferase activity of the senescent p16-
3MR BMSCs in co-culture with MN1 cells, identifying if p16 expression 
developed at earlier time points while in culture, and assaying for SASP factors 
in co-cultures compared to monocultures of p16-3MR BMSCs. 
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The p16-3MR transgenic mouse model is instrumental in studying AML 
induced senescence. It has previously been used to study the role of 
senescent cells in wound healing and in age-related diseases (262). This 
model permits the non-invasive clearing of senescent cells in vivo using 
gancylovir (explained in section 6.7). A similar mouse model, referred to as the 
INK-ATTAC mouse (283, 402) is the only other model where p16 senescent 
cells can be depleted in vivo.  
I have reported that AML cell co-cultures with p16-KD BMSCs significantly 
reduced survival in vitro. This observation can be validated in vivo with the 
p16-3MR model. Using gancylovir, the elimination of senescent cells from p16-
3MR mice that have developed AML, would be expected to increase their 
survival compared to controls (no gancycolvir). Pharmacologically, senolytic 
agents have been shown to effectively and selectively ablate senescent cells. 
An example of this is ABT-263, which inhibits the anti-apoptotic proteins Bcl-2 
and Bcl-xL in senescent cells, leading to their apoptosis. Interestingly, Chang 
et. al. used the p16-3MR mouse model in conjunction with ABT-263 to 
rejuvenate aging HSCs in the BM of mice (403). Importantly, ABT-263 has 
been shown to target AML cells too (404). As it is not known how this 
compound will perform in an AML and BMSC co-culture, its effects will need 
to be evaluated in vitro and in vivo.  
In conclusion, senescence has been shown to be both, tumour-supressing and 
tumour promoting, depending on the biological contexts of the disease being 
studied. In AML, senescence may be induced by both, the treatment and the 
malignancy. This creates a novel therapeutic angle which seeks to manipulate 
the tumour favouring environment to act against the tumour, and may be an 
important and interesting strategy in identifying the state and prognosis of AML 
patients. 
7.4. Conclusions and future directions  
Despite the progress made in understanding the biology of AML cells, 
relatively little has been achieved with regards to the treatment of AML in 
patients >70 years. With accumulating evidence supporting a key role for the 
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BMM in the pathogenesis of AML, it is imperative to believe that unless AML 
cells and critical components of the BM microenvironment are targeted 
concomitantly, progress in AML treatment may not be realised.  
New insights into the cross-talk between AML cells and BMSCs were 
presented in this thesis, where I have identified MIF as a key AML-derived 
cytokine that alters the pro-tumoural BMM. Accordingly, MIF presents itself as 
a potential therapeutic target in AML, and pre-clinical studies of MIF would be 
instrumental in realising this. Moreover, as chemotherapy is indispensable for 
the treatment of AML, it is predicted that MIF inhibitors may improve tolerability 
and treatment outcomes for AML patients treated with chemotherapy.  
Currently, chemotherapy treatment aims to eradicate leukaemic cells. 
However, treatment leaves behind an altered microenvironment that is highly 
permissive to disease recurrence. Tumour and therapy induced senescence 
is a novel aspect of the AML BMM. Future investigation should aim to re-
establish a BMM that is conducive to normal haematopoiesis rather than 
leukaemogenesis. 
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Appendix 
Table 1: Cytogenetic profiles of primary BMSCs 
 
BMSC Sex BMSC cytogenetics AML cytogenetics  
BMSC#1 M N/A Normal 
BMSC#2 F N/A t(5;12)(q13;q24) 
BMSC#3 M Normal Normal 
BMSC#4 F Normal t(8;21)(q22;q22),del(9)(q13q22) 
BMSC#5 M Normal Normal 
BMSC#6 M N/A add(5)(q35),add(6)(q22) 
 
AML cytogenetics refers to the cytogenetics of the AML sample from which 
the BMSC were derived. 
Karyotype reports provided by the Norwich Cytogenetics Service, where the 
karyotyping/cytogenetic analysis was performed, are included below. 
Karyotype results for samples 1 and 2 were communicated by e-mail to Dr 
Stuart Rushworth.  
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Table 2: AML, BMSC and AML/BMSC cytokine array data sets  
Cytokine array blots were analysed for mean optical densities using 
HLimage++ software. Outputs are presented in the tables below. AML only 
refers to AML cell culture control, BMSC only refers to BMSC cell culture 
control. 
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Oxidative stress as a result of elevated levels of reactive oxygen species (ROS) has been observed in almost all cancers, including
leukaemia, where they contribute to disease development and progression. However, cancer cells also express increased levels of
antioxidant proteins which detoxify ROS. This includes glutathione, the major antioxidant in human cells, which has recently
been identified to have dysregulated metabolism in human leukaemia. This suggests that critical balance of intracellular ROS
levels is required for cancer cell function, growth, and survival. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) transcription
factor plays a dual role in cancer. Primarily, NRF2 is a transcription factor functioning to protect nonmalignant cells from
malignant transformation and oxidative stress through transcriptional activation of detoxifying and antioxidant enzymes. However,
once malignant transformation has occurred within a cell, NRF2 functions to protect the tumour from oxidative stress and
chemotherapy-induced cytotoxicity. Moreover, inhibition of the NRF2 oxidative stress pathway in leukaemia cells renders them
more sensitive to cytotoxic chemotherapy. Our improved understanding of NRF2 biology in human leukaemia may permit
mechanisms by which we could potentially improve future cancer therapies. This review highlights the mechanisms by which
leukaemic cells exploit the NRF2/ROS response to promote their growth and survival.
1. Introduction
Acute myeloid leukaemia (AML) is primarily a disease of
the elderly with 75% of cases being diagnosed in patients
over 60 years of age [1]. AML comprises a biologically
heterogeneous group of disorders that occur as a consequence
of a wide variety of genetic abnormalities in haematopoietic
progenitors that are derived from the bone marrow. In
fitter, generally younger patients complete remission can be
achieved only in a minority with current chemotherapeutic
regimens. Patients who are not fit for intensive chemotherapy
are generally managed with a palliative approach without a
chance of cure. Furthermore, even in patients who do achieve
remission following intensive chemotherapy many relapse
from the persistence of a small clone of minimal residual
disease [2, 3] and, despite considerable efforts over the last 30
years to develop and improve therapy, presently two-thirds
of younger adults and 90% of older adults still die of their
disease [4]. It is envisaged that improved outcomes for all
patients will now only come from novel treatment strategies
(beyond increasing doses of conventional cytotoxic drugs)
derived from an improved understanding of the biology of
the disease.
2. Oxidative Stress
Oxidative stress is described as a change in the balance
between reactive oxygen species and antioxidant defence
mechanisms, where the balance is disturbed for the support
of the oxidants [5]. Together, oxidants and antioxidants are
essential for normal cellular function including metabolism
and signal transduction which allow for the maintenance
of cellular homeostasis [6, 7]. However, oxidative stress, if
unconstrained, results in the damage of important cellular
components which may result in DNA mutations or cell
death.
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Reactive oxygen species (ROS) are oxygen-containing
chemical species with reactive properties, including free
radicals such as superoxide and nonradical molecules such
as hydrogen peroxide [8]. These reactive species result from
both endogenous and exogenous cellular sources. Endoge-
nous sources of cellular ROS include oxidative phosphory-
lation within mitochondria, which results in the formation of
dioxygen, which is normally reduced to water but in some
instances is partially reduced to form superoxide. Further
reduction reactions can subsequently give rise to hydrogen
peroxide [9, 10], which has long been thought of as a harmful
molecule; however, recently, new evidence has emerged
which suggests that at low concentrations hydrogen peroxide
acts as an intracellular signalingmolecule involved in survival
and proliferation mechanism. In contrast, exogenous ROS
is produced by many environmental mediators which have
demonstrated involvement in a number of pathological states
including cardiovascular disease [11], chronic inflammation
[12], and neurodegenerative diseases [13] as well as cancer
[14].
3. Reactive Oxygen Species
There is a complex interaction between ROS generation,
signaling, and toxicity that results in the initiation, growth,
and survival of cancer. Cancer may be induced through
oxidative damage to cellular macromolecules as a result of
overproduction of ROS, which subsequently affects antiox-
idant and/or DNA repair mechanisms [15]. In addition,
ROS can stimulate signal transduction pathways leading
to activation of key protumoural transcription factors [16].
Once the malignant state has been established, the same
cellular survival mechanisms that the cell had employed to
protect against tumorigenesis are subsequently subverted to
support a protumoural state and protect the cancer cells from
chemotherapy. ROS have a physiological cellular response to
trigger cellular inflammation and damage that may lead to
cell death.This protective effect is lost in cancer cells and thus
endogenous and exogenous efforts to induce cytotoxicitymay
also be lost in cancer. Specifically in human leukaemia the
NRF2 pathway appears central to the control of the redox
state functioning at least in part through its regulation of
glutathione synthesis and regeneration. It is envisaged that
the identification of tumour-specific dependence within this
pathwaymay ultimately be exploited to developmuch needed
new treatments.
4. Acute Myeloid Leukaemia
AML develops from a common myeloid progenitor, a cell
whichwould physiologically differentiate to formmonocytes,
granulocytes, platelets, and erythrocytes in the bone marrow
[17, 18]. AML is the most common acute leukaemia affecting
adults, and its incidence increases with age [19]. However,
AML is a heterogeneous disease driven by a wide variety of
genetic lesions [20]. In patients fit enough for conventional
intensive cytotoxic chemotherapy, the treatment destroys
actively cycling leukaemic cells and initial remission rates
are high. However, in these patients following remission
induction and despite in many cases the disease becoming
undetectable by current testing technologies, a subpopula-
tion of cells with leukaemic stem cell properties frequently
survives chemotherapy and it is this subpopulation (minimal
residual disease) that is responsible for the relapse commonly
encountered in this disease [21]. In patients not fit for such
cytotoxic chemotherapy, management is presently based
around palliation and symptom control.
The discovery of specific mutant genes in AML has
provided increased biologic understanding, new potential
targets for drug development [22], and new diagnostic meth-
ods for detection of minimal residual disease [23, 24]. For
instance, mutations of the FMS-like tyrosine kinase-3 (FLT3)
receptor (internal tandem duplication (ITD)) are found in
approximately 25% of new cases of AML [25, 26]. FLT3-
ITD has been found to cause increased levels of ROS within
murine Ba/F3 or 32D cells expressing FlT3-ITD as well as
MOLM-14 and MV-4-11 human AML cell lines which carry
FLT3-ITDmutations [27], suggesting that ROS are important
in regulating FLT3 mutated AML.
5. Manipulation of the Redox Status by
Leukaemia Oncogenes
A number of oncogenes such as KRAS, cMYC, BCR/ABL,
NRF2, and NF-kappaB (NF-𝜅B) are able to alter the redox
balance of human cancer cells including leukaemic cells [26,
28–32]. The oncogenic BCR/ABL fusion gene found mainly
chronic myeloid leukaemia (CML) is capable of inducing
ROS levels in both human and murine cell lines [33, 34].
Moreover, BCR/ABL-induced ROS can also result in signal-
ing changes including the upregulation of the nonreceptor
tyrosine kinase FYN [35, 36]. FYN deficiency in the presence
of BCR/ABL expression is a mediator of chronic myeloid
leukaemia (CML) proliferation and CML resistance to the
drug of choice for CML, the BCR/ABL inhibitor, imatinib.
Together, these findings illustrate how a cancer associated
tyrosine kinase can induce ROS resulting in leukaemia
proliferation and drug resistance.
It has also been described that leukaemic oncogenes
may also affect the transcription, stability, or activity of
antioxidant proteins within leukaemic cells. For example,
BCR/ABL and NF-𝜅B can increase the transcription of
NRF2 and by association its regulated genes, which have
been shown to have cytoprotective properties. Furthermore,
activation of NRF2 requires a phosphorylation process which
results in the stabilisation of NRF2 and its release from its
negative regulator allowing transcription of the antioxidant
genes [37]. The transcription factor NRF2 is activated by
increased oxidative stress inducing protection of normal
cells against electrophilic and oxidative stress [38]. This
provides an example of transcriptional pathways by which
leukaemic oncogenes can influence the redox environment of
leukaemia cells and represent possible targets for therapeutic
intervention.
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Figure 1: Glutathione synthesis as seen through NRF2. GSH is a two-step synthesis reaction catalysed by glutamate-cysteine ligase (GCL)
and GSH synthetase. GSH is consumed in many ways, such as by oxidation or conjugation. In addition, cells may lose GSH due to export
of its reduced, oxidized, or conjugated forms and intracellular GSH is regenerated via reduction at the expense of one NADPH molecule.
Highlighted in red are the genes regulated by NRF2 activity.
6. NRF2 Regulated Cellular
Antioxidants in Leukaemia
Our research has previously shown that current standard
AML chemotherapy (cytarabine and daunorubicin) induces
an increase in ROS inAML cells as part of theirmechanism of
cytotoxic action [39]. Furthermore, we also recently reported
that malignant blasts from AML patients have inappropriate
constitutive NRF2 activation, resulting in increased cell
survival and chemotherapy resistance [40, 41]. The NRF2
signaling pathway is a major cellular pathway that under
normal conditions protects nonmalignant cells against elec-
trophilic and oxidative stress [38]; however, in AML as well
as many other malignancies, including chronic lymphocytic
leukaemia (CLL), NRF2 is constitutively activated [42]. In
AML, constitutive activation of NRF2 occurs not through
somatic mutation of NRF2 or its inhibitor KEAP1 but as a
result of upstream constitutive activation of NF-𝜅B.
NRF2 regulates the expression of over 200 genes includ-
ing many antioxidant genes and phase II enzymes such
as heme oxygenase-1 (HO-1) and NAD(P)H: quinone oxi-
doreductase 1 (NQO1) [43, 44] and genes involved in glu-
tathione metabolism and regeneration [45–48]. No single
gene induced by NRF2 can be identified as the most impor-
tant for cell protection, as cell protection is a result of the coor-
dinated induction of NRF2 target genes. As well as the work
on AML, NRF2 genes have also been dysregulated in other
human blood cancers including CLL and multiple myeloma
(MM). In CLL, experiments show the presence of NRF2
signaling and suggest that altered NRF2 responses may con-
tribute to the observed selective cytotoxicity of electrophilic
compounds in this disease [49]. In MM, HO-1 is increased in
bortezomib-resistant MM cells, suggesting a possible role for
HO-1 and NRF2 in chemotherapy resistance [50]. Together
these results highlight the importance of NRF2 in human
blood cancer.
6.1. Glutathione Metabolism, Regeneration, and Control of
ROS. GSH has emerged as an important regulator of
chemotherapy resistance in human cancer. GSH is present in
all mammalian tissues at 1–10 millimolar concentrations and
protects against oxidative stress [51]. In the cell GSH exists
in the thiol-reduced GSH and disulfide-oxidized (GSSG)
forms [52] and its major reservoir is the cytosol (80–85%)
[53–55]. GSH synthesis occurs via a two-step ATP-requiring
enzymatic process and exerts a negative feedback inhibition
on key rate limiting enzymes including glutathione cysteine
ligase (GCL) [56, 57] either by phosphorylation or by protein
expression [58]. The regulation of GSH synthesis is under
tight control involving key enzymes including GCL, GSH
synthetase, and GSH reductase. More importantly these
enzymes are all regulated, at least in part, by NRF2 through
its activation of the ARE [59].This highlights the importance
of addressing the link between NRF2 and GSH in disease,
especially leukaemia. Figure 1 shows the link between NRF2
and GSH synthesis and regeneration.
It is becoming apparent that NRF2 is the main transcrip-
tion factor that controls the regulation of many aspects of
GSH synthesis and regeneration [60, 61]. Importantly the
regulation of GCL at the transcriptional level is essential
for the maintenance of GSH homeostasis in response to
oxidative stress. In addition, levels of GCLC and GCLM are
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decreased in NRF2 knockout mice; the resulting lack of GSH
synthesis is lethal during embryogenesis [62].Moreover, GSH
synthetase which catalyses the second step of GSH generation
is also regulated by NRF2 and overexpression of either NRF1
or NRF2 induced the GSS promoter activity by 130 and
168%, respectively. Other genes involved in GSHmetabolism,
regeneration, and function are also regulated by NRF2
activation, which include GSH S-transferases (GSTs), GSH
reductase (GR), and GSH peroxidase (GPX) [48, 63, 64].
Together, this information suggests that NRF2 controls the
effectiveness of GSH to combat the excess of ROS.
Hydrogen peroxide is one of the main activators of
the NRF2-KEAP1 pathway. It is metabolised by GPX in
the cytosol resulting in GSH being oxidized to GSSG in
the mitochondria. GSSG can be reduced back to GSH by
GR at the expense of NADPH, thereby forming a redox
cycle, where organic peroxides can be reduced by either
GPX or GSH S-transferase (GST) [65]. GSTs are a family of
phase II conjugation enzymes under the regulation of the
NRF2/ARE pathway [66]. The main role of GST is to catal-
yse the detoxification of various harmful compounds [67].
This detoxification process is under the tight control of NRF2
as GST mRNA and protein expression are decreased in
NRF2-null mice, and NRF2 is required for GST induction
[68]. Moreover, the mRNA expression of GST is markedly
increased in KEAP1-null mice [69]. This provides evidence
that not only GSTs but also many other enzymes that are
involved in GSH synthesis and regeneration are coordinately
regulated by NRF2 and justifies the necessity to address the
NRF2 GSH axis in human cancers, especially leukaemia.
6.2. NRF2, GSH, and Leukaemic Cell Survival. Although
NRF2 is protective against tumorigenesis by reducing the
amount of ROS and DNA damage in cells, tumour cells were
found to be capable of harnessing the protective function
of NRF2 for their own protection and survival [42, 70].
Indeed, NRF2 activity itself is elevated in some leukaemia
types where it contributes to leukaemogenesis [71]. Elevated
nuclear localization of NRF2 and the subsequent genetic
changes result in reduced sensitivity to proteasome inhibitors
inAML cell lines [41], suggesting thatNRF2may also regulate
sensitivity to ROS-producing therapeutic agents. Moreover,
molecular analyses have revealed that treatment with stress
inducers (e.g., tumour necrosis factor) results in increased
NRF2 activity inTHP-1,HL-60, andAML 193 cell lines, which
in turn increases the transcription of antioxidants [72].
Primitive hematopoietic stem and progenitor cells reside
within the bone marrow and express the CD34 surface
antigen [73, 74].Moreover, primitive AML cells also generally
express CD34 and are more resistant to chemotherapy [74,
75]. A recent study by Pei et al. evaluates the characteristics
of primary CD34+ cells derived from patients with AML in
comparison to normalCD34+ controls [76].This is consistent
with the finding that CLL cells have elevated levels of reactive
oxygen species (ROS) compared to normal controls [77].
Taken together, this suggests that altered GSH content might
be a common property of primary hematopoietic malignant
tissues.
The prognostic value of GST deletions in adult AML,
including individuals with GSTM1 or GSTT1 deletions (or
deletions of both), is found to have enhanced resistance
to chemotherapy, lower complete remission, and a shorter
survival [78]; this further supports the suggestion of a dis-
turbed glutathione metabolism in AML cells. AML cells have
elevated expression of multiple GSH metabolising enzymes
including GCL and GST compared to control CD34+ cells
and knockdown of GCLC or GPX1 impaired the growth
of leukaemic cells in vitro [76]. Moreover, a significantly
decreased GSH to GSSG ratio further indicates aberrant
glutathione homeostasis in AML cells; this is consistent with
findings of increased basal levels of nuclear NRF2 in primary
AMLs [41]. This highly suggests that increased NRF2 activity
inAMLcells is responsible for the elevated expression of these
genes as a mechanism by which AML cells compensate for
increased oxidative stress in leukaemic cells. The aberrant
glutathione metabolism presents a unique and potentially
useful asset for targeting of primitive leukaemic cells.
7. Conclusion
ROS play an important functional role in human leukaemia.
NRF2 and its control of GSH regulate ROS. Recent data
suggests that GSH is fundamental to NRF2 function in AML
suggesting that this pathway may yield future therapeutic
targets for leukaemia cells in which GSH is dysregulated.
Abbreviations
ABCC/MRP1: Multidrug resistance proteins
AML: Acute myeloid leukaemia
GSR: GSH reductase
GPX1: GSH peroxidase
GST: GSH S-transferase
NADPH: Nicotinamide adenine dinucleotide
phosphate
ATP: Adenosine triphosphate
ADP: Adenosine diphosphate
H
2
O
2
: Hydrogen peroxide
GCL: Glutamate-cysteine ligase
ROS: Reactive oxygen species
NRF2: Nuclear factor (erythroid-derived 2)-like 2
FR: Free radicals
RNS: Reactive nitrogen species
CML: Chronic myeloid leukaemia.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
The authors wish to thank Worldwide Cancer Research,
National Institutes for Health Research (Flexibility and Sus-
tainability Funding), and The Big C. Amina Abdul-Aziz is
funded by a Ph.D. studentship from the Department of
Oxidative Medicine and Cellular Longevity 5
Higher Education and Scientific Research of the Libyan
government.
References
[1] G. Juliusson, P. Antunovic, A˚. Derolf et al., “Age and acute
myeloid leukemia: Real world data on decision to treat and
outcomes from the Swedish Acute Leukemia Registry,” Blood,
vol. 113, no. 18, pp. 4179–4187, 2009.
[2] F. Buccisano, L. Maurillo, M. I. del Principe et al., “Prognostic
and therapeutic implications of minimal residual disease detec-
tion in acute myeloid leukemia,” Blood, vol. 119, no. 2, pp. 332–
341, 2012.
[3] K. J. Hope, L. Jin, and J. E. Dick, “Acute myeloid leukemia
originates from a hierarchy of leukemic stem cell classes that
differ in self-renewal capacity,”Nature Immunology, vol. 5, no. 7,
pp. 738–743, 2004.
[4] J. M. Rowe and M. S. Tallman, “How I treat acute myeloid
leukemia,” Blood, vol. 116, no. 17, pp. 3147–3156, 2010.
[5] H. Sies, “Oxidative stress: from basic research to clinical
application,” The American Journal of Medicine, vol. 91, no. 3,
supplement 3, pp. S31–S38, 1991.
[6] B. Halliwell, “How to characterize a biological antioxidant,” Free
Radical Research Communications, vol. 9, no. 1, pp. 1–32, 1990.
[7] B. Halliwell, “Free radicals, proteins and DNA: oxidative dam-
age versus redox regulation,” Biochemical Society Transactions,
vol. 24, no. 4, pp. 1023–1027, 1996.
[8] A. M. Shah and K. M. Channon, “Free radicals and redox
signalling in cardiovascular disease,” Heart, vol. 90, no. 5, pp.
486–487, 2004.
[9] M. Saraste, “Oxidative phosphorylation at the fin de siecle,”
Science, vol. 283, no. 5407, pp. 1488–1493, 1999.
[10] K. J. Davies, “Oxidative stress: the paradox of aerobic life,”
Biochemical Society Symposium, vol. 61, pp. 1–31, 1995.
[11] D. J. Reuland, J. M. McCord, and K. L. Hamilton, “The role of
Nrf2 in the attenuation of cardiovascular disease,” Exercise and
Sport Sciences Reviews, vol. 41, no. 3, pp. 162–168, 2013.
[12] S. Singh, S. Vrishni, B. K. Singh, I. Rahman, and P. Kakkar,
“Nrf2-ARE stress response mechanism: a control point in
oxidative stress-mediated dysfunctions and chronic inflamma-
tory diseases,” Free Radical Research, vol. 44, no. 11, pp. 1267–
1288, 2010.
[13] C. P. Ramsey, C. A. Glass, M. B. Montgomery et al., “Expression
of Nrf2 in neurodegenerative diseases,” Journal of Neuropathol-
ogy & Experimental Neurology, vol. 66, no. 1, pp. 75–85, 2007.
[14] J. E. Klaunig, Y. Xu, J. S. Isenberg et al., “The role of oxidative
stress in chemical carcinogenesis,” Environmental Health Per-
spectives, vol. 106, supplement 1, pp. 289–295, 1998.
[15] D. Ziech, R. Franco, A. Pappa, and M. I. Panayiotidis,
“Reactive Oxygen Species (ROS)—induced genetic and epige-
netic alterations in human carcinogenesis,”Mutation Research/
Fundamental and Molecular Mechanisms of Mutagenesis, vol.
711, no. 1-2, pp. 167–173, 2011.
[16] A. K. Jaiswal, “Nrf2 signaling in coordinated activation of
antioxidant gene expression,”Free Radical Biology andMedicine,
vol. 36, no. 10, pp. 1199–1207, 2004.
[17] K. Akashi, D. Traver, T. Miyamoto, and I. L. Weissman, “A
clonogenic common myeloid progenitor that gives rise to all
myeloid lineages,” Nature, vol. 404, no. 6774, pp. 193–197, 2000.
[18] D. G. Tenen, R. Hromas, J. D. Licht, and D.-E. Zhang, “Tran-
scription factors, normal myeloid development, and leukemia,”
Blood, vol. 90, no. 2, pp. 489–519, 1997.
[19] B. Lo¨wenberg, J. R. Downing, and A. Burnett, “Acute myeloid
leukemia,” The New England Journal of Medicine, vol. 341, no.
14, pp. 1051–1062, 1999.
[20] J. Radich, “The molecular biology of acute myeloid leukemia,”
in Advances in Malignant Hematology, pp. 86–102, Wiley-
Blackwell, 2011.
[21] F. Ishikawa, S. Yoshida, Y. Saito et al., “Chemotherapy-resistant
human AML stem cells home to and engraft within the bone-
marrow endosteal region,” Nature Biotechnology, vol. 25, no. 11,
pp. 1315–1321, 2007.
[22] M. S. Tallman, D. G. Gilliland, and J. M. Rowe, “Drug therapy
for acutemyeloid leukemia,”Blood, vol. 106, no. 4, pp. 1154–1163,
2005.
[23] S. Schnittger, C. Schoch, M. Dugas et al., “Analysis of FLT3
length mutations in 1003 patients with acute myeloid leukemia:
correlation to cytogenetics, FAB subtype, and prognosis in the
AMLCG study and usefulness as a marker for the detection of
minimal residual disease,” in Proceedings of the the 42nd Annual
Meeting of the American Society of Hematology, vol. 100, pp. 59–
66, San Francisco, Calif, USA, December 2002, abstract 3569.
[24] P. Gorello, G. Cazzaniga, F. Alberti et al., “Quantitative assess-
ment ofminimal residual disease in acutemyeloid leukemia car-
rying nucleophosmin (NPM1) gene mutations,” Leukemia, vol.
20, no. 6, pp. 1103–1108, 2006.
[25] P. D. Kottaridis, R. E. Gale, M. E. Frew et al., “The presence
of a FLT3 internal tandem duplication in patients with acute
myeloid leukemia (AML) adds important prognostic informa-
tion to cytogenetic risk group and response to the first cycle of
chemotherapy: analysis of 854 patients from the United King-
dom Medical Research Council AML 10 and 12 trials,” Blood,
vol. 98, no. 6, pp. 1752–1759, 2001.
[26] T. Kindler, D. B. Lipka, and T. Fischer, “FLT3 as a therapeutic
target in AML: still challenging after all these years,” Blood, vol.
116, no. 24, pp. 5089–5102, 2010.
[27] A. Sallmyr, J. Fan, K. Datta et al., “Internal tandem duplication
of FLT3 (FLT3/ITD) induces increased ROS production, DNA
damage, and misrepair: implications for poor prognosis in
AML,” Blood, vol. 111, no. 6, pp. 3173–3182, 2008.
[28] J. L. Bos, “ras Oncogenes in human cancer: a review,” Cancer
Research, vol. 49, no. 17, pp. 4682–4689, 1989.
[29] X. Dolcet, D. Llobet, J. Pallares, and X. Matias-Guiu, “NF-kB
in development and progression of human cancer,” Virchows
Archiv, vol. 446, no. 5, pp. 475–482, 2005.
[30] A. B. Raitano, J. R. Halpern, T. M. Hambuch, and C. L. Sawyers,
“The Bcr-Abl leukemia oncogene activates Jun kinase and
requires Jun for transformation,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 92, no.
25, pp. 11746–11750, 1995.
[31] H. Kiyoi, T. Naoe, Y. Nakano et al., “Prognostic implication of
FLT3 and N-RAS gene mutations in acute myeloid leukemia,”
Blood, vol. 93, no. 9, pp. 3074–3080, 1999.
[32] J. E. Roderick, J. Tesell, L. D. Shultz et al., “c-Myc inhibition
prevents leukemia initiation in mice and impairs the growth of
relapsed and induction failure pediatric T-ALL cells,”Blood, vol.
123, no. 7, pp. 1040–1050, 2014.
[33] M. Sattler, S. Verma, G. Shrikhande et al., “The BCR/ABL
tyrosine kinase induces production of reactive oxygen species
in hematopoietic cells,”The Journal of Biological Chemistry, vol.
275, no. 32, pp. 24273–24278, 2000.
6 Oxidative Medicine and Cellular Longevity
[34] J. H. Kim, S. C. Chu, J. L. Gramlich et al., “Activation of the
PI3K/mTOR pathway by BCR-ABL contributes to increased
production of reactive oxygen species,” Blood, vol. 105, no. 4,
pp. 1717–1723, 2005.
[35] K. Ban, Y. Gao, H. M. Amin et al., “BCR-ABL1 mediates up-
regulation of Fyn in chronicmyelogenous leukemia,” Blood, vol.
111, no. 5, pp. 2904–2908, 2008.
[36] Y. Gao, A. Howard, K. Ban, and J. Chandra, “Oxidative stress
promotes transcriptional up-regulation of Fyn in BCR-ABL1-
expressing cells,” The Journal of Biological Chemistry, vol. 284,
no. 11, pp. 7114–7125, 2009.
[37] M. McMahon, K. Itoh, M. Yamamoto, and J. D. Hayes, “Keap1-
dependent proteasomal degradation of transcription factor
Nrf2 contributes to the negative regulation of antioxidant
response element-driven gene expression,” The Journal of Bio-
logical Chemistry, vol. 278, no. 24, pp. 21592–21600, 2003.
[38] E. Kansanen, S. M. Kuosmanen, H. Leinonen, and A.-L.
Levonenn, “TheKeap1-Nrf2 pathway:mechanisms of activation
and dysregulation in cancer,” Redox Biology, vol. 1, no. 1, pp. 45–
49, 2013.
[39] S. A. Heasman, L. Zaitseva, K. M. Bowles, S. A. Rushworth,
and D. J. MacEwan, “Protection of acute myeloid leukaemia
cells from apoptosis induced by front-line chemotherapeutics is
mediated by haem oxygenase-1,” Oncotarget, vol. 2, no. 9, pp.
658–668, 2011.
[40] S. A. Rushworth, L. Zaitseva, M. Y. Murray, N. M. Shah, K.
M. Bowles, and D. J. MacEwan, “The high Nrf2 expression in
human acute myeloid leukemia is driven by NF-𝜅B and under-
lies its chemo-resistance,” Blood, vol. 120, no. 26, pp. 5188–5198,
2012.
[41] S. A. Rushworth, K. M. Bowles, and D. J. MacEwan, “High
basal nuclear levels of Nrf2 in acute myeloid leukemia reduces
sensitivity to proteasome inhibitors,” Cancer Research, vol. 71,
no. 5, pp. 1999–2009, 2011.
[42] J. D. Hayes and M. McMahon, “NRF2 and KEAP1 mutations:
permanent activation of an adaptive response in cancer,” Trends
in Biochemical Sciences, vol. 34, no. 4, pp. 176–188, 2009.
[43] B. N. Chorley, M. R. Campbell, X. Wang et al., “Identification of
novel NRF2-regulated genes by ChiP-Seq: influence on retinoid
X receptor alpha,” Nucleic Acids Research, vol. 40, no. 15, pp.
7416–7429, 2012.
[44] Y.-S. Keum, Y.-H. Han, C. Liew et al., “Induction of heme
oxygenase-1 (HO-1) and NAD[P]H: quinone oxidoreductase 1
(NQO1) by a phenolic antioxidant, butylated hydroxyanisole
(BHA) and its metabolite, tert-butylhydroquinone (tBHQ) in
primary-cultured human and rat hepatocytes,” Pharmaceutical
Research, vol. 23, no. 11, pp. 2586–2594, 2006.
[45] A. C. Wild, J. J. Gipp, and R. T. Mulcahy, “Overlapping antiox-
idant response element and PMA response element sequences
mediate basal and 𝛽-naphthoflavone-induced expression of the
human 𝛾-glutamylcysteine synthetase catalytic subunit gene,”
Biochemical Journal, vol. 332, part 2, pp. 373–381, 1998.
[46] A. C. Wild, H. R. Moinova, and R. T. Mulcahy, “Regulation of
𝛾-glutamylcysteine synthetase subunit gene expression by the
transcription factor Nrf2,” The Journal of Biological Chemistry,
vol. 274, no. 47, pp. 33627–33636, 1999.
[47] H. Sasaki, H. Sato, K. Kuriyama-Matsumura et al., “Electrophile
response element-mediated induction of the cystine/glutamate
exchange transporter gene expression,”The Journal of Biological
Chemistry, vol. 277, no. 47, pp. 44765–44771, 2002.
[48] C. J. Harvey, R. K. Thimmulappa, A. Singh et al., “Nrf2-
regulated glutathione recycling independent of biosynthesis is
critical for cell survival during oxidative stress,” Free Radical
Biology and Medicine, vol. 46, no. 4, pp. 443–453, 2009.
[49] R. P.Wu, T.Hayashi,H. B. Cottam et al., “Nrf2 responses and the
therapeutic selectivity of electrophilic compounds in chronic
lymphocytic leukemia,” Proceedings of the National Academy of
Sciences of theUnited States of America, vol. 107, no. 16, pp. 7479–
7484, 2010.
[50] L. N. Barrera, S. A. Rushworth, K. M. Bowles, and D. J. MacE-
wan, “Bortezomib induces heme oxygenase-1 expression in
multiple myeloma,” Cell Cycle, vol. 11, no. 12, pp. 2248–2252,
2012.
[51] P. J. Ansell, S.-C. Lo, L. G. Newton et al., “Repression of cancer
protective genes by 17beta-estradiol: ligand-dependent interac-
tion between human Nrf2 and estrogen receptor alpha,”Molec-
ular and Cellular Endocrinology, vol. 243, no. 1-2, pp. 27–34,
2005.
[52] N. Kaplowitz, T. Y. Aw, and M. Ookhtens, “The regulation of
hepatic glutathione,” Annual Review of Pharmacology and Toxi-
cology, vol. 25, pp. 715–744, 1985.
[53] M. J. Meredith and D. J. Reed, “Status of the mitochondrial
pool of glutathione in the isolated hepatocyte,” The Journal of
Biological Chemistry, vol. 257, no. 7, pp. 3747–3753, 1982.
[54] C. Hwang, A. J. Sinskey, and H. F. Lodish, “Oxidized redox state
of glutathione in the endoplasmic reticulum,” Science, vol. 257,
no. 5076, pp. 1496–1502, 1992.
[55] L. Yuan and N. Kaplowitz, “Glutathione in liver diseases and
hepatotoxicity,” Molecular Aspects of Medicine, vol. 30, no. 1-2,
pp. 29–41, 2009.
[56] S. C. Lu, “Regulation of hepatic glutathione synthesis: current
concepts and controversies,”The FASEB Journal, vol. 13, no. 10,
pp. 1169–1183, 1999.
[57] C. C. Franklin,D. S. Backos, I.Mohar, C. C.White,H. J. Forman,
and T. J. Kavanagh, “Structure, function, and post-translational
regulation of the catalytic and modifier subunits of glutamate
cysteine ligase,” Molecular Aspects of Medicine, vol. 30, no. 1-2,
pp. 86–98, 2009.
[58] W.-M. Sun, Z.-Z. Huang, and S. C. Lu, “Regulation of 𝛾-
glutamylcysteine synthetase by protein phosphorylation,” Bio-
chemical Journal, vol. 320, no. 1, pp. 321–328, 1996.
[59] P. Xue, Y. Hou, Y. Chen et al., “Adipose deficiency of Nrf2 in
ob/obmice results in severemetabolic syndrome,”Diabetes, vol.
62, no. 3, pp. 845–854, 2013.
[60] Y. Chen, H. G. Shertzer, S. N. Schneider, D. W. Nebert, and T.
P. Dalton, “Glutamate cysteine ligase catalysis: dependence on
ATP and modifier subunit for regulation of tissue glutathione
levels,”The Journal of Biological Chemistry, vol. 280, no. 40, pp.
33766–33774, 2005.
[61] Y. Yang, M. Z. Dieter, Y. Chen, H. G. Shertzer, D. W. Nebert,
and T. P. Dalton, “Initial characterization of the glutamate-
cysteine ligase modifier subunit Gclm(-/-) knockout mouse.
Novelmodel system for a severely compromised oxidative stress
response,” The Journal of Biological Chemistry, vol. 277, no. 51,
pp. 49446–49452, 2002.
[62] J. Y. Chan and M. Kwong, “Impaired expression of glutathione
synthetic enzyme genes in mice with targeted deletion of the
Nrf2 basic-leucine zipper protein,” Biochimica et Biophysica
Acta—Gene Structure and Expression, vol. 1517, no. 1, pp. 19–26,
2000.
[63] A. Singh, T. Rangasamy, R. K.Thimmulappa et al., “Glutathione
peroxidase 2, the major cigarette smoke-inducible isoform of
GPX in lungs, is regulated by Nrf2,” The American Journal of
Oxidative Medicine and Cellular Longevity 7
Respiratory Cell and Molecular Biology, vol. 35, no. 6, pp. 639–
650, 2006.
[64] R. K. Thimmulappa, K. H. Mai, S. Srisuma, T. W. Kensler,
M. Yamamoto, and S. Biswal, “Identification of Nrf2-regulated
genes induced by the chemopreventive agent sulforaphane by
oligonucleotidemicroarray,”Cancer Research, vol. 62, no. 18, pp.
5196–5203, 2002.
[65] J. Nordberg and E. S. J. Arne´r, “Reactive oxygen species, antiox-
idants, and the mammalian thioredoxin system,” Free Radical
Biology and Medicine, vol. 31, no. 11, pp. 1287–1312, 2001.
[66] K. Itoh, T. Chiba, S. Takahashi et al., “An Nrf2/small Maf
heterodimer mediates the induction of phase II detoxifying
enzyme genes through antioxidant response elements,” Bio-
chemical and Biophysical Research Communications, vol. 236,
no. 2, pp. 313–322, 1997.
[67] R. N. Armstrong, “Glutathione S-transferases: reaction mecha-
nism, structure, and function,”Chemical Research in Toxicology,
vol. 4, no. 2, pp. 131–140, 1991.
[68] L. E. Huang, Z. Arany, D. M. Livingston, and H. F. Bunn,
“Activation of hypoxia-inducible transcription factor depends
primarily upon redox-sensitive stabilization of its 𝛼 subunit,”
Journal of Biological Chemistry, vol. 271, no. 50, pp. 32253–32259,
1996.
[69] S. A. Reisman, I. I. Csanaky, L. M. Aleksunes, and C. D.
Klaassen, “Altered disposition of acetaminophen in Nrf2-null
and keap1-knockdownmice,”Toxicological Sciences, vol. 109, no.
1, pp. 31–40, 2009.
[70] X.-J. Wang, Z. Sun, N. F. Villeneuve et al., “Nrf2 enhances
resistance of cancer cells to chemotherapeutic drugs, the dark
side of Nrf2,” Carcinogenesis, vol. 29, no. 6, pp. 1235–1243, 2008.
[71] S. A. Rushworth, D. J. MacEwan, and M. A. O’Connell,
“Lipopolysaccharide-induced expression of NAD(P)H:quinone
oxidoreductase 1 and heme oxygenase-1 protects against exces-
sive inflammatory responses in humanmonocytes,”The Journal
of Immunology, vol. 181, no. 10, pp. 6730–6737, 2008.
[72] S. A. Rushworth andD. J. MacEwan, “HO-1 underlies resistance
of AML cells to TNF-induced apoptosis,” Blood, vol. 111, no. 7,
pp. 3793–3801, 2008.
[73] D. S. Krause, M. J. Fackler, C. I. Civin, and W. S. May, “CD34:
structure, biology, and clinical utility,” Blood, vol. 87, no. 1, pp.
1–13, 1996.
[74] A. Blair, D. E. Hogge, and H. J. Sutherland, “Most acute myeloid
leukemia progenitor cells with long-term proliferative ability
in vitro and in vivo have the phenotype CD34+/CD71− /HLA-
DR−,” Blood, vol. 92, no. 11, pp. 4325–4335, 1998.
[75] R. T. Costello, F.Mallet, B. Gaugler et al., “Human acutemyeloid
leukemia CD34+/CD38− progenitor cells have decreased sen-
sitivity to chemotherapy and Fas-induced apoptosis, reduced
immunogenicity, and impaired dendritic cell transformation
capacities,”Cancer Research, vol. 60, no. 16, pp. 4403–4411, 2000.
[76] S. Pei,M.Minhajuddin, K. P. Callahan et al., “Targeting aberrant
glutathionemetabolism to eradicate human acute myelogenous
leukemia cells,”The Journal of Biological Chemistry, vol. 288, no.
47, pp. 33542–33558, 2013.
[77] D. Trachootham, H. Zhang, W. Zhang et al., “Effective elimi-
nation of fludarabine-resistant CLL cells by PEITC through a
redox-mediated mechanism,” Blood, vol. 112, no. 5, pp. 1912–
1922, 2008.
[78] M. T.Voso, F.D’Alo’, R. Putzulu et al., “Negative prognostic value
of glutathione S-transferase (GSTM1 and GSTT1) deletions in
adult acute myeloid leukemia,” Blood, vol. 100, no. 8, pp. 2703–
2707, 2002.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
Microenvironment and Immunology
MIF-Induced Stromal PKCb/IL8 Is Essential in
Human Acute Myeloid Leukemia
Amina M. Abdul-Aziz1, Manar S. Shafat1, Tarang K. Mehta2, Federica Di Palma2,
Matthew J. Lawes3, Stuart A. Rushworth1, and Kristian M. Bowles1,3
Abstract
Acute myeloid leukemia (AML) cells exhibit a high level of
spontaneous apoptosis when cultured in vitro but have a
prolonged survival time in vivo, indicating that tissue micro-
environment plays a critical role in promoting AML cell sur-
vival. In vitro studies have shown that bone marrow mesen-
chymal stromal cells (BM-MSC) protect AML blasts from spon-
taneous and chemotherapy-induced apoptosis. Here, we report
a novel interaction between AML blasts and BM-MSCs, which
beneﬁts AML proliferation and survival. We initially examined
the cytokine proﬁle in cultured human AML compared with
AML cultured with BM-MSCs and found that macrophage
migration inhibitory factor (MIF) was highly expressed by
primary AML, and that IL8 was increased in AML/BM-MSC
cocultures. Recombinant MIF increased IL8 expression in BM-
MSCs via its receptor CD74. Moreover, the MIF inhibitor ISO-
1 inhibited AML-induced IL8 expression by BM-MSCs as well
as BM-MSC–induced AML survival. Protein kinase C b
(PKCb) regulated MIF-induced IL8 in BM-MSCs. Finally,
targeted IL8 shRNA inhibited BM-MSC–induced AML surviv-
al. These results describe a novel, bidirectional, prosurvival
mechanism between AML blasts and BM-MSCs. Furthermore,
they provide biologic rationale for therapeutic strategies in
AML targeting the microenvironment, speciﬁcally MIF and IL8.
Cancer Res; 77(2); 303–11. 2016 AACR.
Introduction
Survival of patients with acute myeloid leukemia (AML) is
presently poor; two thirds of young adults and 90% of older
adults die of their disease (1). Even in patients who achieve
remission with chemotherapy, relapse is common and occurs
from minimal residual disease sequestered in protective
niches in the bone marrow microenvironment (2). According-
ly, it is envisaged that improved outcomes will come from
novel treatment strategies derived from an improved under-
standing of the biology of AML within the bone marrow
microenvironment.
AML cells exhibit a high level of spontaneous apoptosis when
cultured in vitro but have a prolonged survival time in vivo,
indicating that the tissue microenvironment plays a critical role
in promoting AML cell survival (3–6). Knowledge of the com-
plexity of the bone marrow microenvironment is increasing,
especially with respect to the bonemarrowmesenchymal stromal
cells (BM-MSC), which are considered amajor protective cell type
(7). BM-MSCs generate various factors whose primary functions
are to inﬂuence tumor cell survival and homing (4, 8, 9). The
apoptotic defect in AML is not cell autonomous but highly
dependent on extrinsic signals derived from their microenviron-
ment. The complex cell–cell interactions between the AML tumor
cells and their microenvironment are therefore essential for
tumor growth and survival and thus present an attractive target
for novel drug therapies.
Macrophage migration inhibitory factor (MIF) is a pleiotropic
cytokine, which under normal conditions regulates cell-medi-
ated immunity and inﬂammation (10). In cancer, MIF is over-
expressed in a number of solid tumors, including breast, pros-
tate, and colon cancers (11–13). MIF has also been shown to be
overexpressed in various blood cancers, including chronic lym-
phocytic leukemia (CLL; ref. 14). In CLL, MIF is expressed by the
malignant cells and induces protective IL8 release in an auto-
crine-dependent manner. Blocking either MIF or IL8 reduces
survival of CLL. The increased secretion of IL8 from tumor cells
is thought to have wider signiﬁcance to the tumor microenvi-
ronment. Serum IL8 is known to be higher in patients with AML,
myelodysplasia (MDS), and non-Hodgkin lymphoma than in
normal controls, and levels of IL8 in these patients are similar to
those found in patients with multiple organ failure of nonseptic
origin (15, 16). Furthermore, leukemic blasts from the majority
of patients with AML constitutively express IL8 (17). In addi-
tion, inhibition of the IL8 receptor, CXCR2, selectively inhibits
proliferation of MDS/AML cell lines and patient samples (18).
Together, these studies suggest that MIF and IL8 are functionally
important in regulating the survival and proliferation of mul-
tiple tumors, including AML.
In the current study, we investigate how AML cells program
BM-MSCs via MIF to produce the survival cytokine IL8 and
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characterize the signaling pathways underlying this interdepen-
dent cell–cell communication.
Materials and Methods
Materials
Anti-PKC, MAPK, and AKT antibodies were purchased from
Cell Signaling Technology. Anti-CD74, anti-CXCR2, and anti-
CXCR4 antibodies were purchased from Miltenyi Biotec. All
inhibitors were purchased from Tocris. The CD74 blocking anti-
body was purchased from BD Biosciences. Proteome Proﬁler
Human XL array and recombinant human MIF were purchased
from R&D Systems. MIF ELISA was purchased from BioLegend.
IL8ELISAwaspurchased fromeBioscience. All other reagentswere
obtained from Sigma-Aldrich
Cell culture
For primary cell isolation, heparinized blood was collected
from volunteers, and human peripheral bloodmononuclear cells
were isolated by Histopaque (Sigma-Aldrich) density gradient
centrifugation. AML samples that comprised less than 80% blasts
were puriﬁed using the CD34 Positive Selection Kit. Cell type was
conﬁrmed by microscopy and ﬂow cytometry. BM-MSCs were
isolated by bone marrow aspirates from AML patients. Mononu-
clear cells were collected by gradient centrifugation and plated in
growth medium containing DMEM and 20% FBS and 1% L-
glutamine. The nonadherent cells were removed after 2 days.
When 60% to 80% conﬂuent, adherent cells were trypsinized and
expanded for 3 to 5 weeks. BM-MSCs were checked for positive
expression of CD105, CD73, and CD90 (BM-MSC markers) and
the lack of expression of CD45 and CD34 by ﬂow cytometry. All
patient information, including genotype and WHO classiﬁcation
for AML and genotype and phenotype of AML BM-MSCs, are
included in Supplementary Tables S1 and S2.
RNA extraction and real-time PCR
Total RNA was extracted from 5  105 cells using the Nucleic
Acid PrepStation from Applied Biosystems, according to the
manufacturer's instructions. Reverse transcription was performed
using the RNA PCR Core Kit (Applied Biosystems). Relative qRT-
PCR used SYBR Green technology (Roche) on cDNA generated
from the reverse transcription of puriﬁed RNA. After preampliﬁ-
cation (95C for 2minutes), the PCRswere ampliﬁed for 45 cycles
(95C for 15 seconds and 60C for 10 seconds and 72C for 10
seconds) on a 384-well LightCycler 480 (Roche). Each mRNA
expression was normalized against GAPDH mRNA expression
using the standard curve method.
Western immunoblotting and ELISAs
SDS-PAGE and Western blot analyses were performed. Brieﬂy,
whole-cell lysates were extracted and SDS-PAGE separation was
performed. Protein was transferred to nitrocellulose membrane
and Western blot analysis performed with the indicated antisera
according to theirmanufacturer's guidelines. To examineMIF and
IL8 secretion into media, we used LEGEND MAX Human Active
MIF ELISA Kit (BioLegend) andHuman IL-8 ELISA Ready-SET-Go
(eBioscience).
shRNA silencing of CD74, PKCb, and IL8
Five Mission shRNA targeted lentivirus particles (Sigma-
Aldrich) for each target were obtained. BM-MSCs (2  104 cells)
were infected with each lentivirus. For all gene expression experi-
ments, the cells were incubated for 72 hours posttransfection
before RNA extraction.
Flow cytometry
Flow cytometry formeasuring AML cell numberwas performed
on the Cube 6 (Sysmex Partec). For the AML/BM-MSC cocultures,
AML cell viability was measured using ﬂow cytometry. After
exclusion of BM-MSCs by electronic gating using forward scatter,
AML cells were counted using CD34 gating.
Cytokine array expression analysis
Primary AML blasts 0.25  106 were cultured alone or cocul-
tured on conﬂuent primary BM-MSCs. Conditionedmediumwas
then collected from these cultures aswell as fromBM-MSC culture
and analyzed using the Proteome Proﬁler Human XL Cytokine
Array following themanufacturer's instructions.Quantiﬁcationof
cytokine optical densities was obtained with the HLimageþþ
software (WesternVision).
Statistical analyses
The Mann–Whitney U test was used to compare test groups
where stated. Results where P < 0.05 were considered statistically
signiﬁcant. Results represent the mean  SD of four or more
independent experiments. We generated statistics with GraphPad
Prism 5 software (GraphPad). For Western blotting, data are
representative images of three independent experiments.
Study approval
AML cells and BM-MSCswere obtained fromAMLpatient bone
marrowor blood following informed consent andunder approval
from the UK National Research Ethics Service (LRECref07/
H0310/146).
Results
BM-MSCs support AML survival
The microenvironment supports AML survival and prolifera-
tion (4, 5, 19). To study the cell–cell communicationbetweenBM-
MSCs and AML cells, we established a coculture system using
primary AML cells and BM-MSCs derived from treatment-na€ve
AML patients. Here, we show a signiﬁcant difference in primary
AML survival when cultured on BM-MSCs for 6 and 14 days
compared with AML blast survival when cultured in basal media
alone (Fig. 1A; Supplementary Fig. S1). Supplementary Figure S2
shows the different combinations of AML and BM-MSCs in all
experiments.
To determine what factors are responsible for improved pri-
mary AML blast survival on BM-MSCs, we analyzed the proﬁle of
cytokines and chemokines present in primary AML cultures, BM-
MSC cultures, and primary AML blasts cultured in combination
with BM-MSCs. Cytokine array proﬁles of the three culture con-
ditions (Fig. 1B) show a consistent upregulation of IL8 in the
coculture sample media (Fig. 1C). Moreover, we also observed
high levels ofMIF in all AML supernatants, low levels ofMIF in all
BM-MSC supernatants, and high levels of MIF in the AML/BM-
MSC cocultures (Fig. 1B and D). To verify these observations, we
carried out IL8- and MIF-speciﬁc ELISAs. IL8 concentrations peak
at 8 and 24 hours in the AML/BM-MSC coculture supernatants
(Fig. 1E), whereas MIF concentrations were high and at similar
levels in AML culture supernatants and AML/BM-MSC coculture
supernatants (Fig. 1F).
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AML-derived MIF induces IL8 expression in BM-MSCs
Next, we looked to determine whether BM-MSCs needed
direct contact with AML to increase IL8 expression. RT-PCR
showed that IL8 mRNA from BM-MSCs incubated with AML
increased by 57-fold when in direct contact and by 50-fold
when in indirect contact with AML blasts (Fig. 2A). This
conﬁrms that direct tumor cell to stromal cell contact is not
necessary for AML to induce increased IL8 expression by
BM-MSCs.
Next, we examined the mRNA expression levels of MIF in
primary AML (n ¼ 5) and BM-MSC (n ¼ 5) cultures. RT-PCR
showed that primary AML cultures, but not BM-MSC cultures,
express high levels of MIF mRNA under normal basal conditions
(Fig. 2B). As MIF expression has been shown to be increased in
AML patients compared with normal patients (20) and the ability
of MIF to induce IL8 production by primary CLL (14), we
hypothesized that MIF from AML was responsible for the
increased IL8 expression in BM-MSCs. To test this hypothesis,
we stimulated BM-MSCs with 100ng/mL recombinant human
MIF and assayed for IL8 mRNA and protein expression over a
period of 24 hours. We show that IL8 mRNA and protein
increased (Fig. 2C and D) in response to MIF. To conﬁrm that
MIF secreted from AML cells regulates IL8 expression, we used
ISO-1, a nontoxic inhibitor ofMIF, which functions by binding to
bioactive MIF at its N-terminal tautomerase site (21). MIF-stim-
ulated BM-MSCs pretreated with ISO-1 showed a decrease in
IL8 mRNA levels compared with untreated BM-MSCs (Fig. 2E).
Moreover, AML survival was inhibited when cultured with BM-
MSCs in the presence of ISO-1 compared with control AML–BM-
MSC cultures (Fig. 2F). Together, these data conﬁrm that MIF
secreted by AML cells induces IL8 expression in BM-MSCs.
MIF-induced IL8 upregulation is mediated through CD74
Depending on the cellular context and the disease involved,
MIF signaling is mediated by its receptors CXCR2 (IL8 receptor,
ILR8) and/or CXCR4 (stromal-derived factor 1 receptor),
and/or CD74 (22, 23). BM-MSCs have been reported to express
all three receptors (24–26). Using CD105 as a BM-MSC marker
to conﬁrm mesenchymal cell phenotype, we show that CD74
and CXCR4 are expressed but CXCR2 is not expressed on
Figure 1.
BM-MSCs support AML survival.
A, AML blasts (0.25  106) were
cocultured with primary BM-MSCs on
a 12-well plate for 6 days (n¼ 20); AML
blast number was assessed
using Trypan blue exclusion
hemocytometer–based counts and
CD34þ staining using ﬂow cytometry.
B, Cell-free supernatants from
7 individual AML patient blasts
(0.25  106) were cocultured with
primary BM-MSCs for 24 hours and a
representative cytokine antibody
array of each of the cell culture
conditioned media using the Human
Cytokine Proteome Proﬁler Array.
C, Fold induction of cytokines
between BM-MSCs and AML cultured
on BM-MSCs. Results from 7 different
primary AML on four different
BM-MSCs. Bars, mean and SEM.
Signiﬁcantly upregulated cytokines
are included in the graph. D,
Quantiﬁcation of cytokine optical
density of AML only arrays
(7 individual AML samples). Graph
shows the top 8 cytokines expressed
by AML. Bars, mean and SEM. E, IL8
ELISA of each of the cell culture
conditioned media from various time
points (three individual AML samples).
F,MIF ELISA of each of the cell culture
conditioned media from various time
points (three individual AML samples).
The Mann–Whitney U test was used to
compare between treatment
groups ( , P < 0.05).
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all primary BM-MSCs isolated from AML patients (Fig. 3A).
BM-MSCs were further characterized using CD73 and CD90,
and lack of CD45 expression.
We used speciﬁc inhibitors of CXCR2, CXCR4, and CD74 to
determine which receptor/s were responsible for MIF-induced
IL8 upregulation. Inhibition of CXCR2 and CXCR4 using
pertussis toxin (a GPCR inhibitor) had no effect on MIF-
induced IL8 mRNA expression (Fig. 3B). However, the anti-
CD74 blocking antibody inhibited MIF-induced IL8 expression
in BM-MSCs (Fig. 3C). These results suggest that CD74 is the
dominant receptor in regulating MIF-induced IL8 expression
in AML patient-derived BM-MSCs. To further characterize this
interaction, we used lentiviral-mediated knockdown (KD) of
CD74 in AML patient-derived BM-MSCs, conﬁrming reduced
mRNA and protein expression of CD74 after transduction with
control KD or CD74 KD lentivirus (Fig. 3D). Furthermore, we
Figure 2.
AML-derived MIF induces IL8
expression in BM-MSCs. A, AML blasts
from 5 patients (0.25  106) were
cocultured with primary BM-MSCs
either in direct contact (DC) or indirect
contact (IC, transwell insert) for
24 hours. IL8 mRNA in BM-MSCs was
then assessed by real-time PCR. mRNA
expression was normalized to GAPDH
mRNA levels (n ¼ 5). B, BM-MSCs and
primary AML from 5 patients were
cultured alone and measured for MIF
mRNA levels (n¼ 5). mRNA expression
was normalized to GAPDH mRNA
levels. C, BM-MSCs from 5 patients
were treated with rhMIF (100 ng/mL)
for indicated times, and then extracted
RNA was assessed for IL8 mRNA by
real-time PCR. mRNA expression
was normalized toGAPDHmRNA levels
(n ¼ 5). D, BM-MSCs from 5 patients
were treated with rhMIF (100 ng/mL)
for indicated times, and then, media
were assessed for IL8 protein
expression by ELISA. (n ¼ 5).
E, BM-MSCs from four patients were
pretreated with ISO-1 (10 mmol/L) for
5 minutes before treatment with rhMIF
(100 ng/mL) for 4 hours and then
assessed for IL8 mRNA expression
(n ¼ 4). F, BM-MSCs were pretreated
with ISO-1 (10 mmol/L) for 5 minutes
before the addition of primary AML
blasts from 10 patient samples for
48 hours. AML blast number was
assessed using Trypan blue exclusion
hemocytometer–based counts (n¼ 10).
The Mann–Whitney U test was used to
compare between treatment groups
(, P < 0.05).
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demonstrate that CD74 knockdown inhibits MIF-induced IL8
mRNA expression in AML patient-derived BM-MSCs (Fig. 3E).
Pharmacologic inhibition of PKCb inhibits MIF-induced
IL8 induction in BM-MSCs
We next investigated the signaling cascade in AML patient-
derived BM-MSCs downstream of MIF-induced CD74 activa-
tion. It has been shown that MIF binding to CD74 activates
downstream signaling through the PI3K/protein kinase B
(AKT) and MAPK signaling pathways and promotes cell pro-
liferation and survival (27). In addition, Lutzny and colleagues
recently described the activation of a PKC pathway in murine
stromal cells cocultured with chronic lymphocytic leukemia
(28). We treated AML-stimulated BM-MSCs with LY294002
(a PI3K/Akt inhibitor), PD098059 [a MAPK kinase (MEK)
1 inhibitor], or Ro-31-8220 (a PKC pan inhibitor) to determine
which pathway/s regulate AML-induced BM-MSC IL8 mRNA
induction. We show that Ro-31-8220, the PKC inhibitor, was
able to signiﬁcantly inhibit IL8 expression by approximately
80%, whereas LY294002 and PD098059 had little or no effect
(Fig. 4A). Similarly, we found that Ro-31-8220 was able to
inhibit IL8 expression by circa 90% in experiments where BM-
MSCs were directly activated using recombinant human MIF
(rhMIF; rather than AML cells; Fig. 4B). However, in addition,
we observed that PD98059 was able to moderately inhibit
rhMIF-induced IL8 mRNA induction in BM-MSCs by approx-
imately 30% (Fig. 4B).
To clarifywhether PKC,MAPK,or both are activated in response
to MIF, we performed Western blot analysis on BM-MSCs for
speciﬁc phosphorylation of PKC isoforms, MAPK, or AKT in
response to MIF activation. BM-MSCs were activated by AML for
15 minutes or MIF treatment (100 ng/mL) for various times. We
initially show that MIF and AML both induce phosphorylation
of PKC a/bII and PKC b in BM-MSCs (Fig. 4C). BMSCs from
4 patient samples treated withMIF had no increase in phosphory-
lationof AKT andMAPK (Fig. 4D).Next, the PKC isoform–speciﬁc
inhibitors, Go6976 (PKCa/b) and enzastaurin (PKCb), were used
to blockMIF-induced IL8 expression in BM-MSCs. Both inhibitors
showed inhibition of MIF-induced IL8 upregulation (Fig. 4E).
Finally, we used lentiviral-mediated KD for PKCb, conﬁrming
reduced mRNA expression of PKCb after transduction of BM-
MSCs with control KD or PKCb KD virus (Fig. 4F). We then
Figure 3.
MIF-induced IL8 upregulation is
mediated through CD74. A, BM-MSCs
were assessed for CD105, CD74,
CXCR2, and CXCR4 using ﬂow
cytometry. B and C, BM-MSCs from
four patient samples were pretreated
with the GPCR inhibitor pertussis toxin
(PTX; 100 ng/mL) or for CD74 (aCD74
ab; 10mg/mL) for 30 minutes before
being stimulated with MIF for 4 hours.
RNA was extracted and assessed for
IL8 mRNA by real-time PCR. mRNA
expression was normalized to GAPDH
mRNA levels (n¼4).D,BM-MSCs from
four patient samples were infected
with control shRNA or CD74 shRNA for
72 hours and analyzed for CD74mRNA
expression by RT-PCR and protein
expression by ﬂow cytometry. E, BM-
MSCs from four patient samples were
infected with control shRNA or CD74
shRNA for 72 hours and then treated
with recombinantMIF and analyzed for
IL8 mRNA expression by RT-PCR. The
Mann–Whitney U test was used to
compare between treatment groups
( , P < 0.05).
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demonstrate that knockdown of PKCb inhibits MIF-induced IL8
mRNA expression (Fig. 4G). Together, these results conﬁrm that
MIF-induced IL8 expression in AML patient-derived BM-MSCs
requires PKCb.
Targeting the MIF–PKCb–IL8 axis disrupts BM-MSC–induced
protection of primary human AML blasts
Finally, to examine the effect of blocking IL8 on BM-MSC
protection and survival of primary AML blasts, we cocultured
Figure 4.
Inhibition of PKCb regulates AML-derived MIF-induced IL8 mRNA induction in BM-MSCs. A, BM-MSCs from four patients samples were pretreated with Ro-
31-8220 (1 mmol/L), PD98059 (10 mmol/L), and LY294002 (10 mmol/L) and then incubated with primary AML blast for 4 hours. RNA was extracted and
assessed for IL8 mRNA by real-time PCR. mRNA expression was normalized to GAPDH mRNA levels (n ¼ 4). B, BM-MSCs from four different samples
were pretreated with Ro-31-8220 (250 nmol/L), PD98059 (10 mmol/L), and LY294002 (10 mmol/L) and then incubated with MIF for 4 hours. RNA
was extracted and assessed for IL8 mRNA by real-time PCR. mRNA expression was normalized to GAPDH mRNA levels (n ¼ 4). C, BM-MSCs were
cultured with AML for 15 minutes or recombinant MIF (100 ng/mL) for various times. Protein was extracted and Western blotting performed. Blots
were probed for pPKCa/bII, pPKCb, PKD/PKCm, PKCd, and PKCd/q. Blots were then reprobed for b-actin to show equal sample loading. D, Four
different BM-MSCs with recombinant MIF (100 ng/mL) at various times. Protein was extracted and Western blotting performed. Blots were probed for pAKT
and pMAPK as well as total AKT and total MAPK. Blots were then reprobed for b-actin to show equal sample loading. E, Four different BM-MSCs
were pretreated with Go 6976 (1 mmol/L) and enzastaurin (1 mmol/L) and then incubated with MIF for 4 hours. RNA was extracted and assessed for
IL8 mRNA by real-time PCR. mRNA expression was normalized to GAPDH mRNA levels (n ¼ 4). F, Four different BM-MSCs were infected with
control shRNA or PKCb shRNA for 72 hours and analyzed for PKCb mRNA expression by RT-PCR. G, Four different BM-MSCs were infected with control
shRNA or PKCb shRNA for 72 hours, then treated with recombinant MIF and analyzed for IL8 mRNA expression by RT-PCR. The Mann–Whitney U test
was used to compare between treatment groups ( , P < 0.05).
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primary AML blasts derived from treatment-na€ve AML patients
with BM-MSCs (either control KD or IL8 KD). First, we used
lentiviral-mediated KD for IL8. Figure 5A and B shows the mRNA
expression andprotein expression of IL8 after transduction of BM-
MSCs with control KD or IL8 KD virus. Figure 5C demonstrates
that knockdown of IL8 inhibits MIF-induced IL8 mRNA expres-
sion. Next, we show that KD of IL8 in BM-MSCs signiﬁcantly
inhibits AML survival when in coculture compared with control
KD BM-MSCs (Fig. 5D). Finally, blocking the IL8R using
SB225002 inhibited AML survival when cultured with BM-MSCs
(Fig. 5E). Taken together, these results identify a novel protumoral
regulatory pathway in the AML microenvironment.
Discussion
AML is primarily a disease of the elderly with a median age at
diagnosis in the SwedishAcute LeukemiaRegistry of 72years (29).
Outcomes for the 75% of patients who get AML over the age of 60
remain generally poor, largely because the intensity and side
effects of existing curative therapeutic strategies (which are com-
monly used to treat younger ﬁtter patients), coupled with patient
comorbidities, frequently limit their use in this older less ﬁt
population (30). Accordingly, there is an urgent need to identify
pharmacologic strategies to tackle AML, which are not only
effective but can also be tolerated by both older and less well
patients. It is envisaged that treatments that target the tumor
microenvironment may well help realize this goal.
Here, we report a novel survival pathway within the human
AMLmicroenvironment, which functions as a feedback/autocrine
loop involving the constitutive expression of the chemokine MIF
by the AML blasts, which in turn induces IL8 expression in BM-
MSCs. Interestingly, another group showed that the repertoire of
constitutive in vitro chemokine release from AML shows variation
between different AML patient samples (31). We ﬁnd that
although baseline expression of MIF by AML varies between
patient samples tested, all samples analyzed expressed MIF.
Moreover in coculture experiments, AML patient-derived BM-
MSCs were found to be ubiquitously responsive to AML-derived
MIF, which resulted in an increase in IL8 expression by the BM-
MSCs. This is in keeping with similar reports on other cytokine
pathways, which have shown that BM-MSCs can constitutively
express various chemokines (32), and AML cells are able to
respond to these chemokines (32, 33). In this study, we also
examined the genotype of six BM-MSCs used for the experiments
and found three of six to be normal and in other three, the
genotyping failed (Supplementary Table S2). This is apparently
in contrast to Huang and colleagues, who found that three of four
BM-MSCs from AML patients tested had cytogenetic abnormal-
ities within the stromal cells (34). Presently therefore, the inci-
dence and functional consequences of cytogenetic mutations
within stromal cells remain undeﬁned. Nevertheless, taken
together, despite the established heterogeneity in AML, we ﬁnd
the MIF/IL8 autocrine loop a constant ﬁnding across the samples
we tested, which makes this an attractive druggable target.
IL8 is a proinﬂammatory chemokinewhose primary function is
to activate two cell surface G protein–coupled receptors, CXCR1
and CXCR2, which promote neutrophil migration and degranu-
lation (35–37). Elevated IL8 secretion in tumor biology is well
characterized, with a number of studies showing the importance
of this chemokine in AML. In 1993, Tobler and colleagues
described the constitutive expression of IL8 and its receptor in
human myeloid leukemia, and more recently, Schinke and
Figure 5.
Targeting MIF–PKC–IL8 axis in AML
disrupts BM-MSC–derived protection.
A and B, BM-MSCs from six samples
were infected with control shRNA or
IL8 shRNA for 72 hours and analyzed
for IL8 mRNA expression by RT-PCR
and protein expression by ELISA.
C, BM-MSCs from six samples were
infected with control shRNA or IL8
shRNA for 72 hours and then treated
with recombinant MIF and analyzed
for IL8 mRNA expression by RT-PCR.
D, BM-MSCs were infected with
control shRNA or IL8 shRNA for
72 hours and cocultured with AML
blasts from seven samples for 48
hours. AML blast number was
assessed using Trypan blue exclusion
hemocytometer–based counts
(n ¼ 7). E, BM-MSCs were pretreated
with SB225002 (100 nmol/L) for
30 minutes before the addition of
primary AML blasts from 10 samples
for 48 hours. AML blast number was
assessed using Trypan blue exclusion
hemocytometer–based counts. The
Mann-Whitney U test was used to
compare between treatment groups
( , P < 0.05).
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colleagues have reported that inhibition of the IL8 receptor
CXCR2 selectively inhibits immature hematopoietic stem cells
fromMDS/AML samples (17, 18). In other malignancies, IL8 has
been characterized in endothelial cells and tumor-associated
macrophages, suggesting that IL8 has a function in the liver and
prostate tumor microenvironments (38, 39). As rodents lack a
direct homologue of IL8, we puriﬁed BM-MSCs extracted from
patient bone marrow aspirates at the time of diagnosis of AML.
Our study describes for the ﬁrst time how AML stimulates the
production of IL8 from BM-MSCs and inhibiting this process
prevents AML survival.
Extensive studies of MIF function have revealed its central role
in innate and adaptive immunity (10). More recently, the ability
of this cytokine to support tumor progression has been highlight-
ed, revealing MIF as a potential target for anticancer therapies in
melanomaand colon cancer (40).MIF occurs in immunologically
distinct conformational isoforms, reduced MIF and oxidized MIF
(oxMIF), with the latter predominantly expressed in patients with
inﬂammatory diseases (41) and is highly expressed by various
cancer cell lines (42). This has led to the evaluation of an oxMIF¼
blocking antibody (imalumab) in early-phase clinical studies of
selected solid tumors (https://clinicaltrials.gov/ct2/show/
NCT01765790). Our ﬁndings provide a biological rationale for
the clinical assessment of imalumab or other MIF inhibitors in
AML patients.
Activation of PKC signaling pathway has been characterized in
cancer cells. In hematologic malignancies, different PKC isoforms
have been identiﬁed as key players in the leukemia microenvi-
ronment. In multiple myeloma, pharmacologic inhibition of
activated PKCbII using enzastaurin inhibited growth factors and
cytokines secreted by multiple myeloma–derived bone marrow
stromal cells (28). In CLL, PKCb is immediately downstream of
the B-cell receptor andhas been shown to be important to CLL cell
autocrine survival and proliferation in vivo (43). PKCb is also
essential for the development of CLL in the TCL1 transgenic
mouse model, making it a valid therapeutic target in this malig-
nancy (44). Furthermore, induction of PKCbII in stromal cells is
required for the survival of leukemic B cells, and stromal PKCbII is
upregulated in samples from CLL, ALL, and MCL patients (28).
Our results demonstrate that in primary samples from AML
patients at diagnosis, PKCb is phosphorylated in the BM-MSCs
in response to MIF stimulation. This leads us to hypothesize that
this pathway may commonly be activated in other hematologic
malignancies, and moreover, the cancer cell is inducing this
activation. In summary, this study links secretion of MIF from
primary AML to a speciﬁc BM-MSC pathway, utilizing PKCb to
feedback survival signals, including IL8 secretion toAML. In doing
so, we have identiﬁed in vitro the potential efﬁcacy of targeting any
one of these molecules to disrupt AML/BM-MSC prosurvival
interactions.
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